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use#LAAINTRODUCTION
The diet pills fenuramine (Pondimin) and dexfenuramine (Redux) were pulled from the market voluntarily
by American Home Products (through its subsidiaries A.H. Robins and Wyeth-Ayerst) on September 15,
1997.1 Those two pills made up the \fen" portion of the extraordinarily popular fen-phen diet drug combi-
nation. Redux and Pondimin allegedly caused valvular heart disease, primary pulmonary hypertension, and
in some cases neurotoxic brain injury. The U.S. Department of Health and Human Services, the American
College of Cardiology, and the American Heart Association all made recommendations for persons who had
ingested Redux and Pondimin. Following the widespread publication of the heart valve and primary pul-
monary hypertension (\PPH") problems associated with fen-phen use, many Redux/Pondimin users led
lawsuits against American Home Products. While some of these plaintis had actually been diagnosed with
valvular heart disease and PPH, many were suing for the right to medical monitoring paid for by American
Home Products. American Home Products has settled several cases out of court and jury verdicts were
returned in two important trials, the Lovett trial in Texas and the Washington trial in Mississippi. All
the federal cases were consolidated in 1997 in MDL 1203 before Judge Louis Bechtle in the U.S. District
Court for the Eastern District of Pennsylvania in Philadelphia. Several state cases were consolidated as
well, including cases in New York and California. In October of 1999 American Home Products reached a
Settlement Agreement with plaintis' lawyers for all valvular heart disease claims. Judge Bechtle has given
preliminary approval to that Settlement Agreement, and he will make a decision on whether to grant Final
Judicial Approval after a Fairness Hearing scheduled for May 1 { 5, 2000. The litigation has raised issues
concerning o-label drug prescriptions, drug manufacturer liability, class actions, and medical monitoring
1See U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), FDA An-
nounces Withdrawal Fenuramine and Dexfenuramine, CDER Website P97-32, Sept. 15, 1997, online at
www.fda.gov/cder/news/fenphenpr81597.htm
1claims.
This paper is divided into three sections. The rst section discusses the diet drugs used in the fen-phen
combination and the health problems associated with those drugs.2It also considers the matter of o-label
drug prescriptions and the role of obesity/cosmetic-weight loss in fen-phen prescriptions.
The second section addresses issues raised in the fen-phen litigation. It begins with a discussion of drug
manufacturer liability and of the main fen-phen defendant, American Home Products. It follows with a dis-
cussion of medical monitoring, the multi-district litigation, the fen-phen class actions, and a comprehensive
description of the proposed Settlement Agreement. Key state trials and settlements, particularly in Texas,
Mississippi, and Massachusetts, are also examined in this section.
The third part of the paper identies some of the lessons learned by the entire fen-phen experience, and
specically a major lesson related to the widespread use of the diet drugs for cosmetic weight loss and the
dangers of o-label diet drug prescriptions. The paper argues that in light of the context of societal pres-
sure for weight loss and the insatiable thirst of the American population for weight loss drugs, the FDA
should have more stringent approval standards for diet drugs than for other pharmaceuticals, and o-label
prescriptions of diet drugs should be prohibited. This is because of the propensity for misuse of diet drugs
for cosmetic weight loss, where their original risk-benet analysis goes astray because often the `disease' they
are being used to combat is actually nonexistent. O-label prescribing for diet drugs should be prohibited
(it is otherwise legal).
The paper concludes with an assessment of the likely outcome of the fen-phen litigation situation. It is
important to note that this is an ongoing situation and the paper cannot address the nal outcome of the
fen-phen litigation. While the opt-out deadline for the Settlement was a March 30, 2000 postmark, the results
of opt-out numbers will not be posted until the paper is completed. In addition, the Fairness Hearing for the
2It is important to note that American Home Products maintains that there is no clear causal link between
Pondimin and/or Redux and valvular heart disease.
2Settlement is not scheduled until May 1 { 5, 2000, and the outcome of that hearing will play an extremely
critical role on the eventual results of the fen-phen experience. This paper asserts that the Settlement will
be approved and assesses who wins and loses in that situation.
The fen-phen aair has spawned thousands of lawsuits and a multitude of scientic studies concerning
valvular heart disease. It has also led to a lively debate over o-label prescriptions, medical monitoring,
and class actions. The proposed Settlement Agreement, while an attempt to put an end to the valvular
litigation, will not be the end of the fen-phen aair. The Settlement Agreement has been widely criticized
and plaintis' lawyers have indicated that there will be a large number of opt-outs, which could lead to
a termination of the Agreement by American Home Products. In addition, PPH claims are generally not
settled by the Agreement and plaintis are free to pursue those claims in court. American Home Products
may be facing liability for fen-phen for years to come, and there is still much to be learned about the valvular
heart disease associated with Redux and Pondimin use. In addition, there are new diet drug concerns related
to an attempt to recreate fen-pen by the use of Prozac in place of Redux and/or Pondimin, and the new
diet drug Meridia works in a very similar way to Redux and Pondimin. The lessons learned from fen-phen
will be invaluable in other mass-tort pharmaceutical drug liability situations, and also with other diet drugs
that are currently or soon to be on the market.
PART I
THE WIDESPREAD USE OF FEN-PHEN, THE WITHDRAWAL OF FENFLURAMINE AND DEXFENFLURAMINE FROM THE MARKET, AND RESULTING HEALTH PROBLEMS OF FORMER FEN-PHEN USERS
3FEN-PHEN { THE DIET DRUGS
FENFLURAMINE, DEXFENFLURAMINE, AND PHENTERMINE
The Fen-Phen Cocktail
The combination of drugs popularly referred to as \fen-phen" actually consists of a cocktail of two drugs, fen-
uramine (Pondimin) or dexfenuramine (Redux) (the \fenuramines") and phentermine. The fenuramine
or dexfenuramine is the \fen" part of the drug combination, and the phentermine makes up the \phen"
portion.3 It is the \fen" part of the fen-phen cocktail which is the alleged cause of the medical problems
at issue in the fen-phen litigation. Dexfenuramine and fenuramine are the drugs that are associated with
the problems and they have been removed from the market. Phentermine is still on the market and is not
generally considered to have caused the health problems associated with the fen-phen combination.
The Food and Drug Administration (\FDA") approved fenuramine in 1973 and phentermine in 1959 as
\INDIVIDUAL agents for short-term use [a few weeks] in the medical management of obesity. The use of the
products concomitantly has never been approved in the United States, although recently, the combination of
the two products has been used `o-label' by many American health care practitioners for the management
of obesity."4 An article written by Michael Weintraub5 in 1992 indicated that the use of fenuramine and
3See U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), FDA An-
nounces Withdrawal Fenuramine and Dexfenuramine, CDER Website P97-32, Sept. 15, 1997, online at
www.fda.gov/cder/news/fenphenpr81597.htm
4U.S. Food and Drug Administration/U.S. Department of Health and Human Services Public Health Service, Reports of
Valvular Heart Disease in Patients Receiving Concomitant Fenuramine and Phentermine, FDA Public Health Advisory,
Dear Health Professional Letter, July 8, 1997.
5Michael Weintraub, the researcher who began the fen-phen craze, was a University of Rochester obesity researcher when he
wrote about the o-label long-term combination use of fenuramine and phentermine. His actions and behavior from the 1992
study forward have raised serious ethical and moral concerns. Weintraub joined the FDA in 1993 as a top ocial, and he served
as division director for over the counter drugs and head of an oce that managed three divisions. While at the FDA he served
on a fen-phen task force formed in 1997 to review reports of valvular heart disease in fen-phen patients. Weintraub was at the
FDA for ve years, and he left in 1998 to become a pharmaceutical industry consultant. While at the FDA, Weintraub agreed
to advise John Trevena, a Florida lawyer, about starting a diet-center business. Trevena was to use fen-phen at his centers.
Trevena was a fen-phen user himself who later developed valvular regurgitation, as did his wife, also a fen-phen user. His diet
centers failed and he went into business and personal bankruptcy. Trevena is now practicing law in the private sector and has
4phentermine together could produce dramatic weight loss eects.6 The article indicated that \the anorexi-
genic eects of fenuramine could be duplicated and its side eects minimized by the use of smaller doses of
the drug in combination with phentermine"7 The authors reported that the fen-phen combination was safe
and eective.8 After the publication of this article, which studied 121 obese patients who lost an average of
30 pounds while using fenuramine and phentermine, the popularity of fen-phen spread quickly.9 By 1996
total U.S. prescriptions for fenuramine and phentermine together reached a number over 18 million.10 Most
of the use of fen-phen was in women and in people under 60 years of age. Overall, \[b]ased on an assumed
treatment course of 3-12 months and an average prescription length of 1 month, an estimated 1.2-4.7 million
led a lawsuit against Wyeth-Ayerst that he has attempted to get the government to join and prosecute, to no avail. Trevena
had oered to pay Weintraub for his diet center advice, but Weintraub refused to accept money because of governmental ethics
policies. However, Weintraub made sta recommendations for Trevena's medical centers, spoke favorably about the centers to
the media, allowed his name to be used in advertising for the centers, talked with and wrote to prospective Trevena clients who
were considering the use of fen-phen, and ew to Florida to recommend that the State Medical Board not ban fen-phen. One
Trevena center client who spoke with Weintraub about fen-phen asked for a physician referral and Weintraub sent back a reply
on FDA stationary that recommended Trevena's marketing consultant. Weintraub said that he saw himself oering Trevena
the same help that he gave others, and he did not consider himself as helping Trevena start his diet business. He said he may
have spoken to some potential Trevena clients, but he did not recall for sure. He said that he always used a checklist that
included all potential side eects when anyone asked about fen-phen and he stressed the need for a full physical. Weintraub
said that he could not reject talking to people who called him regarding fen-phen because he believed that the drugs could be
of great benet to people. Weintraub claims his FDA superiors knew of his work but did not object because he informed them
that he was not being paid by outside interests.
See Donna Shaw, Tarnish on FDA's Vaunted Image: The Researcher Responsible For the Fen-Phen Drug Used
His Expertise To Promote A Florida Diet Center, Philadelphia Inquirer, Sept. 26, 1999, available online at
www.phillynews.com/inquirer/99/Sep/26/front page/DIE126.htm.; See also Kris Huntley, Fen-Phen King Turns Tables On
Drug Maker: Once a Promoter and User of the Weight-Loss Drug Combination, John Trevena Has Filed a Civil Suit Against
Drugmaker Wyeth-Ayerst Laboratories, Inc., Accusing It of Fraud, St. Petersburg Times, Oct. 10, 1999, Business Section.
6See M. Weintraub et al., Long-term weight control study: I-VII, 51 Clinical Pharmacology and Therapeutics 581-646 (1992)
See also Jaime A. Wilsker, One Half-Phen In the Morning/One Fen Before Dinner: A Proposal For FDA Regulation of O-
Label Uses of Drugs, 6 J.L. & Pol'y 795, 823 (1998) for a discussion of Dr. Weintraub's fen-phen study. In the study, he
administered the combination of 60 mg fenuramine and 15 mg phentermine in addition to behavior modication to 121 obese
women for 190 weeks. He found this combination drug therapy to lead to signicant weight loss over 210 weeks. 26 out of the
121 patients lost more than 10% of their body weight. Id.
7Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation { The
Journal of the American Heart Association 1999:99 156-161, 158 (1999).
See also: U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and
Answers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online at
www.fda.gov/cder/news/phen/fenphenqa2.htm. On the Q+A website, the FDA says that \the results of these studies were not
reviewed by FDA, and the conclusion about long term use of the combination of drugs has not received FDA approval." Id.
8See Weintraub, M., Sundaresan, R.P., Schuster, B., Averbuch, M., Stein, E.C., and Byrne, L. Long-Term Weight Control
Study V (Weeks 190-210); Follow-Up of Participants After Cessation of Medication, Clinical Pharmacological Therapy
51, 651-618 (1992).
9See Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The Story of How Fen-Phen and Redux Came to Be
Used By 6 Million Americans is Chilling, 34 Trial 78 (1998).
10See CNN Interactive, Valvular Heart Disease Associated With Fenuramine-Phentermine { Dr. Heidi M. Connolly {
Manuscript Of Study Submitted To New England Journal of Medicine, CNN Website, July 8, 1997, available online at
www.cnn.com/Heath/0/07/08/fenphen.report/.
5persons in the United States have been exposed to these drugs."11 From 1992 to 1997, new prescriptions for
fen-phen (phentermine and fenuramine) increased by 442% for phentermine and 6390% for fenuramine.12
Many of these prescriptions had been given by doctors who had only a cursory relationship with the patient.
Patients were able to get fen-phen prescriptions over the internet, and Nutri-System and Jenny Craig set up
\medical weight loss" programs where doctors prescribed large numbers of fen-phen to patients with whom
they did not have long term relationships.13
Dexfenuramine was made by Wyeth-Ayerst Laboratories in Philadelphia, Pennsylvania, under a license
from Interneuron Pharmaceuticals, Inc. of Lexington, Massachusetts. Wyeth-Ayerst is a subsidiary of
American Home Products, Inc. Fenuramine was made by A.H. Robins Co., Inc. of Richmond, Virginia.
A.H. Robins Co. was also a subsidiary of American Home Products (see later discussion of American Home
Products). American Home Products is the corporation at issue in the fen-phen litigation. American Home
Products Corporation has proposed to settle the legal claims surrounding the fenuramines in the proposed
Settlement Agreement discussed at length later in this paper.14 Phentermine, the other half of fen-phen, is
not implicated in the proposed Settlement Agreement, has been dismissed from most lawsuits, and has not
been taken o the market.
11Centers for Disease Control, U.S. Department of Health and Human Services Interim Public Health Recommendations, Car-
diac Valvulopathy Associated with Exposure to Fenuramine or Dexfenuramine, CDC Morbidity and Mortality Weekly
Report 1061 Vol. 46, No. 45, Nov. 14, 1997.
12See Archives of Internal Medicine Vol. 157 502-604, March 24, 1997.
13One Illinois plainti said that she obtained fen-phen from a weight-loss clinic and never saw a doctor. She regularly saw
a nurse who gave her the fen-phen prescriptions. Nutri-System centers highlighted the fact that a doctor would provide a fast
check-up and then a fen-phen prescription. Fen-phen could easily also be obtained over the Internet. One doctor, Peter Hitzig,
advertised that he would prescribe fen-phen by other means if you could not make it physically to his oce. Most of these
doctors had little or no training in obesity. See Jaime A. Wilsker, One Half-Phen In the Morning/One Fen Before Dinner:
A Proposal For FDA Regulation of O-Label Uses of Drugs, 6 J.L. & Pol'y 795, 827-828, (1998). This common practice
broke down the alleged careful risk-benet calculation a doctor was supposed to engage in with his or her patient to determine
if the risks of obesity were greater or lesser than the risks associated with fen-phen. The fen-phen risk at issue before the
valvular disease problem became known was the increased PPH risk. See Martha Neil, Lawyer Seeks Plainti Group to Bolster
Diet-Drug Litigation, Chicago Daily Law Bulletin Vol. 143 No. 184, Sept. 19, 1997.
14See Two Weight-Loss Drugs Disrupt Certain Brain Functions in Animals, Doctor's Guide & Other Medical News,
Aug 26, 1997.
6Fenuramine and Dexfenuramine
Dexfenuramine and fenuramine (the \fenuramines") are \cogeners of amphetamines" and are anorectic
agents.15 Both fenuramine and dexfenuramine work by \aecting the metabolism of the neurotransmitter
serotonin in the brain".16 Fenuramine and dexfenuramine promote the rapid release of serotonin and
inhibit its reuptake.17 By getting into the brain and changing serotonin levels, the fenuramines make their
users experience positive feelings and believe they are full. The drugs \trick" the brain into believing that
the user does not desire any more food. The fenuramines are pharmacologically similar to anti-depressants
such as Prozac, and several patients on fen-phen indicated that they felt less depressed while taking the
drugs, although much more so with dexfenuramine than fenuramine18 Fenuramine (Pondimin) did not
have the same anti-depressant eect to the degree of dexfenuramine (Redux) and therefore dexfenuramine
became a popular \fen" part of the fen-phen combination.19
Fenuramine was approved by the FDA in 1973 as a short term single use appetite suppressant. It was to
be used in combination with a diet and exercise weight-loss plan.20 It was not approved as a combination
drug. It is a Class IV controlled substance, which means that there is a low potential for abuse of the drug.
Fenuramine was sold under the trade names Pondimin and Ponderol, and it was produced by A.H. Robins,
a subsidiary of American Home Products. Fenuramine is a sympathomimetic amine, which is a drug that
15See Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 157.
Anorectic agents are appetite suppressants. Anorectic means \characterized by lack of appetite" The New Shorter Oxford
English Dictionary 83 (1993)
16Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Cardiac Valvulopathy Associated with Exposure to Fenu-
ramine or Dexfenuramine; U.S. Department of Health and Human Services Interim Public Health Recommendations, available
online at www.dietdrugsettlement.com.
17See John T. Evans and Robert L. Kerner, Jr., A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def.
Couns. J. 353, 355 (1998).
18See Telephone Interview with Tori Marnell, M.D., University of Texas - Southwestern Medical School in Dallas, Physician
in Tulia, Texas (March 18, 2000).
19See Fenuramine seemed to produce more depression than stimulation in patients, unlike most other similar drugs. Several
patients on fenuramine complained of depression, and many were switched to dexfenuramine as a result of their complaints.
See Interview with Dr. Tori Marnell (March 18, 2000). See also Evans and Kerner, A Primer on Fen-Phen Litigation:
Allegations and Defenses, 65 Def. Couns. J. at 354.
20See Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 354.
7\mimic[s] sympathetic nervous system stimulation", although fenuramine produced more depression than
stimulation, unlike other sympathomimetic amines. The usual fenuramine dose is 20 milligrams three times
per day, which may be increased by one tablet after each week of use. The maximum dose is 120 milligrams
per day. Fenuramine is:
contraindicated in patients with glaucoma, hypersensitivity to sympathomimetic amines, his-
tory of drug abuse, history of psychosis and/or symptomatic cardiovascular disease. Fenu-
ramine has been shown to cause paranoia, depression and psychosis in alcoholics. It has been
associated with numerous cases of pulmonary hypertension and there is one report of fatal
cardiac arrest following induction of anesthesia. Fenuramine is not recommended for use in
children under 12 years of age. It is embryonic in rats, but there have been no adequate studies
involving pregnant women.21
Dexfenuramine,22 the dex isomer of fenuramine, was approved on April 29, 1996, also as an appetite
suppressant.23 It is a puried form of fenuramine, and it was thought to have less side eects and toxicity
than fenuramine. It acts in basically the same way as fenuramine, as a serotonin reuptake inhibitor and
releaser.24 Dexfenuramine can be pharmacologically distinguished from fenuramine in that \fenuramine
contains dexfenuramine and levofenuramine. Levofenuramine may have some activities not directly re-
lated to appetite suppression. Dexfenuramine contains only dexfenuramine."25
22The corporate history of Redux's approval and marketing is as follows \Les Laboratories Servier, S.A., a French phar-
maceutical company, held the intellectual property rights to dexfenuramine and entered into a licensing agreement with
Interneuron for the development of dexfenuramine in the United States market. Interneuron is in the business of testing
pharmaceuticals and obtaining FDA approval for their sale in the United States. Following FDA approval of dexfenuramine,
Interneuron sublicensed the United States distribution rights for dexfenuramine to an entity which is now American Home
Products Corporation. American Home Products marketed dexfenuramine under the brand name `Redux' and began sell-
ing the drug in June 1996. Under the sublicensing agreement, Interneuron received royalties from American Home Products'
sales of Redux.... An estimated 2 million individuals ingested Redux during the course of its almost sixteen-month market
life." In re Diet Drugs Products Liability Litigation (Phentermine, Fenuramine, Dexfenuramine), MDL Docket No. 1203
Civil Action No. 98-20594, Memorandum and Pretrial Order, U.S. District Court for the Eastern District of Pennsylvania.
23Note: the Redux labeling indicated that safety had not been shown for over one year of use of Redux. This one year
limit reects the length of the study upon which the FDA approved dexfenuramine. The study took place in Europe, it
had 1,000 subjects, and 500 of those subjects were given dexfenuramine. 80% of the subjects were women and the average
age was 41. There was no note of heart disease, and no follow up study to determine the presence of heart disease was
undertaken. Dexfenuramine had been on the market in Europe for over 10 years without any indication of a link between
dexfenuramine and heart disease. See U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER),
Questions and Answers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online
at www.fda.gov/cder/news/phen/fenphenqa2.htm.
24See Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 158.
25U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and An-
swers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online at
www.fda.gov/cder/news/phen/fenphenqa2.htm.
8Dexfenuramine (Redux) was the rst anti-obesity drug approved in the U.S. in over 20 years, and sales of
Redux were expected to reach $1 billion within the rst ve years of use.26 Dexfenuramine was approved as
a \single-drug, prescription appetite suppressant for longer term use in markedly obese persons, noting that
safety beyond 1 year of use had not been established in clinical trials."27 Literature from Redux manufac-
turers stated of the drug, \Redux, combined with a reduced-calorie diet, is indicated for the management of
obesity, including weight loss and maintenance of that weight loss. In clinical trials, Redux helped produce
a signicant reduction in weight during the rst 4 to 6 months, and that loss was maintained during the
year-long therapy. The safety and eectiveness of Redux beyond one year have not been determined."28
Redux's popularity came about partly because of its anti-depressant aects, and it quickly became popular
as a part of the fen-phen cocktail.
Dexfenuramine's \[a]pproval did not have an easy passage: the vote for approval was close, 6:5. After
approval, a unanimous vote insisted on postmarking studies and careful labeling concerning patient selec-
tion."29 Initially, the FDA Advisory Committee declined to approve Redux by a ve to three vote. They
cited inadequate evidence of the drug's safety. After Redux's approval, \many neuroscientists sent a letter
to the FDA, criticizing the agency for ignoring animal tests that suggested that prolonged use of Redux
damaged brain tissue."30
The dicult approval of dexfenuramine also came amidst concerns about PPH. Reports of PPH linked to
the fenuramines had appeared throughout the European literature in the 1980's and 1990's.31 Two months
26See Archives of Internal Medicine Vol. 157 502-604, March 24, 1997.
27See Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Cardiac Valvulopathy Associated with Exposure to Fenu-
ramine or Dexfenuramine; U.S. Department of Health and Human Services Interim Public Health Recommendations, available
online at www.dietdrugsettlement.com.
28Letter from Marc W. Deitch, M.D., Senior Vice President, Medical Aairs and Medical Director, Wyeth-Ayerst Laboratories
Division of American Home Products Corporation, to Redux Prescribing Physicians (Aug. 22, 1997).
29Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 158.
30Apryl A. Ference, Rushing to Judgment on Fen-Phen and Redux: Were the FDA, Drug Manufacturers, and Doctors Too
Quick To Respond To Americans' Infatuation With A Cure-All Diet Pill For Weight Loss?, 9 Alb. L.J. Sci. & Tech. 77, 84
(1998).
31See Roche, N., Labrune, S., Braun, J.M., and Huchon, G. Letter on Pulmonary Hypertension and Dexfenuramine, Lancet
339, 436-437, (1992).
9after dexfenuramine's approval, the International Primary Pulmonary Hypertension Study (\IPPHS") in-
dicated that anorectic agents increased PPH to a level of between 23 and 46 per million, rather than the
normal 1-2 per million background risk. However, concern over the increased PPH risk from the IPPHS
was considered by many to be outweighed by the potential for the fenuramines to contribute to weight loss
for the seriously obese. One editorial in the New England Journal of Medicine stated, \the possible risk of
pulmonary hypertension associated with the use of dexfenuramine is small and appears to be outweighed
by the benet (from treating obesity) when the drug is used appropriately."32 The FDA did approve Redux
\only on the condition that it be prescribed for obesity, dened as a body mass index of 30 kilograms/m2
or greater."33 The brochure Wyeth-Ayerst provided to doctors for Redux patients said of the PPH risk:
There is a small risk of a serious, potentially life-threatening cardiovascular condition called
pulmonary primary hypertension associated with the use of prescription weight-loss drugs.
In a review of PPH cases where any weight-loss drug was used (excluding 10 cases where the
specic drug or date of use were unknown), the risk was estimated to be about 18 cases per
1 million patients per year. In the general population, the yearly incidence of PPH is one to
two cases per million persons. Warning signals of PPH are shortness of breath, chest pain,
fainting, and swelling of the legs, ankles, or feet. If you have had any of these symptoms
before starting Redux therapy, or if they occur during therapy, please discuss them with your
health care provider34
After its approval, dexfenuramine, marketed as Redux, appeared in stores in June of 1996.35 Much ad-
vertising surrounded its release, and 1.2 million Redux prescriptions were lled. Amid the excitement over
Redux and the massive advertising program, \little heed was paid to the manufacturer's cautions about du-
ration of use or to drug interactions with other serotonin releasers. No information was provided { because
none was available { about the eectiveness and consequences of taking the drug for > one year. Lost in the
hyperbole of advertising was the limited ecacy of the drug, i.e., that continued usage leads only to small
32Manson, J.E. and Faich, G.A. Editorial - Pharmacotherapy For Obesity: Do The Benets Outweigh The Risks?, N. Engl.
J. Med. 335, 659-660, (1996).
33Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 355.
35See Interneuron Pharmaceuticals licensed Redux to Wyeth-Ayerst (American Home Products subsidiary) for marketing.
See Michael D. Lemonick et al., The New Miracle Drug? There's Great Excitement About Redux, The First Diet Pill Approved
By The FDA In 23 Years. But It's Hardly The Ideal Way To Lose Weight, Time, Sept. 23, 1996, at 61, 63.
10sustained weight loss averaging 10% compared with the 6% weight loss of control subjects."36 For both the
obese and the non-obese, dexfenuramine was widely prescribed in combination with phentermine, until the
report by the Mayo Clinic in 1997 set o the alarm over valvular heart disease.
Dexfenuramine and fenuramine were both pulled from the market after the 1997 Mayo Clinic discovery of
a high incidence of valvular heart disease among fen-phen users. The 1998 Physician's Desk Reference \con-
tains an introductory warning that fenuramine has been reported to be associated with serious regurgitant
cardiac valvular disease."37
Phentermine
The FDA approved phentermine in 1959 as an appetite suppressant, marketed under the trade names
\Fastin", \Adipex", and \Ionamin". It is marketed primarily by SmithKline Beecham. Phentermine, like
fenuramine, is a Class IV controlled substance.38 The usual phentermine dose is 30 milligrams per day,
taken in the morning. Phentermine is to be used \only for a few weeks as an adjunct to a diet,"39 and under
strict doctor's supervision. Phentermine acts as a stimulant, and it was approved for single drug use for a
few weeks for obesity treatment. Phentermine increases the metabolism and aects dopamine levels in the
brain. It is a nonamphetamine appetite suppressant, although it can produce the same adverse eects as
amphetamine appetite suppressants. Phentermine produces \central nervous system stimulation, elevation
of blood pressure, tolerace and tachyphylaxis. Tachyphylaxis is the rapid immunization of the body to a
toxic dose of a drug."40 Phentermine was thought to reduce undesirable side eects of fenuramine, like
36Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 158.
37Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 355.
38See Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 354.
39Bert Stern and Lawrence D. Chilnick, The Pill Book 5th edition 708 (1992).
40Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 354.
11drowsiness.41 Common side eects of phentermine include \a false sense of well-being, nervousness, over-
stimulation, restlessness, and trouble sleeping."42 Less common side eects include palpitations, high blood
pressure, weakness, dizziness, and headache.43
Phentermine is generally not implicated in the fen-phen litigation44, and it has not been pulled from the
market by the FDA. Dr. Heidi Connolly, the Mayo Clinic doctor who rst discovered the valvular heart
disease problem associated with fen-phen use, said \initially we thought it may be the combination of medi-
cations (fenuramine and phentermine) that caused the valve problems, but it appears to be the fenuramine
medication alone."45 Phentermine appears safe when used alone, and by itself has not proven to be a cause of
valvular regurgitation.46 In the FDA's Question and Answer section on its Fen-Phen Website, the question
\[w]hy isn't phentermine being withdrawn from the market" is answered with, \[a]t the present time, no cases
of heart valve disease meeting FDA's case denition have been reported with phentermine alone. Analysis
41See Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The Story of How Fen-Phen and Redux Came to Be
Used By 6 Million Americans is Chilling, 34 Trial at 78.
42Bert Stern and Lawrence D. Chilnick, The Pill Book 5th edition 706 - 707 (1992).
43See id.
44On January 11, 2000 Judge Bechtle in the multi-district litigation in Philadelphia ruled on several plaintis' motions to
amend their complaints to add phentermine defendants. The phentermine defendants objected to being added at the late stage
in the case where discovery was almost complete. The phentermine defendants claimed that they would be unduly prejudiced
by having to begin discovery after numerous deadlines in the multi-district litigation had passed. The plaintis argued that the
phentermine defendants were aware of the issues involved in the multi-district litigation and therefore would not be prejudiced
by being added at the later date. The plaintis also stated that the phentermine defendants could participate in discovery
that had not yet gone forward. Judge Bechtle denied the motions of the plaintis since they sought to add the phentermine
defendants at such a late stage, and because the plaintis did not timely serve their amended complaints upon the phentermine
defendants pursuant to Pretrial Order No. 19 of the multi-district litigation. Pretrial Order No. 19 required the plaintis to
serve their complaint and a summons on each defendant not served previously no later than 30 days after the date on which
their action was docketed in the Eastern District of Pennsylvania.
See: In re Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Davoust v. Wyeth-Ayerst v. American Home Products Corporation
and Howard v. A.H. Robins Co. v. American Home Products Corporation, Memorandum and Pretrial Order No. 1056, U.S.
District Court for the Eastern District of Pennsylvania, Jan. 11, 2000, WL 62307. (E.D. Pa.).
45Fen-Phen Valvulopathy Presented by Heidi M. Connolly, M.D., F.A.C.C., Cases in Echocardiography, Directed by
Rick A. Nishimura, M.D., F.A.C.C. and Fletcher A. Miller, Jr., M.D., F.A.C.C., Edited Transcript of a Talk Presented by Dr.
Connolly at the Heart House Learning Center, (1999).
46See Edward G. Lance, IV and Philip Tortorich, Popular Diet Drugs Pulled From Market, 9 Loy. Consumer L. Rep. 296
(1997).
One article discussing the fen-phen litigation summed up the situation of phentermine with the statement: \Phentermine, the
other half of the fen-phen mix, hasn't been liked to problems when taken alone. It is made by another company [than American
Home Products] and is still on the market." Amy Westfeldt, Many Decline Diet Drug Settlement, Associated Press, Oct. 15,
1999.
12of the data points to an association of heart valve disease with fenuramine and dexfenuramine."47 The
data so far indicates that the valvular heart disease and PPH increase is associated with serotonin levels and
serotonin absorption. The fenuramines are the drugs that aect brain serotonin metabolism, while phen-
termine acts primarily only as a stimulant. The problem that comes in with phentermine use in combination
with fenuramine and dexfenuramine use is that phentermine \interferes with the pulmonary clearance of
serotonin, which may explain its association with primary pulmonary hypertension."48 Since fenuramine
and dexfenuramine cause an increase in the amount of serotonin released by the body and a decrease in the
amount the body reabsorbs, when phentermine interferes with the pulmonary clearance of that serotonin,
it magnies the serotonin related eects of the fenuramines in the lungs. Phentermine alone is not the
problem, but it can compound the problems caused by fenuramine and dexfenuramine. Independent of
serotonin problems, phentermine can also cause cardiac arrhythmias and increased blood pressure (a danger
with all stimulants).49
While phentermine alone appears not to cause the valvular problems and PPH associated with combined use
with phentermine and dexfenuramine or fenuramine, the FDA stated that phentermine \has only mixed
[weight loss] results when used alone."50 However, some patients who had weight loss success with fen-phen
are now having continued weight loss success with phentermine alone.51
In one of the rst major fen-phen cases, Linnen, which eventually settled in January of 2000, Judge Raymond
Brassard of the Massachusetts Superior Court dismissed a former phentermine manufacturer on the grounds
that the plaintis failed to present sucient evidence that phentermine contributes to or causes PPH. Judge
Brassard ruled to exclude the testimony of Texas A&M University scientist Paul Wellman, stating that
47U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and An-
swers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online at
www.fda.gov/cder/news/phen/fenphenqa2.htm
48Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 354.
49See Archives of Internal Medicine Vol. 157 502-604, March 24, 1997.
50Lance and Tortorich, Popular Diet Drugs Pulled From Market, 9 Loy. Consumer L. Rep. at 296.
51See website of Ben Krentzman, M.D., available online at www.loop.com/bkrentzman.
13there was \no evidence that Wellman `utilized sound scientic methodology in arriving at his opinions in
this case."'52 The conclusions of Paul Wellman were cited in over 400 fen-phen suits in the United States,
so Judge Brassard's decision is likely to have wide-ranging eects on phentermine manufacturer liability in
all fen-phen litigation. Judge Brassard reached his decision on expert testimony admissibility pursuant to
the standards set forth in Daubert v. Merrell Dow Pharmaceuticals, Inc. and Commonwealth v. Lannigan.
Judge Brassard found that there was \no testing of the [plaintis'] experts hypotheses, no known error rate,
lack of acceptance among the scientic community for the hypotheses proposed by the experts, and an insuf-
cient degree of scientic certainty by the experts themselves regarding their key theories."53 The lawyers
for the phentermine manufacturers expressed the hope that \this decision will mark a turning point in all
of the fen-phen litigation... [and stated that] Judge Brassard's thorough and thoughtful decision is likely to
inuence the court's approach to this issue nationwide."54 Phentermine is also not included in the proposed
Settlement Agreement with American Home Products. The proposed settlement agreement for the diet drug
litigation only addresses fenuramine (Pondimin) and dexfenuramine (Redux), not phentermine.
NEW DIET DRUGS REPLACING FENFLURAMINE AND DEXFENFLU-
RAMINE
Meridia
While both fenuramine and dexfenuramine have been pulled from the market in light of the valvular prob-
lems and PPH risk increase, the current diet drug Meridia (sibutramine) also works by aecting serotonin
52Bloomberg, Judge Balks at Testimony in AHP Fen-Phen Lawsuit, Paper Says, Madison, New Jersey Bloomberg Re-
port, Jan. 6, 1999.
53Business Wire { Boston, Phentermine Dismissed From Massachusetts `Fen-Phen Case, Business/Legal Editors, Jan. 7,
2000.
54id.
14levels in the brain, making the user believe he or she is full.55 The FDA approved sibutramine on November
24, 1997. It is also an appetite suppressant and works by inhibiting the re-uptake of serotonin and nore-
pinephrine (neurotransmitters that send messages in the brain).56 Fenuramine and dexfenuramine worked
by aecting the release of brain neurotransmitters. The dierence between Meridia and the fenuramines
is that Meridia does not cause an increase in the release of serotonin from nerve cells, rather it only slows
the body's reabsorption of serotonin that was naturally produced.57 Several experts claim that it was the
release of serotonin from nerve cells that caused the PPH and valvular heart damage associated with the
fenuramines.58 However, the FDA stated that clinical studies on Meridia did not show any increased PPH
risk or any higher rates of valvular heart disease in Meridia users.59 However, in light of the problems with
fen-phen, Meridia does not remain an extremely popular anti-obesity drug today, and it is target marketed
at the clinically obese, with more care taken to avoid the fen-phen type of rampant use for cosmetic weight
loss.60 Meridia's manufacturer, Knoll Pharmaceuticals, has been \conservative and cautious in its recom-
mendations and advertisements. The company's market launch, described by one journalist as `low-key',
is replete with warnings and caveats that conne the administration of Meridia to a highly restricted class
of obese patients.... Knoll cautions cosmetic dieters against using the product, and it intends to chastise
doctors who prescribe the drug for patients the company does not consider appropriate for treatment with
Meridia".61 Both Meridia's manufacturer and the FDA want to prevent the type of rampant cosmetic weight
loss use with Meridia that plagued fen-phen. \Dr. James Bilstad, FDA's metabolic drug chief, told USA
55See Interview with Dr. Tori Marnell (March 18, 2000).
56See Heart Information Network, Anti-Obesity Drug Sibutramine Approved by FDA { Not Recommended for Heart Patients,
Heart Information Network Website, Nov. 1997, available online at www.heartinfo.org.
57See id.
58See Mayo Clinic Health Oasis, Heart Valve Disease and Fen-Phen: An Interview With Mayo Cardiologist Heidi Connolly,
M.D., Mayo Clinic Website, July 8, 1997, available online at www.mayohealth.org/mayo/9707/htm/fen.lsb.htm.
59See Heart Information Network, Anti-Obesity Drug Sibutramine Approved by FDA { Not Recommended for Heart Patients,
Heart Information Network Website, Nov. 1997, available online at www.heartinfo.org.
60Many doctors do not want to put their patients on Meridia in light of its similarities with fenuramine and dexfenuramine.
Xenical is the more popular drug to prescribe to patients to lose weight, since it does not aect serotonin levels and works
completely dierently than the fenuramines. See Interview with Dr. Tori Marnell (March 18, 2000).
61Steven R. Salbu, The FDA And Public Access To New Drugs: Appropriate Levels Of Scrutiny In The Wake of HIV, AIDS,
and the Diet Drug Debacle, 79 B.U. L. Rev. 93, 128 (1999).
15Today that sibutramine is not intended to be used by people who simply want to lose a few pounds { it
is for people who are obese. Specically, the FDA reports that sibutramine is indicated for people with a
body mass index (BMI) of 30 or more (e.g. a person 5'6 weighing 185 pounds or more).62 People with other
risk factors such as diabetes are also candidates for the drug if their BMI is at least 27 (e.g. a person 5'6
weighing at least 167 pounds). The drug is indicated for use with a reduced calorie diet."63
FDA clinical trials with over 6,000 people showed that Meridia combined with a reduced calorie diet and
exercise could lead to a weight loss in 6 months of between 10 to 15 pounds (depending on dose) that could
be maintained for one year. Meridia's common side eects include headache, dry mouth, and insomnia.
Meridia can also lead to an increase in blood pressure and is not recommended for patients with heart
disease, congestive heart failure, or patients with a stroke history.64 The American Heart Association urges
caution when considering Meridia because in some individuals it elevated blood pressure or led to increased
pulse rates or irregular heartbeats (atrial brillation).65
Xenical
The more popular diet drug today, Xenical, does not work by aecting serotonin levels like the fenu-
ramines.66 Xenical works by preventing absorption of fat by the body, and uncomfortable stomach pains
caused by eating fatty foods while on Xenical can work to `train' patients to cut their fat intake. Because
62The literature that accompanied fen-phen also included this guideline of above 30 BMI. See Interview with Dr. Tori Marnell
(March 18, 2000).
63Heart Information Network, Anti-Obesity Drug Sibutramine Approved by FDA { Not Recommended for Heart Patients,
Heart Information Network Website, Nov. 1997, available online at www.heartinfo.org.
See also FDA Talk Paper, FDA Approves Sibutramine to Treat Obesity, USA Today, Nov. 24, 1997; Damaris Christensen,
FDA Approves New Obesity Alternative, Medical Tribune News Service, Nov. 25, 1997; and FDA Approves New Diet Drug,
Reuters Health Information Services, Inc., Nov. 25, 1997.
64See Heart Information Network, Anti-Obesity Drug Sibutramine Approved by FDA { Not Recommended for Heart Patients,
Heart Information Network Website, Nov. 1997, available online at www.heartinfo.org.
65See American Heart Association, AHA Urges Caution on New Diet Drug (NR 97-4832 Statement/Meridia), American
Heart Association Media Advisory, Dallas, Texas, Nov. 1998.
66See Interview with Dr. Tori Marnell (March 18, 2000).
16Xenical does not work like the fenuramines, it is signicantly more popular than Meridia as a weight loss
drug today in light of the PPH and valvular heart disease scares associated with the fenuramines. Some
patients are not as enthusiastic about Xenical as they were about fen-phen because of its unpleasant eects
on the stomach when patients eat fatty foods. However, in light of Meridia's similarities to Redux and
Pondimin in terms of aecting serotonin, Xenical is currently the more popular diet drug. Doctors have had
good results with Xenical and it has not produced any seriously harmful side eects at the present time.67
\Phen-Pro" { Prozac and Phentermine
Although there have been no studies on the use of Prozac and other anti-depressants in conjunction with
phentermine in an attempt to recreate the fen-phen weight loss phenomenon, some doctors have been pre-
scribing this combination using Prozac and its close relatives to mimic the use of the fenuramines in a
\new" fen-phen cocktail.68 After the FDA had already warned of the dangers of long-term use of the fen-
phen combination but before Redux and Pondimin were pulled from the market, \a spokesperson for the
Nutri-System Weight Loss Centers announced that the company would discontinue its use of the appetite
suppressant drugs [fenuramine and dexfenuramine] in the treatment of obesity. Instead, phentermine
and the anti-depressant Prozac will be prescribed at the weight loss centers. This combination is known
as phen-pro."69 Despite use of this combination, the FDA has not established that the phen-pro combi-
nation is safe and eective. On the FDA website appears the question \[c]an selective serotonin reuptake
inhibitor (SSRI) antidepressants such as Prozac, Zoloft, Luvox and Paxil be substituted for fenuramine in
67See id.
68Eli Lilly has come out against the use of Prozac in combination with phentermine. The manufacturers of Ionamin (phen-
termine) have also sent letters to physicians stating that their product should not be combined. See Ben Krentzman, M.D.,
What About Phen-Pro?, available online at http://www.loop.com/bkrentzman/editorials/morefaqs.htm.
69Heart Information Network, Weight Loss Center Responds to New Warnings About Fen-Phen, Heart Information Net-
work Website, available online at www.heartinfo.org. See also Nutri-System is Dropping Fen-Phen Drug, The New York
Times, Sept. 4, 1997.
17the fen-phen combination?", and the FDA responded, \FDA has not reviewed the safety or ecacy of such
combinations and has not approved their use.70 And while the SSRI drugs are similar to the fenuramines
in that they aect \serotonin metabolism,... [they] have somewhat dierent activity than fenuramine and
dexfenuramine. No currently available weight-loss drugs have been studied adequately in combinations to
permit a recommendation by FDA for combined use."71
HEALTH PROBLEMS ASSOCIATED WITH THE FEN-PHEN COMBINATION
There are two major health problems currently allegedly associated with use of the fenuramines. The rst
is vascular heart disease, which is at issue in the proposed class action Settlement Agreement with American
Home Products. The Settlement Agreement covers all valvular heart disease claims by fen-phen plaintis.
The fenuramines-vascular heart disease connection was unknown at the time fen-phen began to be used on
a widespread basis, and it was discovered by Mayo Clinic doctors in 1997.72
70Note: The FDA did not per se approve the use of fenuramine/dexfenuramine and phentermine together either. The
use of fen-phen for extended periods of time was an o-label use of drugs that were approved for single use for short periods.
O-label use is not illegal and is a common practice. Thus forth, absence of FDA approval of use of SSRI antidepressants with
phentermine would not make it an illegal drug, rather it would be an o-label use akin to the use of aspirin for blood thinning
as opposed to pain relief. Many oncology and AIDS drugs are prescribed for o-label use. See Steven R. Salbu, O-Label Use,
Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy, 51 Fla L. Rev
181 (1999).
71U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and Answers
about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, available online at
www.fda.gov/cder/news/phen/fenphenqa2.htm.
72Note: In response to a question on why the valve disease problem was not discovered earlier, the FDA responded by
stating: \The type of valve disease that FDA believes may be associated with fenuramine and dexfenuramine is an extremely
unusual type of drug reaction. Because valve disease is not usually associated with drug use, it is not normally screened for
in human clinical testing of drugs. Since valvular heart disease is not screened for in clinical trials, it would usually not be
detected unless patients developed symptoms. No cases were detected in 500 patients followed for one year in a clinical trial
of dexfenuramine. Furthermore, asymptomatic heart valve disease (heart valve disease without symptoms) would not likely
be detected in patients taking the drugs as part of a weight loss program. The number of patients who have been reported
to have symptoms of heart valve disease associated with recent exposure to the [diet] drugs has been very small, compared to
the number of recent prescriptions, although there may be a delay in the development of symptoms. And even in symptomatic
patients, the link between the symptoms and drug use may not be obvious because such a reaction is not common. These factors
may explain why this problem was not discovered earlier." U.S. Food and Drug Administration Center for Drug Evaluation
and Research (CDER), Questions and Answers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux),
18The second major health problem, which is extremely severe, is PPH. The increased risk of PPH with drugs
like the fenuramines was known at the time fen-phen became extremely popular. An increased risk of PPH
had been identied in European studies and the level was increased by the multinational IPPHS done in
1996, shortly after dexfenuramine's FDA approval. PPH claims are not included in the proposed class
action Settlement Agreement, and plaintis with PPH claims can pursue them in court even if they do not
opt out of the Settlement Agreement.73 The existence of an increased PPH risk was known and identied
during the entire fen-phen craze, and the increased risk found with the IPPHS was eventually reected in
new FDA mandated labeling on the fenuramines. Thus forth, patients were aware of the PPH risk when
they took the diet drugs and presumably patients and doctors assessed that risk in making the decision
whether or not to take fen-phen.74 On the other hand, valvular heart disease was not a known risk and did
not gure per-se into the risk benet calculus of fen-phen patients and their prescribing doctors.75
There is also a third medical problem that may or may not be linked to fen-phen use, which is serotonin
neurotoxicity that may aect brain functions. Because the fenuramines aect brain serotonin levels, several
animal studies have found adverse neurotoxic aects resulting from long-term fenuramines use. No human
studies are available, and the proposed class action Settlement Agreement clearly precludes all present and
future neurotoxicity claims for any plaintis who do not opt-out.
CDER Website, available online at www.fda.gov/cder/news/phen/fenphenqa2.htm
73Pursuant to certain limited restrictions set forth in the Settlement Agreement. Certain PPH claims may be classied as
\Settled Claims".
74However, in many cases that risk was not fully processed by the patients and many doctors did not have careful consultations
with patients to assess the PPH risk. See Interview with Dr. Tori Marnell (March 18, 2000).
75There have been allegations that the valvular heart damage link with anorectic drugs was known throughout most of the
fen-phen craze. In 1994, Dr. Marianne Wealenko, a cardiologist in Belguim, reported nding valvular regurgitation in 7 of her
patients, all of whom had taken anorectic diet pills. She informed the manufacturer and spoke about the unusual link between
leaky valves and anorectic drugs at several obesity conferences. See Vivi Vanderslice, Viability of a Nationwide Fen-Phen/Redux
Class Action Lawsuit in Light of Amchem v. Windsor, 35 Cal. W. L. Rev. 199, 201, (1998).
19Valvular Problems
Discovery of Valvular Problems in Fen-Phen Users and FDA Action
Valvular heart disease occurs when the heart valve is damaged and cannot open properly or does not close
properly, which causes blood to leak backwards.76 Mayo Clinic doctors discovered the link between fen-phen
and valvular heart disease in 1997.77
Dr. Heidi Connolly was the primary author of the clinical observation of valvular heart disease that was
publicly reported in the New England Journal of Medicine on July 8, 1997. It included 24 cases of valvular
heart disease in women who had been treated with fenuramine and phentermine. The report prompted an
FDA Public Health Advisory and the eventual removal of fenuramine and dexfenuramine from the U.S.
market.78 By September 30, 1997 the \FDA had received 144 individual, provider initiated reports involving
fenuramine or dexfenuramine, with or without phentermine, in association with valvulopathy (this total
included the 24 publicly reported cases)."79
The initial problem was identied through Mayo Clinic doctors coming into contact with a series of patients
[24 in total] who had valvular disease and who had also been taking fen-phen. The rst patient they saw
had valve surgery at the Mayo Clinic and developed a second valve problem following the surgery. Dr.
Connolly and her colleagues noted that he did not have an underlying cause for valvular disease such as
76See American Heart Association, AHA Urges Caution on New Diet Drug (NR 97-4832 Statement/Meridia), American
Heart Association Media Advisory, Dallas, Texas, Nov. 1998.
77See Centers for Disease Control, U.S. Department of Health and Human Services Interim Public Health Recommenda-
tions, Cardiac Valvulopathy Associated with Exposure to Fenuramine or Dexfenuramine, CDC Morbidity and Mortality
Weekly Report 1061 Vol. 46, No. 45, Nov. 14, 1997.
78See id.
79Id.
Note: According to the CDC Report, out of those 132 spontaneous reports, 113 met the case denition of fenuramine
or dexfenuramine associated cardiac valvulopathy, which is dened as \documented aortic regurgitation of mild or greater
severity and/or mitral regurgitation of moderate or greater severity after exposure to these drugs". Id. Of the 113 cases, 111
occurred among women, the median patient age was 44, 2% used fenuramine alone, 14% used dexfenuramine alone, 79% used
fenuramine/dexfenuramine and phentermine, and 5% used a combination of dexfenuramine, fenuramine, and phentermine.
The median duration of drug use was 9 months, 77% of the cases were symptomatic, 24% of patients required valve replacement
surgery, and 3 of those patients died after the surgery. See id.
20carcinoid80cancer or having taken the migraine medications ergotamine or methysergide. In January of 1997
Mayo Clinic doctors saw another patient with valvular disease, and additional patients were then referred
to the Mayo Clinic by Dr. Jack Crary, a cardiologist from Fargo, North Dakota. The 24 patients had been
taking fen-phen for an average of 12 months and their average age was 43. Dr. Connolly noted that it was
unusual for patients of that age to have such a high incidence of valvular disease, and none of the 24 patients
had any previously known cardiac or pulmonary disease, aside from high blood pressure. Eight of the women
also had newly documented PPH. Dr. Connolly noted that the pulmonary valve was the least commonly
aected, and that the damaged valves were identical to the valves seen in patients with carcinoid heart disease
(cancer) and in patients with valve damage resulting from use of the migraine medications methysergide and
ergotamine. The damaged valves in the fen-phen users were dierent from valvular damage resulting from
rheumatic heart disease and infection. The damaged valves were thickened and did not function normally.
Fibrous material was layered on the valve leaet and created a glistening white appearance like that of
patients with ergotamine induced or carcinoid induced valvular damage.81 Dr. Connolly noted that \in
carcinoid syndrome, patients with high circulating levels of serotonin are more likely to have valve disease
than those with lower levels. In ergotamine-induced valve disease, it is suggested that valve injury is due to
the fact that ergotamine and serotonin have a similar chemical structure."82 Dr. Connolly followed up on
the connection between serotonin and fen-phen associated valvular heart disease in stating, \[w]e know that
fenuramine { the `fen' in fen-phen { alters serotonin metabolism by promoting its release and decreasing its
reuptake in the brain. And we know that phentermine { the `phen' in fen-phen { may have some eect on
serotonin metabolism in the lung. We postulate that there may be valve injury by the alteration of serotonin
80Carcinoid tumors secrete a large amount of serotonin. \It is the eects of serotonin that are believed to cause severe
regurgitant cardiac valvular disease and pulmonary hypertension. Serotonin is secreted by nuclei that originate in the brain
stem. It acts as an inhibitor of pain pathways in the spinal cord and is believed to control the mood of the person and induce
normal sleep." Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 353.
81See Mayo Clinic Health Oasis, Heart Valve Disease and Fen-Phen: An Interview With Mayo Cardiologist Heidi Connolly,
M.D., Mayo Clinic Website, July 8, 1997, available online at www.mayohealth.org/mayo/9707/htm/fen.lsb.htm.
82Id.
21metabolism in the body. We do know from our experience with other patient groups { the carcinoid patients
and the patients with ergotamine-induced valve disease { that serotonin or serotonin-like structures appear
to be related to valve disease. Pathologically, the carcinoid and ergotamine-induced valve disease is identical
to the ndings in the 24 women reported."83
Dr. Connolly stated that the Mayo Clinic observation suggests that:
there appears to be an association between this combination of medications [fen-phen] and
heart disease, but we can't prove it based on current information... we suspect there is an
association between fen-phen and valve disease, but we don't know who taking this combi-
nation of medications is at risk. We don't know how long the medications need to be taken
before patients might develop this problem. And we don't know whether the valve disorder is
reversible. Of the 24 women we've identied who had valve disease, eight also had moderate
or severe pulmonary hypertension, which had not been previously identied. The cluster of
unusual cases of valve disease in fen-phen users suggested that there might be an association
between fen-phen use and valve disease.84
The Mayo Clinic doctors reported their ndings in the New England Journal of Medicine, which began the
series of events that led to the removal of fenuramine and dexfenuramine from the market. The New
England Journal of Medicine report concluded by stating:
signicant de-novo left-sided regurgitant valvular heart disease in a population less than
50 years old is rare. Thus, the association of valvular regurgitation with fenuramine-
phentermine is not likely due to chance. Moreover, the unusual echocardiographic mor-
phology of the lesions further diminishes the likelihood of a coincidental observation. These
cases should raise concern that this combination of appetite suppressants has important im-
plications regarding valvular heart disease. Prospective studies of this association will be
required to validate the possibility that this combination of medications may cause valvu-
lar heart disease. The mechanism of valve injury and the frequency of the association have
yet to be determined. Candidates for fenuramine-phentermine therapy should be informed
about serious potential adverse eects, including pulmonary hypertension and valvular heart
disease.85
In 1997, after the Mayo Clinic report was published, the FDA conducted a study in ve U.S. areas (Florida,
Minnesota, Wisconsin, Indiana, and Pennsylvania) and found a 32.8% (95% Condence-Interval) presence
of lesions causing FDA Positive valvular regurgitation, signicantly higher than is to be expected amongst
83Id.
22the general population.86 This study contributed to the FDA's series of actions leading to the fenuramine
and dexfenuramine withdrawal from the U.S. market.
FDA Actions
On July 8, 1997, the FDA issued a Health Advisory warning over 700,000 health care professionals and in-
stitutions of the valvular heart disease concern associated with fen-phen. The FDA stated that \[p]resently
there is no conclusive evidence establishing a causal relationship between these two products and valvular
heart disease. However, given the seriousness of the reported valvular disease and its rare occurrence in
otherwise healthy obese women in this age range, we believe that patients and health care professionals
should be notied of this information."87 The advisory summarized the reports of valvular heart disease
as of July 8, 1997, at which time there were 33 reports of unusual signicant valvular regurgitation of the
mitral and aortal valves. The 33 patients were all U.S. women between 35 and 72, with a mean age of 43.4,
who had taken fen-phen for an average of 10 months, with a range from 1 to 16 months. Approximately half
of those 33 patients also had pulmonary hypertension. Surgery was required in six of the patients as of July
8, 1997, and the surgery showed valves similar to patients who had carcinoid syndrome or who had taken
the migraine drug ergotamine. The FDA indicated that the course of the valvular heart disease after the
86See Centers for Disease Control, U.S. Department of Health and Human Services Interim Public Health Recommenda-
tions, Cardiac Valvulopathy Associated with Exposure to Fenuramine or Dexfenuramine, CDC Morbidity and Mortality
Weekly Report 1061 Vol. 46, No. 45, Nov. 14, 1997.
See also Questions and Answers Concerning the Department of Health and Human Services (DHHS) Interim
Recommendations For Patients Who Have Taken Either Fenuramine or Dexfenuramine, available online at
www.fda.gov/cder/news/phenqa1111397.htm (noting the following: In addition to the FDA data supporting the link between
the fenuramines and FDA Positive regurgitation, Dr. Mehmood Kahn performed a control study in Minneapolis shortly after
the July 1997 announcement about the fen-phen associated valvular heart disease. Dr. Kahn's data found that approximately
25% of the 226 fenuramine/dexfenuramine users in his study had aortal regurgitation of mild or greater severity, compared
with 1% mild or greater aortal regurgitation in the 81 control patients who did not take fenuramine or dexfenuramine).
87U.S. Department of Health and Human Services, Reports of Valvular Heart Disease In Patients Receiving Concomitant
Fenuramine and Phentermine, FDA Public Health Advisory dear health professional letter, July 8, 1997.
23patients stopped taking fen-phen was unknown at the time.88 In the advisory the FDA told all health care
professionals that \the safety and eectiveness of the use of fenuramine and phentermine in combination
have not been established and that serious concerns about the safety of such combined use have been raised.
Until further information is available, the FDA recommends that, if practitioners choose to use these prod-
ucts in a manner dierent from the approved labeling (i.e., in combination with each other, or for durations
or at dosages dierent than those approved), they should follow patients closely with thorough cardiac eval-
uations, and if signs and symptoms of cardiopulmonary disease develop, further cardiac evaluation should
be pursued."89 The health advisory also asked all health care professionals to report any abnormalities in
fen-phen patients to FDA's MedWatch Program90 or to the drug manufacturers.91 The FDA indicated a
special interest in the dosage and duration of therapy, other medications taken by the patient, a history of
pre-existent cardiac disease, and the degree of obesity of the patient when they began taking fen-phen92
By August 22, 1997, the FDA had received reports of 82 cases of valvular heart disease in patients who
ingested fen-phen. Sixteen of those 82 patients required surgery to repair their heart valves, and at least one
patient died following surgery.93
88See id.
89U.S. Department of Health and Human Services, Reports of Valvular Heart Disease In Patients Receiving Concomitant
Fenuramine and Phentermine, FDA Public Health Advisory dear health professional letter, July 8, 1997.
90The MedWatch System run by the FDA conducts `passive surveillance', relying on health care professionals to report
details of serious adverse reactions to the FDA. In the wake of the fen-phen situation it has been criticized for not identifying
the problem before 18 million fen-phen prescriptions had been written. Raymond Woosley, a professor of pharmacology at
Georgetown University, said that MedWatch is the \best voluntary system in the world, but... it's not enough. In France,
they have 30 centers around the country with people trained to look for adverse drug eects. They go into hospitals, look at
charts, talk to patients, talk to doctors, ll out forms and enter them into a database. We don't have one site like that". Steve
Sternberg, Lawsuits: Drug Development's Side Eects, USA Today, Jan 12, 2000, Health Section. In response to Woosley's
criticisms of MedWatch and the French comparison, \FDA Deputy director Peter Honig says the agency plans to graft a similar
program onto MedWatch. In the new program, trained sta members would actively seek out unexpected drug reactions. Honig
says a mandatory reporting system would generate too much information for the agency to handle eciently." Id.
91See U.S. Department of Health and Human Services, Reports of Valvular Heart Disease In Patients Receiving Concomitant
Fenuramine and Phentermine, FDA Public Health Advisory Dear health professional letter, July 8, 1997.
92After the July warnings went out, reduced sales of fenuramine and phentermine suggested a 40% decline in their com-
bination use in the United States. After the FDA warned of the dangers, the Jenny Craig diet center recommended that its
doctors no longer prescribe fen-phen until further studies determined whether long-term use of the drug combination is safe.
The Nutri-System Weight Loss Centers also ceased prescribing fen-phen following the FDA notice. See Heart Information
Network, FDA Warns of Potential Danger of Fen-Phen Diet Drugs, Heart Information Network Website, available online
at www.heartinfo.org.; See also Heart Information Network, Weight Loss Center Responds to New Warnings about Fen-Phen,
Heart Information Network Website, available online at www.heartinfo.org.
93See Fen-Phen Update, available online at www.fda.gov/cder/fenphenupdate.htm/.
24On August 28, 1997, the FDA requested all manufacturers of phentermine, fenuramine, and dexfenu-
ramine to stress the potential risk of cardiac valvular disease in a black box warning in the drugs' labeling
and in patient package inserts. The FDA required these black box warnings to ensure that the potential
serious valvular heart disease risks associated with combination fen-phen long-term use would be known
to prescribers and patients. The new safety information was to be displayed prominently in a black box
located at the beginning of the label. The warning was to state that the safety had not been established
for combined fen-phen use or for the use of phentermine, fenuramine, or dexfenuramine for longer than
the short-term use approved by the FDA. The FDA also reiterated that the drugs should only be given to
people with serious obesity problems, not for cosmetic weight loss purposes.94
On September 8, 1997, Florida temporarily banned prescriptions of combination fen-phen. The Board of
Medicine in Florida voted to suspend fen-phen use pending the establishment of strict rules regulating the
drug combination. Following the Board of Medicine decision, Florida doctors were prohibited from prescrib-
ing the combination fen-phen to new patients and patients taking fen-phen at the time of the decision had
to be weaned o the drug combination within 30 days.95
On September 15, 1997, the FDA asked manufacturers to voluntarily withdraw dexfenuramine and fen-
uramine from the market. The manufacturers agreed to voluntarily withdraw the drugs.96 The FDA did
not request phentermine's withdrawal. The FDA recommended that anyone using fenuramine or dexfen-
uramine either alone or with phentermine cease taking the drugs either immediately or by quickly tapering
o their use.97 The FDA took this action in response to \new ndings from doctors who have evaluated
94See Fen-Phen Update, available online at www.fda.gov/cder/fenphenupdate.htm/.
95See Florida Temporarily Bans Prescriptions on Fen-Phen, The Wall Street Journal Interactive Edition, Sept 8,
1997.
96In response to the U.S. withdrawal, the French company Servier, which sold fenuramine and dexfenuramine globally,
withdrew dexfenuramine and fenuramine abroad. It was estimated that 60 million people had taken the drugs throughout
the world. See Lance and Tortorich, Popular Diet Drugs Pulled From Market, 9 Loy. Consumer L. Rep. at 296.
97Dr. Heidi Connolly of the Mayo Clinic stated that \Depression has been reported in some patients stopping the
medications suddenly. So particularly for patients on a high dose, we would encourage physician consultation and taper-
ing therapy if the medications are to be discontinued." Mayo Clinic Health Oasis, Heart Valve Disease and Fen-Phen:
An Interview With Mayo Cardiologist Heidi Connolly, M.D., Mayo Clinic Website, July 8, 1997, available online at
25patients taking these two drugs with echocardiograms... These ndings indicate that approximately 30% of
patients who were evaluated had abnormal echocardiograms, even though they had no symptoms. This is a
much higher than expected percentage of abnormal test results... [t]hese new ndings suggest fenuramine
and dexfenuramine are the likely cause of heart valve problems of the type that prompted FDA's two
earlier warnings concerning fen-phen."98 Michael A. Friednam, M.D., Lead Deputy Commissioner of the
FDA, stated that \[t]hese ndings call for prompt action... fenuramine and the chemically closely related
dexfenuramine present an unacceptable risk at this time to patients who take them."99
At that time the FDA also requested all health care professionals to report any valvular heart disease or
PPH cases to the FDA's MedWatch Program or to the fenuramine/dexfenuramine manufacturers. The
information the FDA requested included (1) The patients' age, sex, weight, height, and blood pressure; (2)
The daily dosage of fenuramine, dexfenuramine, phentermine; (3) The duration of use of appetite suppres-
sant drugs; (4) The interval of time since stopping the use of the appetite suppressant drugs and the time of
echocardiography; (5) Clinical history of the patient, including the presence or absence of an audible cardiac
heart murmur; (6) Echocardiogram results, including the presence of regurgitation at each valve, the severity
grading of regurgitation, and the presence or absence of pulmonary hypertension and estimated pulmonary
artery pressure; and (7) The use by the patient of any medications other than fenuramine, dexfenuramine,
or phentermine.100 The FDA continues to receive reports of valvular heart disease in fen-phen patients.101
www.mayohealth.org/mayo/9707/htm/fen.lsb.htm.
98U.S. Food and Drug Administration, For Immediate Release - FDA Announces Withdrawal of Fenuramine and Dexfenu-
ramine (Fen-Phen) P97-32, FDA Website, Sept. 15, 1997, available online at www.fda.gov/cder/news/fenphenpr81597.htm.
99Id.
100See U.S. Food and Drug Administration, Information Requested for MedWatch Reports of Valvular Dysfunction with Use
of Appetite Suppressant Drugs, FDA CDER Website, Nov. 13, 1997, available online at www.fda.gov/cder/inforeqvalv.htm.
101See U.S. Food and Drug Administration, For Immediate Release - FDA Announces Withdrawal of Fenuramine and Dexfen-
uramine (Fen-Phen) P97-32, FDA Website, Sept. 15, 1997, available online at www.fda.gov/cder/news/fenphenpr81597.htm.
26Discussion of the Medical Aspects of the Vascular Heart Disease
Heart valve abnormalities have appeared in diet drug users primarily in the valves on the left side of the heart.
Lesions have developed in both the aortic valves and the mitral valves. The aortic valve allows blood to ow
out of the heart, and the mitral valve is the valve between the upper and lower chambers of the heart. The
upper chamber of the heart takes in blood from the lungs and the lower chamber pumps the blood to the rest
of the body. The lesions that have formed on the valves of the diet drug users cause blood to ow backwards
instead of forwards, which is called \regurgitation".102 Regurgitation can be either (1) trace or physiologic;
(2) mild; (3) moderate; or (4) severe. Mitral valve and aortic valve regurgitation that is trace or physiologic
is extremely common among the general population and is not considered abnormal by the FDA. The FDA
also considers mild mitral valve regurgitation to be common in the general population and not abnormal.
However, aortic valve regurgitation that is mild, moderate, or severe is considered abnormal and may be
`medically signicant'. Mitral valve regurgitation that is moderate or severe is also considered abnormal and
may also be `medically signicant'. Mild, moderate or severe aortic regurgitation and moderate or severe
mitral regurgitation are considered \FDA Positive Regurgitation", and the valvular lesions that cause FDA
Positive Regurgitation are classied as \valvular heart disease".103 The FDA reported that less than 5%
of the general U.S. adult population has signicant valvular regurgitation that would be classied as FDA
Positive, but in September of 1997 the FDA found that out of 291 people who used fen-phen, approximately
30% had FDA Positive regurgitation as identied by echocardiogram.104 Dr. Connolly of the Mayo Clinic
102Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research, said that \[heart] valves are a lot like
valves in a pump or a car. The ow is supposed to go forward and not backward. If your valves are aected there can
be backward leakage... it means the heart has to pump harder because it is less ecient". Maggie Fox, Fen-Phen Pulled!,
Washington (Reuters), Sept. 15, 1997, Health and Science.
103Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation Settlement.
p. 5
104See Heart Information Network, Government Recommends Exams for Former Users of Diet Drugs, Heart Information
Network Website, Nov. 1997, available online at www.heartinfo.org.
27stated that \when severe regurgitation is present, the patient may have a lack of energy, shortness of breath,
and eventually, congestive heart failure."105
Valvular heart disease may have no visible symptoms. It is possible that the patient's doctor may hear a
new heart murmur, or the physician may detect the valvular disease with an echocardiogram. It is often
dicult for doctors to hear heart murmurs, especially on obese people who may make up a signicant
portion of fen-phen users.106 An echocardiogram is a painless test that uses ultrasound technology to take
a `moving picture' of the heart, and it allows the doctor to see any valvular lesions and determine if the
patient suers from mitral or aortal regurgitation. If the patient has serious valvular heart disease, the
patient may experience some outward symptoms like shortness of breath, edema (swelling of the legs), chest
pains, fainting, and excessive tiredness.107
Researchers are not certain of the health implications of valvular heart disease. At a lecture on fen-phen
valvulopathy, Dr. Connolly concluded by stating \there is actually probably more that we don't know about
this entity... than that we do know. We don't really know the natural history. We don't know who is at risk
for developing valve disease, the mechanism of valve injury, nor the public health impact. We do know that
up to 30% of patients who have taken diet drugs may develop valve disease and it is estimated that millions
of people have developed valve disease from diet drugs. From personal communication with the FDA, they
believe this is one of the largest adverse drug reactions they have ever dealt with."108
What is known at the present time is that valvular heart disease causes increased vulnerability to an infection
105Mayo Clinic Health Oasis, Heart Valve Disease and Fen-Phen: An Interview With Mayo Cardiologist Heidi Connolly,
M.D., Mayo Clinic Website, July 8, 1997, available online at www.mayohealth.org/mayo/9707/htm/fen.lsb.htm.
106See Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation
Settlement. p. 6
107See Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and An-
swers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online at
www.fda.gov/cder/news/phen/fenphenqa2.htm.
108Fen-Phen Valvulopathy Presented by Heidi M. Connolly, M.D., F.A.C.C., Cases in Echocardiography, Directed by
Rick A. Nishimura, M.D., F.A.C.C. and Fletcher A. Miller, Jr., M.D., F.A.C.C., Edited Transcript of a Talk Presented by Dr.
Connolly at the Heart House Learning Center, (1999).
28of the heart when patients undergo certain types of medical or dental procedures.109 \Many doctors believe
that individuals who have FDA Positive valvular regurgitation may be at risk for developing an infection in
their hearts if bacteria enter the bloodstream during routine dental hygiene or surgery. Therefore, current
medical practice is to recommend that individuals with VHD receive antibiotics when they have their teeth
cleaned or undergo some kinds of surgery."110
If the valvular regurgitation is severe, it will need to be treated so that it does not cause heart damage.
Treatment options may include medication or valve replacement through open heart surgery.111
109Some reports have also identied other problems associated with fen-phen use. One woman asserted that her son suered
heart damage as a result of her ingestion of fen-phen during pregnancy. Dawn Serina's son Nicholas suers from blue baby
syndrome, which caused her to sue Nutri-System, American Home Products, and several drug stores. Nutri-System said that
clients sign a health release and are pre-informed about all medications they receive from Nutri-System centers. Serina'a
attorney claims that Nutri-System downplayed fen-phen's side eects. Two other women also have complained that their
babies were born with health problems after they took Redux and/or Pondimin while pregnant. A spokesperson for the FDA
says that the connection between Redux and/or Pondimin and birth defects has not been proven, although the damage to the
babies could have been caused by the drugs. In response to Serina's complaint the FDA asked all parents who think that their
children may have fen-phen related health problems to have their doctors contact the FDA.
See CNN News Network Fen-Phen Article, October 10, 1997, available online at
www.cnn.com/HEALTH/9710/10/fen-phen.babies/.
Also, there have been some reports of fen-phen related problems during surgery. Anesthesiologists believe that fenuramine
may reduce the body's amount of norepinephrine, which lowers blood pressure. A patient can have a heart or a stroke if blood
pressure becomes too low for too long a period of time. Some fen-phen patients had experienced extremely low blood pressure
during surgery, which can be a life-threatening situation. In Tyler, Texas, in two surgeries on fen-phen patients, anesthesiologists
had to inject norepinephrine to increase the patients' blood pressure, which is a rare occurrence. Tyler hospitals thereafter
instituted a rule that in all non-emergency situations, patients had to be o fen-phen for two weeks before surgery. Numerous
other hospitals followed suit, including Cedars-Sinai in Los Angeles. There were been problems with patients failing to admit
that they were taking fen-phen. Wyeth-Ayerst and the FDA identied one case of a 19-year-old fen-phen patient who went into
cardiac arrest during anesthesia. In addition, the American Society of Anesthesiologists issued a statement saying its members
were concerned about reports that some patients taking fen-phen were experiencing `adverse and potentially deadly reactions
while under general anesthesia."' However, there is no denitive proof that fen-phen caused dramatic blood pressure decreases,
and most fen-phen patients have not had problems during surgery. And many anesthesiologists did not see any reason to delay
operations, although others were more cautious and preferred not to take any chances.
See Elizabeth Cohen, CNN News Network Article, Diet Drug Combo May Cause Problems During Surgery, Nov. 4, 1996,
available online at www.cnn.com/HEALTH/9611/04/fen-phen.surgery/
110Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation Settlement.
p. 6.
Note: The CDC Morbidity and Mortality Weekly Report stated that the FDA was aware of at least one person with FDA
Positive regurgitation who \presented with fever and signs and symptoms of cardiac failure and, on echocardiogram, had
both aortic regurgitation, mitral regurgitation, and a large endocarditic vegetation; blood cultures from this patient were
positive for streptococci." Centers for Disease Control, U.S. Department of Health and Human Services Interim Public Health
Recommendations, Cardiac Valvulopathy Associated with Exposure to Fenuramine or Dexfenuramine, CDC Morbidity and
Mortality Weekly Report 1061 Vol. 46, No. 45, Nov. 14, 1997.
111See Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation
Settlement. p. 6.
29At the present time, it is not known for certain whether the valvular heart problems will improve as time
elapses since the patients ingested the diet drugs. (See section below on Recent Studies). Dr. Connolly stated
that there have been anecdotal reports of regression of valvular heart disease after patients stopped taking
Redux or Pondimin.112 In response to the question on reversibility of damage, the FDA responded that \One
report has been submitted to FDA in which the valve disease appeared to improve. However, we encourage
those people who have taken fenuramine or dexfenuramine to contact their physician and discuss the
appropriate follow up, even after stopping their medicine. The full medical implications of these ndings are
not known at this time, especially as they relate to the asymptomatic valvular changes. The FDA and other
governmental agencies, the manufacturers, and medical researchers will aggressively follow this concern and
keep patients and health care providers informed of what is learned about the natural history of the valvular
disease caused by these medications."113 The Ocial Court Notice of the Settlement Agreement states that
\[p]resently, there is little scientic evidence on whether the type of Valvular Heart Disease that has been
linked to diet drug use is progressive in nature. However, many respected doctors and researchers have
concluded that certain other types of Valvular Heart Disease (unrelated to diet drug use) are progressive in
nature { that is, that mild to moderate regurgitation can progress to more severe levels of regurgitation over
time. The American Heart Association and the American College of Cardiology recommend that individuals
with FDA Positive regurgitation see their doctors at least once a year for evaluation."114
112See Fen-Phen Valvulopathy Presented by Heidi M. Connolly, M.D., F.A.C.C., Cases in Echocardiography, Directed by
Rick A. Nishimura, M.D., F.A.C.C. and Fletcher A. Miller, Jr., M.D., F.A.C.C., Edited Transcript of a Talk Presented by Dr.
Connolly at the Heart House Learning Center, (1999).
113See U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Questions and
Answers about Withdrawal of Fenuramine (Pondimin) and Dexfenuramine (Redux), CDER Website, online at
www.fda.gov/cder/news/phen/fenphenqa2.htm
114Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation Settlement.
p. 6.
30Recommendations And Guidelines For Valvular Heart Disease Patients
U.S. Department of Health and Human Services Recommendations
The U.S. Department of Health and Human Services (\DHHS") issued recommendations on November 14,
1997, for those people who were exposed to dexfenuramine or fenuramine. The recommendations were
developed in a joint eort by the Centers for Disease Control, FDA, the National Institutes of Health, and in
consultation with the American Heart Association, the American College of Cardiology, and the American
Heart Association. The recommendations are based on data that associates fenuramine and dexfenuramine
(alone or together with phentermine) with valvular heart disease. DHHS may change the recommendations
as more data becomes available.115
DHHS made three recommendations for people exposed to fenuramine or dexfenuramine for any length
of time, taken alone or with phentermine. These recommendations are: (1) Every one of these people
should see a physician to have a complete medical history taken and physical examination performed with
particular emphasis on the heart and lungs. This examination is to determine primarily if there are any signs
or symptoms of possible heart or lung disease; (2) If the physician nds that heart or lung disease may be
present, then these patients should have an echocardiogram to determine if there is any evidence of signicant
disease of the heart valves.; (3) Even if there is no evidence of heart or lung disease by history or on the
physical examination, in one special situation, these patients' physicians should nonetheless strongly consider
having an echocardiogram performed on the patient to determine if there is any evidence or signicant disease
of the heart valves.116 That situation is IF the patient needs to undergo a medical or dental procedure
115See Centers for Disease Control, U.S. Department of Health and Human Services Interim Public Health Recommenda-
tions, Cardiac Valvulopathy Associated with Exposure to Fenuramine or Dexfenuramine, CDC Morbidity and Mortality
Weekly Report 1061, 1065 Vol. 46, No. 45, Nov. 14, 1997.
116See Questions and Answers Concerning the Department of Health and Human Services (DHHS) Interim
Recommendations For Patients Who Have Taken Either Fenuramine or Dexfenuramine, available online at
www.fda.gov/cder/news/phenqa1111397.htm.
31before which the American Heart Association recommends giving patients with certain valvular disease an
antibiotic117 to help prevent an infection of the heart called bacterial endocarditis.118 The reason for the
echocardiogram in this situation is to \determine if a person without symptoms nonetheless has disease
of the heart valves. If they do have heart valvular disease that needs antibiotic coverage, they need the
antibiotic before undergoing a medical or dental procedure that could possibly lead to a heart infection."119
It is important to note that the proposed Settlement Agreement with American Home Products provides for
every patient who ingested fen-phen for 61 or more days to have an echocardiogram, which goes beyond the
DHHS recommendations.120
117Antibiotics are recommended for the following procedures: Dental { Dental extraction, other peridontal procedures including
surgery, scaling, root planing, probing, recall maintenance, dental implants, and reimplantation of teeth. Surgical { Surgical
procedures that involve the mouth and oral cavity, upper respiratory tract and the gastrointestinal and genitourinary system
(including tonsillectomy, billary tract surgery, and operations involving the intestinal mucosa). Antibiotics are not recommended
for the following procedures: Dental { Local anesthetic injection, placement of rubber dams, suture removal, taking of oral
impressions, uoride treatment, and orthodontic appliance adjustment. Surgical { Vaginal hysterectomy, vaginal delivery,
cesarean section, cardiac catheterization, balloon angioplasty, implanted pacemakers or debrillators, and coronary stents. The
recommended dosage for antibiotics given to prevent bacterial endocarditis is a 2 gram single dose of amoxicillin with no follow
up. Patients who are allergic to amoxicillin should take clarithromycin.
See American Heart Association, Recommendations, The Journal of the American Medical Association 277:1794-1801;
June 11, 1997.
118DHHS denes bacterial endocarditis as \an infection of the tissues that line the heart chambers and cover the heart valves.
Endocarditis can be caused by bacteria getting into the blood stream and infecting the heart lining and valve covering as the
bacteria-laden blood is circulated through the heart. The body's own defense systems do not work as well in the heart as they
do in other parts of the body. As this type of endocarditis is caused by bacteria, it is called bacterial endocarditis." Questions
and Answers Concerning the Department of Health and Human Services (DHHS) Interim Recommendations For Patients Who
Have Taken Either Fenuramine or Dexfenuramine, available online at www.fda.gov/cder/news/phenqa1111397.htm
People with heart valve abnormalities are at an increased risk of endocarditis, which is why they should have antibiotic coverage
before certain medical or dental procedures that can cause large amounts of bacteria to enter the bloodstream. The antibiotic is
usually given as a single dose by mouth. In an emergency situation where a person who has taken fenuramine or dexfenuramine
has not had an echocardiogram and they must have a medical or dental procedure that would require antibiotic coverage, the
person should take the antibiotics before the procedure and later undergo an echocardiogram to determine if antibiotic coverage
will be necessary for future procedures See id.
It should be noted that bacterial endocarditis is a serious infection that has the potential to be fatal. See Heart Information
Network, Government Recommends Exams for Former Users of Diet Drugs, Heart Information Network Website, available
online at www.heartinfo.org.
119Questions and Answers Concerning the Department of Health and Human Services (DHHS) Interim Rec-
ommendations For Patients Who Have Taken Either Fenuramine or Dexfenuramine, available online at
www.fda.gov/cder/news/phenqa1111397.htm.
120See Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation
Settlement. p. 6.
Note: In the March 18, 2000 interview with Dr. Tori Marnell, I asked her if she thought an echocardiogram was necessary for
every patient who had ingested fen-phen for 61 or more days, or if she agreed with the DHHS recommendations only indicating
an echocardiogram if the physician nds signs of heart or lung disease. Dr. Marnell said that she agreed with the DHHS
recommendations and felt that the medical monitoring provision of the Settlement Agreement was excessive. She said that if
she had taken fen-phen she would most likely only get an echocardiogram in accordance with the DHHS recommendations,
and that she will do an echocardiogram if the patient wishes to have one done, but otherwise she is working within the DHHS
guidelines. See Interview with Dr. Tori Marnell (March 18, 2000).
32In its recommendations for people who have been diagnosed with FDA Positive regurgitation, DHHS stressed
that \we don't know yet what happens over time to people with this kind of heart valve problem. Based
on data known at present, many of those patients aected don't have any symptoms of heart disease at
present and don't require any treatment other than careful follow-up by their doctor and pre-treatment with
antibiotics before certain medical or dental procedures... The signicance of mild heart valve leakage in
patients without symptoms is currently unknown."121 DHHS recommends that if patients do develop heart
disease symptoms, including shortness of breath, heart palpitations, leg swelling, and chest pain, that they
go to a cardiologist.122
American Heart Association and American College of Cardiology Guidelines
The DHHS Guidelines were published on November 14, 1997.123 In November of 1998 the American Heart
Association (\AHA") issued new guidelines for diagnosing and treating heart valve disease. The \Guidelines
for the Management of Patients with Valvular Heart Disease" were developed by the American College
of Cardiology (\ACC") and the American Heart Association. They cover all heart-valve disorders, not
just those associated with fen-phen use. The AHA reported that \heart-valve disease contributed to more
than 34,000 deaths and 82,000 hospitalizations in the U.S. in 1995", and noted that serious valve problems
may require surgery for repair or valve replacement. The AHA also noted that the risk of valve problems
increases with age, as constant opening and closing throughout a lifetime may lead to eventual problems.124
121Questions and Answers Concerning the Department of Health and Human Services (DHHS) Interim Rec-




124Robert O. Bonow et. al., ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease, ACC/AHA
Task Force Report, circulation { the journal of the American College of Cardiology Vol. 32, No. 5 1486 { 1582
(1998).
33Robert O. Bonow, M.D., director of the division of cardiology at Northwestern University Medical School in
Chicago and chairman of the joint American College of Cardiology/American Heart Association Committee
on Management of Patients with Valvular Heart Disease, indicated that as the U.S. population ages, doctors
are seeing an increase in valvular heart disease problems. He also noted the variety of possible valvular
diseases, including both leaky valves and valves that are too tight. The fen-phen associated valvular disease
involves leaky valves and resulting regurgitation. Dr. Bonow stated that too tight or leaky valves, \when
severe, increase the work of the heart and ultimately may impair the heart's ability to pump blood."125 The
guidelines include: (1) Extensive recommendations on evaluating heart murmurs and distinguishing those
that pose serious health threats; (2) Recommendations on treating adolescents and young adults who have
valvular heart disease; (3) Recommendations on the use of diagnostic tests including echocardiograms; (4)
Information on which valvular disorders may pose serious threats during pregnancy; and (5) Information
on therapy to be used to prevent blood clots in patients with articial heart valves. 126 The guidelines
recommend an examination for all people who took either fenuramine or dexfenuramine, alone or in
combination with phentermine. They state:
The committee recommends a stethoscope examination for people without symptoms and a follow-
up exam six to eight months later if no problems are found. Those with symptoms or heart
murmurs should be examined by echocardiography. Individuals in whom a heart murmur is
dicult to detect { because of body size { should undergo an ultrasound exam prior to dental
procedures to determine whether they should take precautions against bacterial endocarditis.
Bonow says physicians should use clinical judgment to determine which patients without symptoms
should have precautionary echocardiograms. Some individuals without symptoms who have aortic
regurgitation or mitral regurgitation, in which blood leaks backward through the valve because it
does not close properly, should have surgery to correct the defect.127
The guidelines include extensive detail on which patients should have surgery and which patients should
receive vasodilators to try to reduce the regurgitation level. These guidelines are primarily the same as the
earlier DHHS guidelines with respect to echocardiography, but they go further in identication of patients
125Id.
126See id.
34who may need surgery or other invasive procedures to reduce the backow of blood resulting from valvular
heart disease.128
Recent Studies Presenting Conicting Information on Valvular Heart Disease
The only real conclusion that can be reached on fen-phen and valvular heart disease to date is that studies
have produced \contradictory data on the extent of heart valve disease caused by the diet drug combination
phentermine/fenuramine".129 The FDA/Mayo-Clinic studies suggest a strong association between fen-phen
use and valvular heart disease, and also suggest that the incidence and severity130 of disease increases with
the length of use of the drugs. However, several other studies have presented data that directly conicts with
the FDA and Mayo Clinic data, and those studies are noteworthy in the context of a discussion of fen-phen
litigation.131 A brief summary of these studies follows below.
128See id.
129American College of Cardiology, Study Finds Low Rate of Heart Valve Disease Among Fen-Phen Users, American College
of Cardiology Website, Oct. 1, 1999, available online at http://acc.org/media/highlights/oct99/phenfen.html.
130See id. American Home Products claims that \problems detected to date have been mostly a mild form of valve malfunction
common in the general population and considered relatively harmless." L. Stuart Ditzen, In Mass Litigation, The Serious Cases
can Get Lost, Philadelphia Inquirer, Nov 22, 1999 at A1. American Home Products also maintains that no cause-and-eect
link has been established between Redux and/or Pondimin and serious valvular heart disease. See id.
131An AHP press release concerning the proposed Settlement Agreement stated that \More recent well-controlled clinical trials
{ many of which have already been published in peer-reviewed journals and presented at major medical meetings { indicate
that serious heart valve disease among former diet drug users is rare and the actual prevalence of heart valve regurgitation is
far lower than was suggested at the time of the products' [Redux and Pondimin] withdrawal. These ndings are consistent
with the clinical experience of cardiologists." American Home Products Corporation, American Home Products Announces
Diet Drug Settlement Plan, American Home Products Press Releases, Madison, N.J., Oct. 7, 1999, available online at
www.ahp.com/releases/ahp 100799.htm.
AHP has issued numerous press releases on various studies that have not found a causal connection between valvular heart
disease and Redux or Pondimin. See American Home Products Corporation, Cardiovascular Results of New Redux/Fen-
Phen Study Presented at AHA, American Home Products Press Releases, Dallas, Texas, Nov. 11, 1998, available online at
www.ahp.com/releases/ahp 111198.htm; See also American Home Products Corporation, New Study Examining Cardiovascular
Status And Duration Of Fen-Phen Treatment Presented At ACC, American Home Products Press Releases, New Orleans,
Louisiana, March 9, 1999, available online at www.ahp.com/releases/ahp 030999.htm; See also American Home Products Cor-
poration, Cardiovascular Results of New Fenuramine Study Presented at The European Echocardiography Meeting, American
Home Products Press Releases, Trieste, Italy Dec. 10, 1998, available online at www.ahp.com/releases/ahp 121098.htm; See
also American Home Products Corporation, Study Shows No Signicant Increase In Valve Abnormalities In Patients Taking
Redux, American Home Products Press Releases, Atlanta, Georgia, March 31, 1998, available online at
www.ahp.com/releases/ahp 033198.htm.
35Recent studies reported in late 1999 indicate that the valvular heart disease associated with fen-phen use
may not be as serious as previously believed, and that the disease may improve as time elapses since the
patients took the diet drugs.132 One recent study conducted by Dr. Andrew J. Burger at the Beth Israel
Deaconess Medical Center in Boston looked at the echocardiograms of 226 patients who took fen-phen as
part of a large clinical trial. The study found FDA positive aortic regurgitation in 6.6% of the subjects and
FDA Positive mitral regurgitation in 1.3 percent of their subjects. None of the subjects had symptomatic
valvular heart disease (an audible heart murmur, shortness of breath, fainting, edema). In addition, they did
not nd an association between valvular disease and the length of time the subjects ingested fen-phen.133
The study found that \[t]he rate of heart valve disease was similar to a comparable group of patients who
had been studied previously in the Framingham Heart Study and who had never taken fen-phen. Dr. Burger
and his colleagues observed that a signicant portion of healthy people may have abnormal echocardiograms
without clinical disease, whether or not they took fen-phen."134 The study appeared in the October issue
of the Journal of the American College of Cardiology (JACC). A related editorial by Nelson B. Schiller,
M.D. of the University of California at San Francisco stated that \as studies have become more scientically
rigorous, the role of fen-phen in valve disease appears to be approaching the vanishing point."135 Dr.
Schiller's editorial also stated that \'[t]his was the biggest drug recall the FDA has ever dealt with and has
probably cost billions of dollars if you consider the cost of withdrawal, echocardiograms, and litigation.'...
132A recent article in Self Magazine questioned the connection of fen-phen to the valve problems and their severity. Self
Magazine is a tness/health magazine aimed at young women who want to maintain a trim and healthy body. The fact that
such a statement appeared in Self Magazine is signicant because many of Self's readers are those who may have taken or
would take diet drugs for cosmetic weight loss purposes. By downplaying the fen-phen incident to these readers, they may be
less likely to stay away from anorectic diet drugs in the future. The article stated, \although research has shown that 5 percent
to 38 percent of users experienced heart damage, none of the studies could isolate fen-phen as the cause. Even more reassuring,
the damage that did occur was mild and reversible, according to a recent study". Health-Hazard Hype { Deated: Sometimes,
Scary Medical News Needs a Second Look,
Self Magazine, March 2000, at 80.
133See American College of Cardiology, Study Finds Low Rate of Heart Valve Disease Among Fen-Phen Users, American College of Cardiology Website, Oct. 1, 1999, available online at http://acc.org/media/highlights/oct99/phenfen.html.
134Id.
Note: These studies do not represent the ocial position of the American College of Cardiology
135ACC MediaInfo, Heart Problems Disappear Once Patients Stop Using Diet Pills, American College of Cardiology
Website, Dec. 1, 1999, available online at www.acc.org/media/highlights/dec99/heart.html..
36but instead of turning to the experts from the start... the FDA put out a call for cases from weightloss
centers that lacked expertise in cardiology."136
Another study reported in the December issue of the Journal of the American College of Cardiology focused
on what happens to valvular heart disease after patients ceased taking fen-phen for a signicant period
of time. The study found that the leaky valve problem disappeared after patients ceased ingesting fen-
phen.137 The lead author of the study, Dr. Neil J. Weissman of the Cardiovascular Research Foundation at
Washington Hospital Center in Washington, D.C., stated, \[w]e didn't know if the leakiness we saw at rst
was just the tip of the iceberg... [n]ow we know that instead of progressing, the leakiness probably goes away
once patients stop using the drug."138 Dr. Weissman had patients who had taken Redux as part of an earlier
randomized double blind placebo-controlled trial return for echocardiograms three to ve months after they
ceased taking Redux. Doctors examined 941 echocardiograms including both former Redux users and those
who had taken placebos. \What they found was reassuring: nothing."139 In the previous study where the
patients had taken Redux, researchers found a small increase in valvular abnormalities. However, after three
to ve months they did not nd anything at all.140 While this study is noteworthy and may shed some light
on long term eects of dexfenuramine use, this study is not the denitive statement on whether valvular
heart disease goes away after users stop taking the diet drugs. The general consensus is that there is no
conclusive evidence on whether valvular heart disease associated with fen-phen is progressive or regressive
in nature.141
Another recent study of importance in the fen-phen debate was also reported in 1999. This study conicts
with the Burger study above. The study addressed the connection between the length of time a patient took
136Id.
137See ACC MediaInfo, Heart Problems Disappear Once Patients Stop Using Diet Pills, American College of Cardiology




141See Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation
Settlement. p. 6.
37fen-phen and any resulting valvular problems. This multicenter study included 1,200 patients who took fen-
phen for more than 90 days and 670 control patients who never took fen-phen at all. Echocardiography was
used to determine whether any of those patients suered from valvular heart disease. Dr. Thomas Ryan of
Duke University presented the fen-phen study on March 9, 1999 at the American College of Cardiology 48th
Annual Scientic Session, moderated by Dr. Robert Bonow, who chaired the writing group that published
the ACC/AHA Guidelines for Vascular Heart Disease.142 The study found \no signs of valve leakage for
those who took the drug for less than six months. However, [the study found] there was a statistically
signicant increase in the signs and symptoms of leakage in patients treated for more than six months."143
Primary Pulmonary Hypertension
Primary Pulmonary Hypertension Symptoms and Prognosis
Primary Pulmonary Hypertension is a very serious disease with a high mortality rate. PPH occurs when
the blood pressure in the arteries supplying the lungs is extremely abnormally high. PPH is \caused by
a constriction of blood vessels that lead into the lungs. As a result, rst, that part of the heart has to
pump harder to get blood into the lungs and second, the lungs receive less blood and the blood it does
receive is not as well oxygenated."144 The most common PPH symptom is shortness of breath with exercise,
and eventually shortness of breath while at rest. Other symptoms include becoming tired easily, fainting,
142See ACC MediaInfo, Study Explores Duration of Fen-Phen Treatment and Heart Valve Disease, ACC 48th Annual Scien-
tic Session News Conference Highlights, American College of Cardiology Website, March 9, 1999, available online at
www.acc.org/session/conf99/media/confnews/tuephen.html.
143ACC MediaInfo, Highlights of Studies Released at Five News Conferences, ACC 48th Annual Scientic Ses-
sion News Conference Highlights, American College of Cardiology Website, March 9, 1999, available online at
www.acc.org/conf99/media/confnews/fivenewsconf.html.
144Lori Litchman, Philadelphia Jury Returns $8M in Fen-Phen Case, The Legal Intelligencer, Feb 24, 2000.
38coughing, chest pain, swelling of the legs and/or feet, and coughing up blood.145 The median length of
survival after a PPH diagnosis is 2.5 years, according to the National Institute of Health. Overall, \[n]o
one in the diet-drug litigation { including American Home Products Corporation, which marketed Pondimin
and Redux { disputes that PPH is a terrible disease. It causes the veins in the lungs to constrict and close,
restricting the ow of oxygen in the blood. It makes breathing laborious. It saps strength and energy. And
it reduces life expectancy to a few years."146
Connection Between Fenuramine/Dexfenuramine and PPH
It has long been known that anorectic diet drugs like the fenuramines can lead to an increased risk of
PPH. The PPH-anorectic drug connection was rst discovered in Europe and associated with an appetite
suppressant drug called aminorex, marketed under the trade name Menocil. A PPH outbreak in Western
Europe from 1967 to 1972, which increased PPH by a factor of 10 was traced to Menocil.147 \Pulmonary
hypertension has been reported to occur in association with fenuramine... given alone. In addition, the
d-isomer of fenuramine, dexfenuramine, increases the risk of pulmonary hypertension, particularly when
patients receive high doses for more than three months. These drugs may cause pulmonary hypertension
through the vasoconstrictor action of serotonin or by alteration of pulmonary vascular smooth muscle mem-
brane depolarization."148 However, that known risk level was increased two months after dexfenuramine
145See Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Primary Pulmonary Hypertension, available online at
www.dietdrugsettlement.com.
146L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1
(describing a woman with PPH who is almost entirely housebound and on a waiting list for a double lung transplant. The
woman is connected to oxygen tubes 24 hours a day and an IV line delivers medicine directly into her heart from a pump she
must have with her at all times. She said that as soon as she starts to move she gets very weak and can not concentrate. She
likened living with PPH to living on Mount Everest without oxygen).
147See Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 156.
148CNN Interactive, Valvular Heart Disease Associated With Fenuramine-Phentermine { Dr. Heidi M. Connolly {
Manuscript Of Study Submitted To New England Journal of Medicine, CNN Website, July 8, 1997, available online at
www.cnn.com/Heath/0/07/08/fenphen.report/.
39was approved by the FDA when the International Primary Pulmonary Hypertension Study (\IPPHS") was
released. The IPPHS of 1996 set that increased risk at 23-46 cases per million. The background risk for the
general population is 1-2 cases per million.149 Doctors prescribing fenuramines or dexfenuramines, either
alone or in combination with phentermine, even before the IPPHS was released, were told to be extremely
vigilant for symptoms or signs of PPH.150 The IPPHS found that \the use of any anorexigen (appetite
suppressant) within the previous year was associated with a ten-fold risk of developing PPH, and the risk
increased to more than 20-fold with use for longer than three months."151 Dexfenuramine and fenuramine
made up 90% of the anorexigens in the IPPHS.152
Use of anorectics even for short periods of time can lead to PPH in certain cases. In one case \progressive,
fatal pulmonary hypertension developed after she [a 29-year-old-woman] had taken fenuramine and phen-
termine for only 23 days. A postmortem examination disclosed striking obstructive lesions in the muscular
pulmonary arteries that were reminiscent of those induced by aminorex and indistinguishable from those pr
primary pulmonary hypertension."153
PPH Labeling on Pondimin and Redux
Labeling on Pondimin and Redux did reect an increased PPH risk. However, on August 22, 1996, in response
to the IPPHS, Wyeth-Ayerst Laboratories and Interneuron Pharmaceuticals, Inc. sent a \Dear Health Care
Professional" Letter about Redux and the IPPHS. The letter imparted the fact that the nal IPPHS report
found that the incidence of PPH for patients taking anorexigens, including dexfenuramine, was between
149See Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 156.
150See Interview with Dr. Tori Marnell (March 18, 2000).
151Two Weight-Loss Drugs Disrupt Certain Brain Functions in Animals, Doctor's Guide & Other Medical News, Aug
26, 1997.
152See id.
153Alfred P. Fishman, M.D., Current Perspective - Aminorex to Fen/Phen: An Epidemic Foretold, Circulation, at 156.
4023 and 46 cases per million patients per year, as opposed to the background risk of 1 to 2 cases per million
adults per year.154 The letter states that \Although the incidence of PPH for patients taking anorexigens
remains small, PPH is a serious disorder with an estimated 4-year mortality rate of 45%. Therefore, it is
very important that Redux not be prescribed for cosmetic weight loss. Redux is indicated for use only in
those patients with a Body Mass Index (\BMI") of at least 30 kg/m squared (which is approximately 30
percent over desirable weight) or a BMI of at least 27 kg/m squared (which is approximately 20 percent over
desirable weight) in the presence of other risk factors (e.g., hypertension, diabetes or hyperlipidemia)."155
The purpose of the letter was to inform health care professionals that the drug companies and the FDA
were working on new labeling for Redux that would reect the IPPHS, and to provide data to health care
professionals until that new labeling was complete.156
PPH Legal Claims
PPH cases are not included in the proposed Settlement Agreement, and it is expected that American Home
Products may have to spend an additional $1 billion to resolve the PPH cases. American Home Products
has already settled several PPH cases at a cost ranging from $1.5 million to $4.5 million157 In PPH lawsuits,
several plaintis have claimed that American Home Products and its subsidiary Wyeth-Ayerst \downplayed
the dangers and understated the number of known cases of PPH to cash in on the prots from soaring sales
of Pondimin and Redux during the mid-1990s."158 In 1995 only four reports of PPH were cited to have
occurred among Pondimin users, while internal Wyeth-Ayerst documents indicate that that the company
154See Letter - Important Update on Redux (Dexfenuramine Hydrochloride Capsules) C-IV, from Wyeth-Ayerst Laboratories
and Interneuron Pharmaceuticals, Inc. to Health Professionals (Aug. 22, 1996).
155Id.
156See id. Note: The new labeling was complete in 1997.
157See L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
158Id.
41knew of 37 such occurrences. A high level Wyeth-Ayerst employee suggested changing the Pondimin label
to reect the higher incidences of PPH, but no changes were made until 1997.159
Arnold Levin of Levin, Fishbein, Sedran & Berman in Philadelphia, co-chair of the diet drug MDL Plain-
tis' Management Committee and MDL plaintis' liaison, stated that \PPH cases were excluded from the
Settlement `because there is a denitive number of those cases.' He estimated the number to be between
120 and 130 `so far' [and also stated] `[t]hey are very, very severe cases and they are being dealt with on an
individual basis, and they are a nite group'."160 Mr. Levin opined that PPH liability for American Home
Products is likely to be \well in excess of $1 billion."161 American Home Product's V.P. for nance, John
Considine, stated of the PPH cases that they \are relatively few and quite individual in nature."162 Judge
Bechtle in Philadelphia has set up an expedited hearing \fast track" process that has been set up for PPH
cases that were involved in the multi-district litigation. This move reects the more serious nature of these
cases and the fact that the plaintis may die or become very seriously incapacitated before their trials begin
if they remain bunched with the other thousands of cases in the multi-district litigation.163
Neurotoxicity
Since the fenuramines work by impacting the serotonin metabolism in the brain, there has been speculation
that long-term fen-phen use may have had an adverse impact on the brain functions of patients who used
fen-phen for extended periods of time. Literature on Redux from its manufacturers sent to health care




162AHP Agrees to Settle Heart Valve Cases For Up to $3.75 Billion; Meetings Under Way As Some Attorneys
Question Coverage, Adequacy, Mealey's Litigation Report Fen-Phen/Redux, Oct. 12, 1999, available online at
http://mealeys.com/dietdrugsettlement.htm.
163See L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1
42concentrations approximately 10 times those seen in humans, neurochemical changes were observed. The
dose and brain serotonin concentration of dexfenuramine may aect reversibility. The relevance of these
ndings to humans is not known."164 In addition, \a study reported in the September [1997] issue of the
American Medical Association indicated that dexfenuramine and fenuramine can reduce the production
of a key brain-signaling chemical and adversely aect memory, cognition and moods."165
Critics of the FDA's approval of Redux pointed to the concerns over neurotoxicity as a reason to be suspect
about Redux's safety. They looked to a body of research linking dexfenuramine to brain damage in animals
to support their claims. \'This has been observed in every animal species tested to date, from mice to
baboons,' said George Ricaurte, MD, Ph.D., assistant professor of neurology at Johns Hopkins University
School of Medicine. He was among 22 neurology specialists and researchers who in December [1995] asked
the FDA to delay its approval."166 In advising physicians who had prescribed or were considering prescribing
Redux to their patients, Dr. Ricaurte said that \[i]t's important to emphasize to patients and physicians
that as yet, we don't know if dexfenuramine produces brain damage in humans. However, they ought to be
apprised of the animal studies and the potential risk that should be weighed against any potential benets
the drug may oer."167 The FDA responded to those concerns surrounding the approval of Redux by saying
that \the relevance of the [animal] ndings to humans is not known and will require further study".168
While plaintis may be concerned about potential neurological damage resulting from ingestion of fenu-
ramines, the Ocial Court Notice which addresses the proposed Settlement states of the neurotoxicity issue:
\Some people believe that a very subtle kind of brain damage- neuropsychiatric or neurotoxic injury { may
be caused by the use of Pondimin and/or Redux. However, the question of whether such brain injury can
164Letter from Marc W. Deitch, M.D., Senior Vice President, Medical Aairs and Medical Director, Wyeth-Ayerst Laboratories
Division of American Home Products Corporation, to Redux Prescribing Physicians (Aug. 22, 1997).
165See Lance and Tortorich, Popular Diet Drugs Pulled From Market, 9 Loy. Consumer L. Rep. at 296.




43occur as a result of diet drug use is controversial. Also, there are presently no published clinical studies that
show that people who took Pondimin or Redux have any brain injury as a result. The Settlement provides
no benets for neuropsychiatric or neurotoxic injuries."169 Plaintis who accept the benets of the proposed
Settlement Agreement will not be able to pursue any neurotoxicity claims in any courts as a condition of
the proposed Settlement Agreement.170
While, as the Ocial Court Notice indicates, studies have not been done on humans and no conclusive human
data is available, animal studies have shown fen-phen extended use to have negative impacts on the brain
functions in mice and monkeys. One such study which assessed the neurotoxic eects of fenuramine and
phentermine alone and together on the mouse brain, found that its results \suggest that phentermine has the
potential to exacerbate fenuramine-induced serotonin neurotoxcity, if utilized in certain doses. Further, the
present results indicate that phentermine possesses dopamine (DA) neurotoxic potential."171 Una D. Mc-
Cann, M.D. and colleagues from the National Institute of Mental Health conducted the study. The study's
basic lesson that the fenuramines \result in a reduction in brain serotonin when administered to animals" is
signicant because \[s]erotonin is thought to be important in a variety of brain functions, including cognition
and memory and the regulation of mood, anxiety, impulsivity, aggression, sleep and neuroendocrine function.
However, the researchers admit not much is known about the eects of brain serotonin loss. Nor is it known
if the eects on animals are the same in humans."172 The researchers also attempted to determine whether
ceasing use of the fenuramines reversed the neurological changes observed in the animals. They found that
\'loss of serotonin axonal markers after fenuramines is evident weeks, months, and in one primate study,
as long as one year after drug discontinuation'... [t]hey found that some later nerve repair appeared to
169Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation Settlement.
p. 14
170See id.
171McCann, U.D., Juan, U., and Ricaurte, G.A. - Unit on Anxiety and Aective Disorders, Biological Psychiatry Branch,
National Institute on Mental Health, Neurotoxic Eects of +/-Fenuramine and Phentermine, Alone and In Combination, on
Monoamine Neurons in the Mouse Brain, Synapse (3) 239-246, Nov. 30, 1998.
172Two Weight-Loss Drugs Disrupt Certain Brain Functions in Animals, Doctor's Guide & Other Medical News, Aug
26, 1997.
44take place, but in one study in which rats were given higher doses of fenuramine, the repairs were short-
lived."173 The authors of the study urged that doctors of patients who took fen-phen should be aware of
possible serotonin neurotoxicity, which the researchers stated could result in \things such as loss of memory,
irregular moods, anxiety, impulsivity, aggression, and changes in sleep patterns".174 The researchers did
also state that such symptoms may come from a variety of causes, not necessarily use of fenuramines. The
researchers concluded their work with an urging of doctors who see neurotoxicity symptoms to notify either
the fenuramines manufacturer or the FDA's MedWatch program. In addition, they stated that \'before
initiating treatment with fenuramines, patients should be apprised not only of the drugs' benets, but also
of their potential adverse eects and, together with a physician, make an informed decision whether use
of fenuramines is indicated"'175 The study on neurotoxicity was concluded before the fenuramines were
pulled from the market.
The study, while clearly not providing human data showing a connection between serotonin neurotoxicity
and fenuramines176, does warn doctors of the possibility of serotonin neurotoxicity among diet drug users,
as evidenced by the results of several animal studies.177 Since the animal studies do not appear to indicate
that ceasing use of the fenuramines will cause the neurological eects to abate, this warning should be
heeded for years to come. The neurotoxicity animal studies and various human complaints of neurological




176While the neurotoxicity studies have been conned to animals at this point, several people who took fenuramine and
dexfenuramine have complained of various neuropsychological problems. \One woman said she took a butcher knife to her
husband. Some people said they had to be hospitalized. Lesser complaints include mood or behavior changes, and cognitive and
memory loss.... many former fen-phen and Redux users also complain of dizziness, headache, and ushing. These symptoms are
also reported by some people taking antidepressant drugs that increase serotonin levels, like Prozac and Zoloft. The symptoms,
when severe, are sometimes called `serotonin syndrome'." Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs -
The Story of How Fen-Phen and Redux Came to Be Used By 6 Million Americans is Chilling, 34 Trial at 82.
177See McCann, U.D., Juan, U., and Ricaurte, G.A. - Unit on Anxiety and Aective Disorders, Biological Psychiatry Branch,
National Institute on Mental Health, Neurotoxic Eects of +/-Fenuramine and Phentermine, Alone and In Combination, on
Monoamine Neurons in the Mouse Brain, Synapse (3) 239-246, Nov. 30, 1998.
45Settlement Agreement, which allows no recovery for neurotoxicity claims, even if serious neurotoxicity health
problems arise in the future.
OBESITY AS THE DISEASE FEN-PHEN WAS MEANT TO COMBAT
Risk-Benet Calculations of Prescription Obesity Drugs
The debate on the safety of fen-phen necessitates a discussion on obesity. Obesity is a serious health
problem178, and fen-phen was initially hailed as a breakthrough tool in the ght against obesity in the
United States. When the drug companies marketed fen-phen, they indicated to doctors that fen-phen was
to be used for the clinically obese. The literature that came with the drugs to physicians stated that fen-
phen was to be given to persons with 30 or over Body Mass Index, which would be a seriously overweight
person.179 When people are so overweight, they subject themselves to a whole host of other serious medical
problems and the decision to take fen-phen became a risk-weighing calculation of the known heightened risk
of PPH as opposed to the known heightened risk at remaining at an obese weight. Even once the valvular
problems were discovered, fen-phen was not pulled immediately, and physicians were told to factor in the
valvular disease risk into the calculation of whether a morbidly obese person was to be put on fen-phen.
In the manuscript of the Mayo Clinic study that rst identied the alleged fen-phen valvular heard disease
178The Third National Health and Nutrition Examination Survey (NHANES III) (1988-1991) estimates that 33% of the U.S.
population is obese, compared with 25% in NHANES II (1976-1980). Obesity is associated with numerous health problems,
including many forms of heart disease. In the U.S., a reduction in consumption of fat from 40% of calories in 1965 to 34% of
calories in 1991 has not led to a decrease in U.S. obesity, most likely due to an increase in overall caloric intake and reduction
in physical activity. Maintaining a BMI below 25 throughout adult life is recommended. For patients with a BMI between
25 and 30, lifestyle modications like a decrease in caloric intake and increase in exercise are appropriate. Pharmaceuticals
should be considered only with a BMI over 30 or a lesser BMI with other complications such as diabetes or high cholesterol.
For people with a BMI over 35, gastrointestinal surgery may become an option. However, above all, diet and regular physical
exercise are the most healthy ways to maintain good health in obesity management. See Robert H. Eckel, M.D., for the
Nutrition Committee, American Heart Association, Obesity In Heart Disease: A Statement for Healthcare Professionals From
the Nutrition Committee, AHA Medical/Scientific Statement, Circulation: The Journal of the American Heart
Association 96: 3248-3250 (1997).
179See Interview with Dr. Tori Marnell (March 18, 2000)
46link, the report closed with the statement that \[c]andidates for fenuramine-phentermine therapy should be
informed about serious potential adverse eects, including pulmonary hypertension and heart disease."180
One doctor put the trade-o in numbers. He claimed that every year 300,000 people in the U.S. die from
obesity related complications. His numbers indicated that 8 million adults in the U.S. took fen-phen from
1992 to 1997. Using the IPPHS number of 23 PPH cases per one million adults using fenuramine-type
drugs, he found that would be 124 people per year in the U.S. getting PPH as a result of fen-phen. He said
that 300,000 deaths from obesity per year translates to 833 deaths per day from obesity, while 184 deaths
per year from PPH (assuming all PPH patients die) would be 15 deaths per month or one death every other
day as a result of fen-phen. He concluded that the ratio was 833/0.5, or 1,666/1.181 He stated that \[w]ith
200 million adults, and a death total of 300,000 per year from obesity, that means that the death rate from
obesity is 1,500 per million adults each year. Obesity is clearly an epidemic in this country. Why is the media
focusing on the unsubstantiated deaths of under 400 per year, or 23 per million, and ignoring the obesity
death rate?... More people die from aspirin every year than fen-phen."182 However, in the counterargument
to Dr. Krentzman, Dr. Gregory D. Curfman, M.D. stated in a New England Journal of Medicine editorial,
180CNN Interactive, Valvular Heart Disease Associated With Fenuramine-Phentermine { Dr. Heidi M. Connolly {
Manuscript Of Study Submitted To New England Journal of Medicine, CNN Website, July 8, 1997, available online at
www.cnn.com/Heath/0/07/08/fenphen.report/.
181See Ben Z. Krentzman, M.D., Scared by the Media Hammering Away on How Dangerous Fen-Phen Is? I Do Not Blame
You!, available online at www.loop.com/bkrentzman/.
182Id.
47[g]iven the serious health hazards associated with anorectic drugs, can their continued,
widespread use be justied? It has been argued previously that the potential health benets
of anorectic drugs outweigh their risks when considered against the health hazards of obesity.
In fact, it was this argument that last year led the FDA to approve dexfenuramine. I believe
that there are serious problems with this argument. Weight reduction extends health benets
to overweight people only if it is maintained for a long period. It has never been shown, and it
is highly implausible, that appetite-suppressant drugs can maintain weight loss indenitely. To
date, studies of these drugs have demonstrated ecacy only for short-term weight loss. Their
safety if taken over a period of many years is doubtful, since the risk of serious toxicity appears
to increase with the duration of use. Drug holidays would result in weight cycling (i.e. uc-
tuations in body weight), which in epidemiologic studies is associated with adverse outcomes
such as coronary heart disease and death. Furthermore, clinical studies have never shown that
appetite-suppressant drugs can prevent obesity-related illnesses or prolong life. Until we have
a better understanding of the relative health risks and benets of anorectic drugs, physicians
need to distinguish between patients who have a legitimate health indication for the use of the
drugs and those who seek them principally for cosmetic reasons. The only justiable medical
use of anorectic drugs is in seriously obese patients who have obesity-related illnesses such as
coronary heart disease, diabetes, hypertension, and hyperlipidemia.183
Dr. Curfman seems to indicate that it is not a clear tradeo, that the use of fen-phen does not necessarily
correlate with the benets associated with a weight reduction. Dr. Curfman's editorial was written shortly
before Redux and Pondimin were pulled from the market, as was Dr. Krentzman's piece on the obesity/fen-
phen numbers tradeo. Dr. Curfman's idea won out, it appears that the FDA agreed with his idea of the
tradeo in that the risks outweighed the benets of fen-phen.
In a telephone interview with Tori Marnell, M.D., a physician in Tulia, Texas who had several of her patients
on fen-phen before it was withdrawn, Dr. Marnell addressed the risk benet idea of drug prescribing.184
Her view of the fen-phen risk/benet analysis was more akin with Dr. Krentzman, since she felt that it
was imperative that obese patients lose weight to improve their health. She said she had signicant success
with weight loss with patients who were on fen-phen, although several of them have gained back a signicant
amount of the weight they lost without the diet drugs. Many of her patients are now on Xenical and are losing
weight again, and Xenical has the added benet of `training' the patients not to eat the fatty foods since they
184See Interview with Dr. Tori Marnell (March 18, 2000).
48produce an upset stomach for Xenical users. As for the risk-benet calculation for obesity and fen-phen, Dr.
Marnell indicated that all drugs have risks, and she stressed that the decision to take a drug is a risk-benet
calculation in every situation. Dr. Marnell expressed the view that the media played a signicant role in
the \hype" surrounding fen-phen. She used penicillin as an example. She stated that one out of every 1500
people is allergic to penicillin and may go into anaphylactic shock if given a penicillin shot. Still, the benets
of penicillin outweigh their risks, and U.S. doctors continue to give penicillin shots to children and adults
despite the risk of an allergic reaction. If someone is allergic, after the fact people may criticize the doctor
for giving a shot instead of a pill, but on the whole, penicillin's positive attributes outweigh the negatives
of a possible allergy problem. The media has not focused on penicillin's adverse reactions and created a
state of quasi-hysteria as occurred with fen-phen. The same situation happens with childhood vaccinations.
Some children may get the disease being vaccinated against and either die or become very sick and disabled.
However, on the whole, in order to combat a serious societal medical problem in the form of an outbreak
of a disease like polio or smallpox, we continue to give childhood vaccines.185 If we consider obesity to be
a serious enough problem in the U.S. then the calculation regarding fen-phen changes. The PPH problems
were known all along (although the severity of the risk was increased in 1996 with the IPPHS) and were
factored into the calculation of which was the more serious risk { the increased chance of developing PPH
or the risk of death or serious complications resulting from obesity. The valvular problems could be gured
into the same calculus, allowing for the fact that it is more dicult to operate on seriously overweight people
if valvular replacement is needed, since they have wider chest walls, are more dicult to intubate, and may
develop more complications during and after surgery.186 The problem is that \because the diet pills were so
readily available, it is doubtful that the original physical examination necessary to determine suitability of
the drugs was ever done."187 While Dr. Marnell did discuss the risks and benets with her patients, with
185See id.
186See id.
187Vivi Vanderslice, Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in Light of Amchem v. Windsor, 35
49fen-phen on the whole this was not always the case. This leads into the topic of fen-phen use for cosmetic
weight loss and its distortion of the risk benet calculation of the problems associated with obesity versus
the problems associated with Redux and Pondimin.
The Important Issue of the Widespread Use of Fen-Phen for Cosmetic Weight
Loss
The risk benet calculus associated with obesity broke down with fen-phen because of its widespread use
for cosmetic weight loss.188 After the Weintraub article appeared in 1992, \some doctors began to prescribe
fen-phen for people who were not substantially overweight and therefore not at risk of the diseases associated
with morbid obesity. Many doctors, including some associated with weight-loss clinics, prescribed fen-phen
to people who simply wanted to shed a few pounds, a so-called cosmetic use. Worse yet, some doctors
prescribed the drugs without rst doing thorough patient examinations, or any examinations at all. In many
cases, patients were not told of the risks associated with use of the drugs. In fact, the \drugs often were
oered as an inducement to join weight-loss clinics and were promoted as free of side eects."189 A clear cut
risk-benet analysis cannot be completed with fen-phen like it could with penicillin, because fen-phen was
being given out to those who were not obese. For people who wanted to lose weight for cosmetic reasons,
the increased PPH risk and the later found valvular heart disease risk did outweigh the benets of cosmetic
weight loss in all cases. One editorial summed up the cosmetic weight loss issue as follows:
Cal. W. L. Rev. 199, 203 (1998).
188Note: In addition to the breakdown of the risk/benet analysis due to cosmetic weight loss use of fen-phen, the fen-phen
risk/benet analysis also broke down because fen-phen may not be a long-lasting eective treatment of obesity. Appetite
suppressant weight loss often leads to the weight coming back on in a short period of time. See Interview with Dr. Tori Marnell
(March 18, 2000).
189Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The Story of How Fen-Phen and Redux Came to Be
Used By 6 Million Americans is Chilling, 34 Trial at 79.
50The use of appetite suppressants is associated with a rare but potentially fatal risk. On the other
hand, these drugs can help someone with or at high risk for serious medical conditions like heart
disease to substantially reduce that risk. In this way, they are not that dierent from many other
medical interventions, which invariably have both risks and benets. The dierence here is that
many persons are prescribed appetite suppressants not for medical but for cosmetic reasons. It
is dicult to justify even a rare but potentially fatal risk when the goal is purely cosmetic. A
simple rule of thumb: if you really need one of these drugs [fenuramine or dexfenuramine]
because your weight is literally killing you, consider it but only under a doctor's care and in
conjunction with an honest diet and exercise behavioral modication program. However, if you
just want to t into a smaller bathing suit or look better in an evening gown, you should think
again.190
The manufacturers' literature indicated that the drugs should only be given to people with a BMI equal to
or over 30.191 The American Medical News, a publication read by physicians across America, said in June of
1996 that Redux \is recommended for patients who are at lease 30% over their desirable weights. Patients
with other risk factors, such as hypertension or diabetes, may benet if they are 20% over their recommended
weights."192 However, Americans were clamoring for an easy weight loss x, and the American Medical News
warned that \physicians may have to resist pressure from their patients".193 There was much money to be
made all around from America's desire for an easier eective way to lose weight, so the admonition not to
prescribe fen-phen for cosmetic weight loss was often ignored. In an article discussing previous PPH problems
associated with anorectic drugs like fenuramine and dexfenuramine, Dr. Alfred P. Fishman states,
One major weakness in the war against obesity is the blurred outlines of the targets. Although
any degree of overweight is undesirable, not all degrees of obesity call for the same type of
vigor or attack. For example, the goal of a 10% reduction in weight in an individual who
is mildly obese and at risk for systemic hypertension and diabetes warrants more aggressive
measures than does achieving the same weight loss by an individual determined to t into last
year's bathing suit. In turn, both of these indications are much less compelling than weight
loss in a morbidly obese individual in whom quick weight loss may be lifesaving. Moreover,
no matter what the goal in treating overweight and obesity, lasting success in losing weight
calls for recognition that obesity is a chronic disorder that requires a long-term strategy for
sustained success.194
191See Interview with Dr. Tori Marnell (March 18, 2000).
192Wayne Hearn, There's A Weight Loss Drug, But It's No Magic Bullet, American Medical News, June 3, 1996, Media
Rounds Page.
193Id. Dr. Marnell indicated that several patients on fen-phen said they would go to another doctor if she stopped prescribing
it for them, and that they were outraged when she stopped prescribing it after the FDA warnings came out in 1997. See
Interview with Dr. Tori Marnell (March 18, 2000).
51Fen-phen was prescribed over the internet and by doctors who only saw patients for a few moments at a
place like Jenny Craig or Nutri-System.195 These doctors were not engaging in a careful risk benet analysis
in determining whether the risks of obesity were outweighed by the risks associated with an anorectic drug
that increased the risk of PPH and also later caused valvular heart disease. People were taking the drugs
for purely cosmetic reasons, where the risks clearly were not outweighed by the benets. This is a pervasive
problem in obesity management, as much of society ghts to be thin without the more disciplined approach
of calorie intake reduction and increased exercise. People will be looking for the diet pills and will go to
great lengths to get them, regardless of the risks to their health.196 Dr. Curfman, in his editorial in the New
England Journal of Medicine, states of cosmetic weight loss: \People seeking to lose weight should consult
with their own physicians and not try to obtain these drugs from doctors they do not know. For generally
healthy people who want to lose a few pounds, there are safer alternatives. Although the traditional methods
of calorie restriction and regular exercise require personal discipline, the reports [on PPH and valvular heart
disease]... are chilling reminders that succumbing to the allure of diet pills as a quick x for excess weight
may be courting disaster."197
In the interview with Dr. Marnell, she stated that patients were devastated when they learned that she
would no longer be prescribing fen-phen because of the FDA warnings that came out after the Mayo Clinic
study. Before the Mayo Clinic study came out and during the fen-phen craze, Dr. Marnell said that she
kept people on fen-phen for only six months, but that they would attempt to go to other physicians without
the six-month time limit in order to continue taking fen-phen.198 She said that before she put patients on
195See Gregory D. Curfman, M.D., Editorial, New Eng. J. Med. Vol. 337, No. 9, Aug. 28, 1997.
196See Wayne Hearn, There's A Weight Loss Drug, But It's No Magic Bullet, American Medical News, June 3, 1996, Media
Rounds Page. The Hearn article in American Medical News was meant for physicians. It states of fen-phen's popularity,
\millions of overweight Americans, discouraged by failed attempts to shed pounds through dieting and exercise, are pinching
themselves at the notion that the road to success may be just a pill pop away." Id.
197Gregory D. Curfman, M.D., Editorial, New Eng. J. Med. Vol. 337, No. 9, Aug. 28, 1997.
198When a patient enrolled in Nutri-System's \NutriRx" fen-phen program was asked what she would do if her Nutri-System
52fen-phen, she would carefully go over the known increased PPH risk with them and engage in a risk-benet
analysis with the patient. However, she said that most patients seemed to be unfocused on the risks as
opposed to the benets of the diet pills. Dr. Marnell maintained that she would only prescribe fen-phen to
obese patients, but she said that many patients would initially inquire about fen-phen for purely cosmetic
weight loss reasons. Dr. Marnell reiterated many times the need for the morbidly obese to lose weight, and
stressed that a comprehensive risk calculation would be needed for each patient to assess if fen-phen was
right for them. She says that even today, for some morbidly obese patients, the weight that came o with
fen-phen outweighed the risks of the valvular lesions associated with fen-phen use. She has not seen any
patients develop valvular problems who took fen-phen as of the present time, and she is following the U.S.
Department of Health and Human Services guidelines on when to give an echocardiogram to patients who
took fen-phen. Her experience with overweight patients illustrated the deep desire of Americans to take diet
pills and often ignore the risks associated with the medications in the quest to lose weight, as well as the
importance of a risk benet calculation in the decision to take diet pills and to only prescribe the medications
for the seriously obese.
THE OFF-LABEL USE OF PONDIMIN, PHENTERMINE, AND REDUX
IN THE FEN-PHEN COMBINATION
O-Label Use of Prescription Drugs
Congress has delegated to the FDA the power to protect individuals by regulating which drugs are safe and
doctor ceased prescribing fen-phen for her, the patient responded that she would just nd another Nutri-System center and
another doctor. See Laura Fraser, The New Diet Drugs, They Really Do Help Some People Lose Weight: But Are They Worth
The Risk?, 10 Health 52 (1996).
53eective. The Food, Drug, and Cosmetic Act was passed in 1938 and allowed for federal regulation of new
drugs. New drugs must be approved by the FDA in accordance with a process that includes a pre-marketing
investigation involving animal testing, as well as three phases of human clinical investigation. Following the
required human and animal testing, the manufacturer must submit a New Drug Application to the FDA.
The New Drug Application contains all of the studies performed on the drug, including all adverse aects
and benets of the products.199 \Upon a showing that the drug is safe and eective for its proposed use or
uses, the New Drug Application is approved by the FDA. However, such approval does not extend to other
uses"200 When the FDA approves a drug, it approves it \for specic purposes associated with the clinical
trial ndings that supported the drug's application... [and] pharmaceutical companies are required to convey,
in the drug's formal labeling, information regarding only those uses for which the drug was approved."201
The drug's label will include information necessary for safe and eective use, warnings, precautions, clinical
pharmacology, indications, contraindications, and adverse reactions. FDA approved labeling is included as
a product insert and also as an entry in the Physician's Desk Reference. The manufacturer must report
adverse reactions associated with the drug to the FDA in the form of an FDA-1639 Drug Experience Report.
O-label use is the use of drugs in manners other than those described in the FDA approved label { all uses
other than the use(s) for which the drug was approved.202 \After the FDA approves a prescription drug for
one ailment, doctors and researchers often nd other ways to use it, and physicians are allowed to prescribe
a drug for any use if it has been approved by the FDA for some purpose."203
O-Label Use of Fenuramine, Dexfenuramine, and Phentermine
199See Steven R. Salbu, O-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative




203Rebecca Porter, Manufacturers May Promote O-Label Uses For Drugs, 35-oct Trial 92 (1999).
54Fenuramine, dexfenuramine, and phentermine were all approved by the FDA. However, they were approved
as single agent drugs and not for long term use. Specically, fenuramine and phentermine were only
approved for short-term use for a few weeks. The longest study done on dexfenuramine was for one year.
There were three common o-label uses of fenuramine during the fen-phen craze: (1) Extended long term
use beyond brief approved periods; (2) Combination use with phentermine; and (3) Use by people who were
not obese.204 No studies were ever submitted to the FDA to show either the eectiveness or safety of the
combination of dexfenuramine-phentermine or fenuramine-phentermine, nor were any studies presented
that addressed the safety of their long-term use.205
At the time of widespread fen-phen use promotion of o-label uses/prescriptions was impermissible.206 In
Washington Legal Foundation v. Friedman, 13 F. Supp. 2d 51, 51-69 (D.D.C. 1998), Judge Royce Lamberth
issued a permanent injunction against the FDA for restricting dissemination on o-label drug use. The FDA
204Redux was approved by the FDA only on the condition that it be prescribed exclusively for obesity. Obesity was dened
as a BMI (kilograms divided by square meter) of 30 or above. In addition, Redux was to be prescribed only together with an
overall weight loss regimen that included dieting and increased physical activity. The FDA saw it as a drug with a risk that
was to be used for a serious health condition (obesity) under controlled circumstances. This was not the reality at all. Redux
was prescribed widely for people to lose a `few' pounds for cosmetic purposes. Redux sales representatives visited all types of
doctors. It was reported that fen-phen was given away free when people signed up at weight loss centers like Nutri-System,
and that some doctors would give `lectures' to fty to seventy-ve \patients" at a time and then hand out prescriptions where
the physical exam consisted only of a questionnaire. Sometimes the doctor only appeared on videotape. See Vivi Vanderslice,
Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in Light of Amchem v. Windsor, 35 Cal. W. L. Rev.
199, 203 (1998); See also Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard
Combination to Swallow, 15 J. Contemp. Health L. & Pol'y 207, 225 (1998).
205In the interview with Dr. Marnell, she expressed the view that doctors had much to do with creating the fen-phen problem
because they widely prescribed the drugs o-label{ in combination and for longer periods of time than approved by the FDA
{ and they discounted the PPH risks. See Interview with Dr. Tori Marnell (March 18, 2000). A USA Today article from
1999 also expressed that sentiment, stating \Doctors also must share the blame for the fen-phen mess, experts say, because
they prescribed the diet-drug combination even though the drugs weren't tested together or recommended for tandem use. As
many as 6 million people are believed to have obtained prescriptions for the drug combination." Steve Sternberg, Lawsuits:
Drug Development's Side Eects, USA Today, Jan 12, 2000, Health Section. The same thing occurred with American Home
Products' recall of the pain reliever Duract, because it led to cases of kidney failure. The USA Today article follows that
\the Duract tragedy also occurred because the drug was misprescribed. Many doctors oered it for long-term relief of chronic
pain, although AHP warned against using the drug for longer than 20 days. `The doctors structured those treatments,' says
George Sasic, an industry analyst who tracks AHP for Dominick & Dominick in New York." Id. Raymond Woosley, Professor of
Pharmacology at Georgetown, says that these problems should not come as a surprise. He claims that few doctors have sucient
training in pharmacology and doctors are inundated with information from drug companies, journals, and trade publications,
which they must evaluate to the best of their abilities. He says this is dicult for today's doctors, since their average age is 45
and three-fourths of the medicines they prescribe today were not in existence when they were in medical school. See id.
206Note: In January of 1997 Wyeth-Ayerst sent letters to 470,000 medical professionals to advise them that it did not
recommend the concomitant use of fenuramine and phentermine in the fen-phen combination. See Jaime A. Wilsker, One
Half-Phen In the Morning/One Fen Before Dinner: A Proposal For FDA Regulation of O-Label Uses of Drugs, 6 J.L. &
Pol'y at 828.
55changed its policy on the matter with the Food and Drug Administration Modernization Act that President
Clinton signed on November 21, 1997 (the \Modernization Act"). The Modernization Act changed the
law on o-label promotion and made it a permissible practice in certain circumstances.207 The change in
permitting certain o-label promotions did not come about until Pondimin and Redux had been pulled from
the market, so there is no way to tell what changes the Modernization Act may have had on the level of use of
the drugs.208 However, products liability attorney Robert Habush of Milwaukee's Habush, Davis & Rottier
claimed that \had it not been for the [o-label promotion] ban, drug companies undoubtedly would have
disseminated two articles that appeared in peer-reviewed journals touting the drug combination fen-phen as
a diet aid. And that, he said, would have dramatically increased the number of people taking fen-phen"209
Arguments For and Against O-Label Use
207The Modernization Act permits drug manufacturers to disseminate qualied forms of written information concerning
the safety, eectiveness, or benets of o-label uses to certain groups, including health care practitioners, pharmacy benet
managers, health insurance issuers, group health plans, and federal or state governmental agencies. To qualify to disseminate
the information the drug manufacturer must have led an application or received a biologics license for the drug under the Public
Health Service Act. Only authorized information is permitted, which includes unabridged peer reviewed articles (indexed in the
Index Medicus of the National Library of Medicine of the National Institutes of Health) or qualied reference publications. The
information cannot be derived from research conducted by another manufacturer unless the manufacturer received permission
from the rst manufacturer to disseminate the information. The information must be provided to the Secretary of Health and
Human Services sixty days before dissemination. The manufacturer must also forward to the DHHS Secretary any clinical
trial information or reports it has on the o-label use's safety and eectiveness. The statute also requires the manufacturer to
submit a supplemental application for o-label use. The DHHS Secretary can exempt the manufacturer from that provision if
it would be economically prohibitive for the manufacturer to incur the costs necessary for such an application. This exception
addresses very small manufacturers and follow-up studies that would be extremely expensive. In it's o label promotion, the
manufacturer must disclose that the information concerns a drug that has not been approved or cleared by the FDA, must
enclose ocial labeling and labeling updates, and must identify sources of funding for research. The presentation of information
must be complete and not tilted in favor of the manufacturer's promotion for o-label drug use. See Steven R. Salbu, O-Label
Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy, 51 Fla L.
Rev at 209 { 216.
The fen-phen phenomenon predated the Modernization Act, and American Home Products was therefore not authorized to
promote o-label fenuramine/dexfenuramine use. American Home Products maintained that Redux and Pondimin were to
be used only in obese patients, it did not recommend their combined use with phentermine, and it reiterated that Redux had
only been tested for up to one year and Pondimin was only approved for short term use. See id.
208In discussing Redux promotion, one article indicated that Wyeth-Ayerst sent salespeople to visit all types of doctors, not
just obesity specialists, after Redux was approved. See Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The
Story of How Fen-Phen and Redux Came to Be Used By 6 Million Americans is Chilling, 34 Trial at 79. Since Redux was
approved only for the treatment of obesity as dened as a BMI greater to or equal to 30, promoting Redux to non-obesity
specialists may have been an o-label promotion. However, many doctors who are not obesity specialists may treat patients
with a BMI over 30 and obese patients may not necessarily only seek treatment from an obesity specialist. In the interview
with Dr. Marnell she indicated that she had several patients with a BMI over 30 who took fen-phen, and she was not an obesity
specialist who limited her practice to overweight patients. See Interview with Dr. Tori Marnell (March 18, 2000).
209Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The Story of How Fen-Phen and Redux Came to Be
Used By 6 Million Americans is Chilling, 34 Trial at 79
56While it arguably led to serious problems in the fen-phen situation, o-label use is a common and legal
practice.210 The American Medical Association estimates that 40 to 60 percent of all U.S. prescriptions
today are o-label uses, including many AIDS and cancer medications.211 \Today, o-label use has become
an important part of mainstream, legitimate medical practice. Many o-label uses are recommended by
medical textbooks, research institutes, and professional organizations, as well as standard pharmaceutical
reference works. According to some estimates, almost half the United States population may be taking a
medication prescribed for an unapproved reason."212 O-label treatments are considered amongst the most
eective treatments for cancer patients and have been called \the hallmark state of the art treatment".213
In addition, the majority of drugs prescribed for wound healing are o-label, and experts suggest that 90 to
100% of AIDS treatments are o-label, including the new antiretroviral combination therapies.214 O-label
prescribing is common in obstetrics, infectious disease, and pediatrics.215 Most pediatric prescriptions are
o-label because many drugs are not tested in children. Proponents of the practice argue that o-label
prescription and use allows expedition of the use of eective new treatments, since it would be prohibitively
210See Cheyenne v. Heckler, 718 F. 2d 1174, 1191 (D.C. Cir. 1983) (holding that a doctor may, as part of the practice of
medicine, prescribe a dierent dosage or use for the drug as long as the use is not contraindicated); See also Krauss, Loosening
the FDA's Drug Certication Monopoly: Implications for Tort Law and Consumer Welfare, 4 Geo. Mason L. Rev. 470
(1996) (stating that writing an o-label prescription is not per se negligent, and the standard of care is usually established by
evidence of community medical standards).
The American Medical Association's policy is that the doctor may prescribe a drug o-label when the o-label use is based
on sound scientic evidence and sound scientic opinion. Substantial evidence has been dened as two or more adequate and
well-controlled studies performed by experts qualied by scientic training and experience. See Rayburn & Farmer, O-Label
Prescribing During Pregnancy, 24 Obstet. & Gynecol. Clin. N. Am. 471 (1997).
A doctor could be subject to malpractice if he denied a patient what could have been the best possible treatment because that
treatment was not included in the drug's ocial labeling. See Policy Statement { Unapproved Uses of Approved Drugs: The
Physician, the Package Insert, and the Food and Drug Administration: Subject Review, 98 Ped. 143 (1996).
211See Marlene Cimons, Public Policy: FDA's Approval Process Faces Challenge in New Senate Bill Finding the Proper
Balance Between Protecting and Overburdening Americans is at the Heart of Renewed Debate Over the Agency's Mission, Los
Angeles Times, July 22, 1997, at A5.
212Veronica Henry, O-Label Prescribing: Legal Implications, 20 J. Legal Med. 365 (1999).
213Id.
214See Steven R. Salbu, The FDA And Public Access To New Drugs: Appropriate Levels Of Scrutiny In The Wake of HIV,
AIDS, and the Diet Drug Debacle, 79 B.U. L. Rev. at 189.
215Veronica Henry, O-Label Prescribing: Legal Implications, 20 J. Legal Med. at 365.
57expensive and time-consuming for drug-makers to have to le a new drug application with the FDA each
time they discovered a new use for their drug.216 Drug makers would not have an incentive to go through
the timely and costly process, since \if an o-label use is already well known among physicians, then adding
it to the label would have little eect on sales. Furthermore, because less than the full life of the patent
is remaining, it is more dicult for a drug manufacturer to recover the monetary investment in seeking
approval."217 Proponents cite the vast portion of today's drug use that is o-label as support for the
practice, claiming that o-label use has become an entrenched, important, and indispensable part of modern
medical therapy.218
While o-label use is common and legal, the diet drug experience demonstrates that it can lead to problems
when \safe" drugs are used in dierent combinations and for dierent time periods than the FDA has
approved. \The FDA agrees that there are safe o-label uses for drugs, but some uses are hazardous. For
example, Duract, an eective short-term painkiller, proved dangerous when prescribed beyond ten days,
which doctors routinely did. Heart drugs used to treat severe heart irregularities prescribed o-label for
slight arrhythmia have caused an estimated 50,000 deaths."219 Doctors are not regulated in their o-label
prescriptions, even when these prescriptions in eect create a new drug dierent from the one that received
FDA approval. Doctors who prescribed fen-phen and those who prescribe other o-label drugs are, \in
eect, creating a new drug that has not been proved generally safe and eective for human consumption"220
Opponents of o-label use argue that \the lack of regulatory control over o-label applications endangers




219Rebecca Porter, Manufacturers May Promote O-Label Uses For Drugs, 35-oct Trial 92 (1999).
220Jaime A. Wilsker, One Half-Phen In the Morning/One Fen Before Dinner: A Proposal For FDA Regulation of O-Label
Uses of Drugs, 6 J.L. & Pol'y at 798.
221Steven R. Salbu, O-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and
58since o-label drug uses/prescriptions \lack the FDA imprimatur, and therefore also lack the consumer
safeguarding we usually associate with prescription drugs. The law requires that manufacturers submit
rigorously developed evidence of safety and ecacy to receive approval to market a drug for purposes noted
in the labeling. No such requirement is imposed in regard to subsequent, o-label uses. Accordingly,
information regarding proper dosage, as well as drug safety and ecacy for the o-label application, need
not be collected or recorded."222 Opponents of o-label drug use characterize it as `experimenting on the
public' and often cite the fen-phen asco as evidence for their claim that o-label drug use can be harmful
as well as benecial.223
O-Label Use and Physician Liability in Fen-Phen Cases
O-label use can be an issue in attempting to hold the prescribing doctor liable for giving a patient the
fen-phen combination for longer periods than originally approved by the FDA.224 \As the FDA interprets
the law, after the FDA approves a drug with its labeling, the physician `is then responsible for making the
Regulatory Policy, 51 Fla L. Rev at 202.
222Id.
223See id. at 203.
224Although individual doctor liability is of importance when discussing o-label drug use, physician liability is not the focus
of this paper. However, physician liability is clearly a key issue in fen-phen litigation. In addition to liability for o-label
prescriptions, plaintis will \allege that physicians prescribed the drugs for cosmetic weight loss, notwithstanding the fact that
the drugs were designed to treat obesity, as dened by a high body mass index. They will also assert that physicians exceeded
the daily dosage recommendations and failed to monitor the patients for adverse side eects." Evans and Kerner, A Primer on
Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 359.
However, whether or not a physician was negligent in a particular fen-phen case is fact specic and depends on the patient's
weight/health problems and the individual doctor-patient relationship and interaction concerning the fen-phen prescription.
While clearly in many cases there was no real doctor-patient relationship to speak of, where patients got fen-phen o the internet
or from \pill mills", in other cases doctors did discuss the risks they were aware of (PPH) with their patients and conduct a
reasoned analysis of whether the patient's obesity problem warranted the use of fen-phen. \The feasibility of a negligence claim
depends on each patient's experience with their doctor." Caren A. Crisanti, Product Liability and the Prescription Diet Drug
Cocktail, Fen-Phen: A Hard Combination to Swallow, 15 J. Contemp. Health L. & Pol'y at 226. See also Interview with
Dr. Tori Marnell (March 18, 2000).
Whether or not doctors are liable will depend on the particular situation of the doctor and the patient, and \physicians who saw
their patients on a regular basis and performed routine physical examinations before prescribing these drugs will probably fare
better than those who casually prescribed the drugs without adequate follow-up." Evans and Kerner, A Primer on Fen-Phen
Litigation: Allegations and Defenses, 65 Def. Couns. J. at 359.
The liability issues in this paper concentrate on American Home Products. The issue of risk-benet analysis and doctor
patient relationships is discussed in the section on cosmetic weight loss and obesity, which are important issues in the fen-phen
experience.
59nal judgment as to which, if any, of the available drugs the patient will receive in light of the information
available in the labeling and other adequate scientic information available to him"225 In a Philadelphia fen-
phen PPH trial, the prescribing doctor was held liable for half of the $8 Million verdict. The doctor prescribed
fen-phen for the plainti between 1995 and 1997.226 The plainti's lawyer stated that \the claim against
[the prescribing doctor] was that he not only prescribed the drug beyond the two weeks recommended by the
manufacturer, but he prescribed it for years... and he prescribed it until she [the plainti] called him and
said that she had heard on CNN when she was in Italy touring that there were side eects"227 The plainti's
expert at trial testied that \having prescribed the medication for a longer period than the manufacturer
recommended, Guinta [the prescribing doctor] should have monitored Scott [the plainti] more closely than
he had."228 The lawyer for the defendant doctor \countered with evidence that `o-label' usage of the drug
was legal and ethical and appropriate in [this] case."229 The plainti won a verdict of $8 million, which
the jury decided was to be equally split between American Home Products and the prescribing doctor (the
doctor led a cross claim against American Home Products after the plainti led suit against him.) The
$8 million verdict was compensation for pain and suering, lost wages (the plainti was a well-known jazz
musician) and medical expenses.230
Argument O-Label Use Should Be Illegal For Diet Drugs
Overall, o-label use has benets and drawbacks. It has led to numerous innovations in medicine and is
especially critical in the context of AIDS and oncology. However, in the fen-phen situation it was not a great
225Margaret Gilhooley, When Drugs are Safe For Some But Not Others: The FDA Experience and Alternatives for Products
Liability, 36 Hous. L. Rev. 927, 939 (1999).





60success. Diet drugs present a special situation because of the danger of use in cases where the patient is not
suering from any disease (obesity) but rather wishes to improve his or her appearance. In the context of
diet drugs, where the only real potential to reign in cosmetic weight loss use lies with the label, the FDA
should not allow o-label use. This would still allow for o-label use in cases where it leads to new drug
innovations, but it would address the problem of allowing o-label use in the diet drug context where the
label is the prime tool in preventing non-obese persons from taking the drugs. Such a rule could be enforced
by imposing physician liability in cases where diet drugs cause health problems and they were not prescribed
to a clinically obese person. This would provide an incentive to keep diet drugs for the obese. Where the
person is clinically obese and the FDA approved the drug for the treatment of obesity, presumably the FDA
had already considered the risks-benet analysis and decided that the drugs' risks were outweighed by its
benets in treating obesity and its attendant health harms. Where the use was o-label and the patient was
not obese, the doctor would be liable. This would go a long way towards preventing use of diet drugs where
the risks do outweigh the benets of the drugs when the patient does not suer from the disease the drugs
were meant to treat. O-label use is generally benecial and should be permissible, but in the diet drug
context, with the rampant cosmetic weight loss use problem, o-label use should not be permitted.
PART IIFEN-PHEN LITIGATION AGAINST AMERICAN HOME PRODUCTS
LIABILITY OF DRUG MANUFACTURERS FOR PRESCRIPTION DRUGS
The main defendant in the fen-phen products liability cases has been American Home Products and its A.H.
61Robins and Wyeth-Ayerst subsidiaries, who marketed Pondimin and Redux.231 Plaintis care currently
claiming that American Home Products misled doctors, consumers, and regulators about the dangers of
Redux and Pondimin.232 In the opening statements in the Vadino New Jersey medical monitoring class
action trial233, lead plaintis' attorney Esther Berezofsky, said that American Home Products should be held
liable because it \enjoyed healthy sales while withholding information from consumers about its potentially
deadly side eects" and that it was \not being honest with the FDA, not telling the doctors, and not telling
you [the jury]" about the health risks associated with Pondimin.234 One plainti's lawyer, Paul Rheingold,
wrote that \there is blame enough to go around. The doctors who set up store-front fen-phen clinics and
prescribed the drugs are obvious culprits. So are drug companies that proted nancially from the fad and
may have neglected to pass on information about deadly side eects."235 There are several claims plaintis
can bring against American Home Products, and the most likely success plaintis would have is with a
failure to warn claim regarding the increased PPH risk. Since the drugs were all FDA approved, a strict
231There are other fen-phen defendants, namely Interneuron Pharmaceuticals, Laboratories Servier, and the phentermine
defendants (including Eon Laboratories and SmithKline Beecham). However, due to the dominance of American Home Products
as the most prominent defendant, this paper only discusses litigation against American Home Products. American Home
Products is also the defendant involved in the proposed Settlement Agreement dealt with at length in this paper.
232See Bob Van Voris, Diet Drug Class Action Set For August Trial: Plaintis Are Seeking Medical Monitoring, Nat'l L.J.,
Aug. 9, 1999, at A6.
Judge Bechtle described the variety of claims brought by fen-phen plaintis as follows: \The claims in in-
dividual Diet Drug Litigation actions vary, but they principally allege state law claims including product li-
ability, negligence, misrepresentation and breach of warranty. Some of the cases request punitive damages.
The plaintis in these actions allege that their ingestion of the Diet Drugs caused various illnesses, including,
but not limited to PPH and valvular heart disease. In addition, many actions brought by plaintis without
present injury request legal or equitable relief in the form of medical monitoring or refunds of purchase prices."
In re Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Jeers v. American Home Products Corporation,
No. CIV. A. 98-20626 1999, Memorandum and Pretrial Order No. 865, U.S. District Court for the Eastern District of Penn-
sylvania, Aug. 26, 1999, WL 673066 (E.D. Pa.).
233Judge Marina Corodemus dismissed the jury in the Vadino trial on October 4, 1999 as American Home Products and
plaintis' lawyers neared completion of the Settlement Agreement. The Vadino class was seeking echocardiograms for a 10
year period. The cost of such a medical monitoring program could be up to $1 billion for American Home Products. Judge
Corodemus said the case was not dismissed, and that if a Settlement was not reached she would conduct a bench trial. The
Settlement was announced shortly thereafter, and it encompasses all of the plaintis in the Vadino class action. See Edward R.
Silverman, Diet Pill Jury is Dismissed as Settlement Grows Near, New Jersey Star Ledger, Oct. 5, 1999, available online
at www.nj.com/business/ledger/d28061.html; See also Matt Ackermann, Fen-Phen Lawyers Stick to Texas Formula: As New
Jersey Trial Continues, A Similar Class-Action Suit is Dismissed in California, New Jersey Law Journal, Aug. 23, 1999.
234Matt Ackermann, In Fen-Phen Trial, the Uninjured Sue for Preventative Maintenance, New Jersey Law Journal, Aug.
16, 1999.
235Paul D. Rheingold, Fen-Phen and Redux: A Tale of Two Drugs - The Story of How Fen-Phen and Redux Came to Be
Used By 6 Million Americans is Chilling, 34 Trial at 82.
62liability claim is not likely to succeed. In addition, if the valvular heart disease risk was not uncovered until
shortly before the withdrawal of Redux and Pondimin from the market, a failure to warn claim for the valve
problems will not likely be successful. A discussion of the alleged wrongdoing of American Home Products
with respect to Redux and Pondimin follows in the section below on American Home Products. Plaintis'
lawyers have alleged a host of irresponsible actions and failures to warn on the part of American Home
Products, while the company has steadfastly maintained no wrongdoing in relation to the diet drugs.
Failure to Warn Claims
If American Home Products supplied an adequate warning about fenuramine and dexfenuramine, AHP
will not be held strictly liable for adverse eects resulting from ingestion of these drugs.236 Comment k to
x 402A of the Restatement (Second) of Torts provides that strict liability is not applicable to a sale of a
product that is incapable of being made safe for its intended use, so long as its utility outweighs its apparent
risks237 and a warning is supplied. Comment k contains a list of examples of \unavoidably unsafe" products
and all refer to prescription drugs.238 \Many jurisdictions have applied comment k to cases involving the
liability of drug manufacturers [and] [e]ven if a new drug proves less valuable than initially perceived, the
manufacturer may still be exempt from strict liability under comment k provided it was unaware of the drug's
risks. Therefore, an manufacturer that acts reasonably in manufacturing and distributing an unavoidably
unsafe product will not be subject to strict liability for harm caused by this product."239 The law states
that \a manufacturer is not strictly liable for injuries caused by a prescription drug so long as the drug was
properly prepared and accompanied by warnings of its dangerous propensities that were either known or
236See Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to
Swallow, 15 J. Contemp. Health L. & Pol'y at 220.
237See Restatement (Second) of Torts x 402A cmt. k (1965).
Courts generally assume that the health benets of drugs outweigh risks that result from their use.
238See id.
239Jaime A. Wilsker, One Half-Phen In the Morning/One Fen Before Dinner: A Proposal For FDA Regulation of O-Label
Uses of Drugs, 6 J.L. & Pol'y at 815 { 816.
63reasonably scientically knowable at the time of distribution."240 As a matter of law, if a drug is properly
prepared and has received FDA approval, the product cannot be \defective".241 The policy rationale for this
is that drug companies would be discouraged from undertaking research and development of new benecial
pharmaceuticals if they were held strictly liable for prescription drug adverse eects.242
The manufacturer still has a duty to warn of drug dangers. The duty to warn applies to the medical profes-
sion rather than the individual patient.243 The manufacturer must warn the attending physician of the risks
associated with the drug's use. The manufacturer also has a continuous duty to remain informed of scientic
developments relating to the manufacturer's drug and to inform the medical profession of any additional
adverse eects associated with the drug's use. If the manufacturer has given proper warnings of potential
dangers associated with the drug and the warnings were read by the prescribing physician, the manufacturer
240Id.
241See Grundberg v. Upjohn Co., 813 P.2d 89, 97 (Utah 1991).
242See Brown v. Superior Court, 751 P.2d 470, 482-83 (Cal. 1988).
243This is the \learned intermediary" doctrine. In some circumstances the learned intermediary doctrine has been eroding,
and some of these contexts are relevant in the fen-phen situation. See Perez v. Wyeth Laboratories, Inc., 1999 WL 606729
(N.J.) In Perez, on Aug. 9, 1999 the New Jersey Supreme Court limited the learned intermediary doctrine with respect to drugs
where the manufacturer engaged in extensive direct to consumer advertising. The court reasoned that the medical profession
had changed with the advent of direct to consumer drug advertising, along with the prevalence of HMO's and third party payers
of drugs. The court held that drug manufacturers could not engage in direct to consumer advertising while maintaining that
they did not have to inform the consumer of the drug's risks. Direct to consumer advertising attempts to reach out to patients
rather than their doctors, making patients the ones who required/would be receptive to the manufacturer's warnings. See id.
Fen-phen was not per se direct marketed to consumers as was the Norplant contraceptive at issue in Perez. However, weight loss
centers like Jenny Craig ran ads that touted \Medical Weight Loss" programs, arguably reaching patients/consumers directly
without requiring the consumer to go through a doctor to rst get the idea of taking diet drugs. See Interview with Dr. Tori
Marnell (March 18, 2000).
In several states there is a narrow exception to the learned intermediary doctrine for contraceptives. This is because the
physician plays a passive role in prescribing contraceptives to women. Often after an initial consultation with a doctor a woman
will get a contraceptive prescription for up to a year, with limited requirements for continued physician contact. In such a
situation, several courts have held that there is a duty to warn the patient directly rather than the medical profession. In
the Linnen PPH wrongful death trial, the plaintis tried to argue that that exception to the learned intermediary doctrine
applied with fen-phen. The plaintis claimed that the fen-phen prescription situation was very similar to the birth control
prescriptions. They said that most fen-phen users were healthy young women and often there was very limited contact with
doctors, since the drugs were often handed out at \pill mills" run by nurses and were easily available over the phone and
internet. The Linnen court held that such a characterization was inaccurate in the Linnen case and did not hold that the
birth control exception to the learned intermediary doctrine generally applied in fen-phen cases. Mary Linnen had gone to her
doctor to inquire if there was a medical reason that she was having diculty losing weight. Her doctor conducted numerous
tests to determine if she had a medical problem that was preventing her from losing weight. Only when medical tests came
back negative did her doctor suggest fen-phen. In addition, Mary Linnen's doctor only gave her a six-week prescription as
opposed to the typical six month to one year prescription for contraceptives. Based on these facts, Judge Brassard in Linnen
distinguished the fen-phen situation from the birth control context and held that the learned intermediary doctrine did apply.
See Linnen v. A.H. Robins Company, Inc., 2000 WL 89379 (Mass. Supp. 1999).
64has fullled its duty and is not liable.244 However, \when the warning to the intermediary is inadequate or
misleading, the manufacturer remains liable for injuries sustained by the ultimate user."245 The company is
also not liable if the prescribing doctor relies solely on his own knowledge when deciding to prescribe a drug,
although \even in a situation where a doctor is negligent in prescribing a drug, the manufacturer's liability
will not be vitiated when it has failed to warn the `learned intermediary."'246
In the case where a manufacturer fails to provide a warning, that manufacturer is not strictly liable for
failure to warn without a showing of proximate causation that an adequate warning would have prevented
the injury. \If such an injury has never occurred before and with the exercise of due care, the manufacturer
could not have foreseen such an injury, there can be no duty to warn." 247
Plaintis can also bring a negligent failure to warn claim against American Home Products. A drug manu-
facturer has a duty to warn for risks it reasonably should have been aware of. The reason for this negligence
cause of action is so manufacturers do not put their heads in the sand in an attempt to avoid learning about
new risks associated with the drugs they market. This may be a strong claim for fen-phen plaintis, if
they can prove that American Home Products knew or should have known about the valvular heart disease
problems. \Manufacturers are required to continually investigate and update the information and labeling of
their products on the market; this includes conducting appropriate tests as new questions arise."248 Plain-
tis can also allege that the warnings that American Home Products did provide were diluted by the mass
media promotion and hype concerning the fen-phen combination, which gave rise to a duty for American
Home Products to change its warnings to be eective in light of the background dilution. Plaintis could
argue that American Home Products was fully aware of the widespread use of the drug combination and
244In the interview with Dr. Marnell, she indicated that American Home Products had warned of the dangers of PPH
associated with fenuramine and dexfenuramine. She said that she went over that increased PPH risk with each patient who
took fen-phen. See Interview with Dr. Tori Marnell (March 18, 2000).
245In re Norplant Contraceptive Prods. Liab. Litig., 955 F. Supp. 700, 703 (E.D. Tex. 1997).
246Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to Swallow,
15 J. Contemp. Health L. & Pol'y at 220.
247Id.
248Id. at 230.
65should have done additional testing to ensure the safety of the combined use of Redux and Pondimin with
phentermine for longer periods of time. Plaintis can claim that manufacturers are \in the best situation
to assess the pharmacodynamics of their products, and for this reason plaintis will allege that the man-
ufacturers knew of the risks associated with the diet drugs but chose to conceal or downplay them... just
what the manufacturers knew and when they knew it will be a question for the trier of fact."249 It appears
that American Home Products may have had information about PPH cases that it did not report to the
FDA, but the valvular heart disease problem basically appears to have been discovered by the Mayo Clinic
in 1997. Perhaps some evidence may emerge that shows AHP knew of the valvular heart disease problem
all along, but as of the present time this is not the case.250 Overall, \when evaluating the strength of a fen-
phen plainti's case, counsel should consider whether the warning could be deemed to have been diluted by
over-promotion, statements by salesmen, and/or language in the warning. Attorneys will also need to review
reported scientic studies, reports submitted to the FDA, and any reports submitted to the manufacturer
to determine if the manufacturer should have known of the risk."251
Where the drug manufacturer has provided a label, issues of federal preemption come up with state law tort
claims, since the FDA mandates what information must appear on the drug's label. With the fen-phen case
such preemption issues may be overcome because fenuramine and dexfenuramine were not being used in
the manner indicated on their labels.252 The test in a negligent failure to warn case is:
249Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 358.
250There have been claims that the valvular problems were known about to a degree as early as 1994, but the general consensus
is that they were found by Dr. Connolly and her colleagues at the Mayo Clinic in 1997.
251Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to Swallow,
15 J. Contemp. Health L. & Pol'y at 231.
252The law is unclear on federal pre-emption of state law tort claims by the FDCA. The Fifth Circuit has held in Hurley
that FDA warning regulations may implicitly pre-empt failure to warn claims. The court in Hurley did place a limit on such
pre-emption, stating that a manufacturer may still be liable for failure to warn if it did not provide the FDA with information
relevant to approval of the drug or relevant information after the drug's approval. Other courts have disagreed with Hurley and
held that FDA labeling requirements do not pre-empt state failure to warn claims. Such cases include In re Tetracycline Cases,
Mazur v. Merck & Co, and Feldman v. Lederle Lab. See Darrell M. Grams and Sean M. Higgins, Food, Drug and Cosmetic
Act Regulations May Trump State Failure-To-Warn Liability, Natl. L.J., March 15, 1999, at B8. Overall, the law is unsettled
and fen-phen \counsel should be cognizant of arguments for and against conict pre-emption. In rejecting implied conict
pre-emption, courts have characterized FDA regulations as `minimum requirements.' Courts have found strong support for this
in the FDA's reliance on manufacturers to provide clinical and other data to formulate and evaluate warnings. A close reading
66whether the physician, and therefore, the patient, was provided with the detail needed to make
an informed decision regarding the drug therapy. A plainti must prove three elements in a
negligent breach of duty to warn claim: (1) the plainti must show the manufacturer knew or
should have known the danger of the drug; (2) the manufacturer must not have had any reason
to believe that those taking the drug would realize the drug's danger; and (3) the plainti must
prove the manufacturer did not take reasonable steps to inform those taking the drug of its
dangerous condition. If the plainti proves all three elements, the manufacturer may be held
liable for damages.253
One issue that may come up in some jurisdictions regarding the negligence of American Home Products or
the negligence of the prescribing doctor is contributory negligence. Statements by some fen-phen patients
that they would take the drugs again even after suering from heart valve damage and eorts by many
former fen-phen users to obtain fen-phen from Mexico and Thailand indicate that patients may have ignored
warnings in their quests to obtain the diet drugs. One man who lost eighty pounds on fen-phen and gained
it back after Redux/Pondimin were withdrawn from the market said \I'm not so certain I many not risk
fen-phen again to lose weight. But that's a fat person talking."254 Such behavior indicates that in some
situations a stronger warning by American Home Products would not have led to a dierent outcome in
terms of fen-phen usage. \In the fen-phen situation, there may even be evidence to show that the patient,
given adequate warning, would still have decided to take the drug, despite the drug's inherent risk in an
eort to lose weight. This will play an important role in pure contributory negligence jurisdictions."255
The issue with American Home Products is whether they adequately warned the medical profession about
the true level of increased PPH risk (or the true level they should have reasonably been aware of), and also
whether they informed the medical profession about the risk American Home Products knew or reasonably
of FDA labeling regulations, however, suggests potential conicts with state common law failure to warn liability. For example,
a judgment against a manufacturer for failing to warn of a condition the FDA does not deem severe or supported by reasonable
evidence potentially conicts with the FDA warning regulation." Id.
254Kris Huntley, Fen-Phen King Turns Tables On Drug Maker: Once a Promoter and User of the Weight-Loss Drug Com-
bination, John Trevena Has Filed a Civil Suit Against Drugmaker Wyeth-Ayerst Laboratories, Inc., Accusing It of Fraud, St.
Petersburg Times, Oct. 10, 1999, Business Section.
255Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to Swallow,
15 J. Contemp. Health L. & Pol'y at 231.
67should have been aware of regarding valvular heart disease. American Home Products had a duty to warn
the health care profession about risks it knew about that were associated with Redux and Pondimin and
also about risks it reasonably should have known about regarding the use of Redux and Pondimin. Whether
it did this is an issue to be resolved in litigation.
The ultimate liability of American Home on the failure to warn claim is uncertain.256 It can be summed up
as follows:
In the fen-phen situation, there were warnings regarding the danger of the possibility of brain
damage and pulmonary hypertension. The heart-valve defects were only discovered shortly
before the ban. The manufacturers followed FDA guidelines to warn doctors of the known
dangers, and there appears to be no evidence to show that the manufacturers of fenuramine
and phentermine should have known of potential heart valve disgurement caused by the use of
the combined drugs. Here, it must also be noted that the drugs were not manufactured jointly,
the doctor was solely responsible for prescribing their use in combination. Still, a plainti's
case against the manufacturer may have some merit when arguments are posed that more
thorough testing should have been conducted. Possible justications for better testing are that
the manufacturer had reason to believe the diet drug would be misused, or that there was
widespread use of the drug cocktail and therefore, testing the combination of the drugs was
necessary.257
Strict Liability/Design Defect Claims
A manufacturer can be held strictly liable for the side eects of a drug if the drug is unreasonably dangerous
to the consumer. To sustain a strict liability claim, the plainti must prove that the drug was inherently
256There may also be causation problems in valvular heart disease fen-phen litigation. \As the facts stand, there is no
denite causal connection between the drugs and the heart problems. Cardiovascular tests were never run for this pool of
patients before treatment to determine if they had heart problems prior to drug therapy. Furthermore, when dealing with
an overweight population, there is always a tendency toward heart problems due to the strain on the heart caused by excess
weight" Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to
Swallow, 15 J. Contemp. Health L. & Pol'y at 223. While the Mayo clinic studies found approximately 30% of fen-phen
users suered from valvular heart disease as opposed to less than 5% for the background population, some later studies have
found no causal connection between valvular heart disease and fen-phen ingestion. The Mayo clinic also only had a pre-fen-phen
use echocardiogram for one patient who had valvular heart disease after taking fen-phen. The pre-diet drug echocardiogram
for that patient was normal. Several doctors have claimed that further studies need to be completed on overweight people
who recently lost weight with before and after echocardiograms in order to determine if there is a causal connection between
fen-phen and valvular heart disease. For PPH claims the IPPHS provides a solid basis for a causal connection between PPH
and anorectic drugs, so causation will not likely be a heavily contested issue in PPH claims as opposed to valvular heart
disease. See CNN Interactive, Valvular Heart Disease Associated With Fenuramine-Phentermine { Dr. Heidi M. Connolly
{ Manuscript Of Study Submitted To New England Journal of Medicine, CNN Website, July 8, 1997, available online at
www.cnn.com/Heath/0/07/08/fenphen.report/.
68defective.
In defect litigation, prescription drugs are treated dierently than non-drug items such as planes and auto-
mobiles. Prescription drugs are inherently dierent from these other items, as they are inherently unsafe to
a certain degree and prone to cause side eects.258 The Restatement (Third) of Torts does not consider a
prescription drug with adequate warnings to the physician to be defective if the drug is safe and eective for
some patients but not for others. The Restatement (Third) of Torts holds a prescription product defective
\if the foreseeable risks of harm... are suciently great in relation to its foreseeable therapeutic benets
that reasonable health care providers, knowing of such foreseeable risks and therapeutic benets, would not
prescribe the drug... for any class of patients."259 This contrasts with the general test for non medical
products, which asks whether \the foreseeable risks of harm posed by the product could have been reduced
or avoided by the adoption of a reasonable alternative design" The test for prescription drugs is more dicult
to meet so as to give pharmaceutical companies enough discretion to develop useful drugs. The Restatement
assumes that doctors informed by adequate labeling will be able to ensure that the right drugs go to the
right patients, and also that the regulatory system is the best way to set drug design standards.260 The
Restatement (Third) defect test \looks not at the existence of reasonable alternatives, but at whether, in the
judgment of reasonable and informed health care providers, the risks of the product outweigh its benets for
all classes of patients."261 FDA approval is extremely signicant in defect litigation, since \[i]n most cases,
the particular use of any drug approved by the FDA is likely to be considered a reasonable use... In the
typical case, when the FDA-approved use is a reasonable use, the Restatement test will preclude any nding
of a design defect with respect to risks from o-label and other misuses of approved drugs, even if these risks
are unreasonably high. The Restatement test for defective drugs, in eect, leaves the decision on the use of
258Id. at 232.
259Restatement (Third) of Torts: Products Liability x 6(c) & cmt. b (1998).
260See Margaret Gilhooley, When Drugs are Safe For Some But Not Others: The FDA Experience and Alternatives for
Products Liability, 36 Hous. L. Rev. 927 (1999).
261Id at 936.
69an approved drug for other uses, even unreasonable ones, to the judgment of a reasonable physician guided
by adequate warnings."262 The test to determine if a product has a design defect \for prescription drugs
narrowly focuses only on the risks and benets of the particular product, and, unlike the test for non-drug
products, this test does not expressly provide for a comparison with other products or designs... A drug that
has usefulness to any class of patients is not defective in design even if it is harmful to other patients."263
However, there can be liability for failure to warn even if the drug is not \defective".
American Home Products will likely prevail if plaintis attempt to bring a strict liability claim. Fenuramine
and dexfenuramine were approved by the FDA. They were used in an o-label manner for longer time pe-
riods and in combination with phentermine, but American Home Products was not directly promoting such
uses in accordance with the law at that time. The o-label prescribing doctor legally was able to make the
choice to use Redux and Pondimin in the fen-phen combination. The drugs were approved by the FDA
through the normal approval process, and the FDA presumably considered that their risks were outweighed
by their benets. As to whether the problem was foreseeable, the valvular heart damage problem was not
known at the time the drugs were being widely prescribed to the U.S. population. The increased PPH risk
was known, and arguably American Home Products kept the information from the FDA.
American Home Products can also take advantage of two strong armative defenses for strict liability claims
against it. First, a manufacturer cannot be held strictly liable if the benet of the drug outweighs its risks.
In cases of severely obese plaintis, American Home Products will have a strong argument that the risks
of obesity outweighed the risks of valvular heart damage or an increased risk of PPH. This defense may
not be as strong for plaintis who took fen-phen for cosmetic reasons, but American Home Products never
per se promoted the use of fen-phen for people with a BMI below 30 or for any type of cosmetic weight
loss use. Another armative defense available to American Home Products is the \comment k" defense,
262Id.
263Id. at 930.
70which asserts that the drug was unavoidably unsafe but that its benets outweighed its risks. AHP has to
prove that Redux and Pondimin could not be made safe at the present time due to the current limitations
of human knowledge, but that there was such a high degree of social need for the two drugs that their use
was warranted by their benets.264 American Home Products could assert the high social need for Redux
and Pondimin given the high percentage of Americans who suer from a serious weight problem and the
overwhelming desire of those people to lose weight with the assistance of diet drugs.265
AHP also has an advantage on a strict liability claim in that \[h]istorically, courts have avoided deciding
cases on strict liability theory. In light of the fact that diet products are put on the market for the purpose of
alleviating a health problem, there is a general belief that manufacturers should not be held strictly liable if
the risk is reasonable. In addition, there is no exibility for fact-specic circumstances under strict liability.
The resultant risk of a lawsuit poses a serious threat that could deter health research."266
There is a strict liability failure to warn claim that plaintis could bring in the fen-phen cases. The duty to
warn under a strict liability claim requires the manufacturer to \warn or give directions to prevent the drug
from being unreasonably dangerous. The test for strict liability for duty to warn... is whether the doctor was
properly apprised of all the information concerning the drug."267 American Home Products was not aware
of the heart valve dangers associated with combined use of fenuramine/dexfenuramine and phentermine.
Comment j to x 402A of the Restatement (Second) of Torts suggests that the law does not impose a duty
to warn when the danger is not generally known. Fen-phen users were warned of an increased PPH risk but
not the valvular heart damage risk, which was not known until the Mayo Clinic identied the problem in
1997.268
264See 63 Am. Jur. 2d Products Liability x 591 (1996).
265See Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to
Swallow, 15 J. Contemp. Health L. & Pol'y at 233.
266Id.
267Id. at 235 { 236.
268See id. at 237.
71The above discussion presents the claims that plaintis could bring against American Home Products and
assesses their viability based on the facts of the fen-phen situation. The valvular heart disease claims will
likely be settled by the proposed Settlement Agreement, but these issues will come out with the opt-out
plaintis. In addition, the PPH cases will be tried or settled individually, so liability in PPH cases will
continue to be a viable concern. Overall, there are two sides to the American Home Products liability story
and the cases are often fact specic. In essence, \[a] successful claim in a fen-phen case will depend largely on
subjective circumstances unique to the case, including who is the complainant. Examples of issues that will
have a bearing on the success of a case are: whether the plainti followed a doctor's instructions, whether
the instructions were adequate, and whether the plainti read, and understood the warnings, if there were
any."269 The liability for PPH will be determined case by case, and the fate of the Settlement will basically
cover the liability in the valvular heart disease arena.
THE DEFENDANT - AMERICAN HOME PRODUCTS
Basic Overview of American Home Products
American Home Products is one of the world's largest pharmaceutical companies. It was founded in 1926,
has annual sales of $13.6 billion, and operates in over 100 countries. American Home Products spent over
$1.7 billion in research and development in 1999. American Home Products is a leader in the prescrip-
tion drug market, over the counter drugs, vaccines, biotechnology, agricultural products, and animal health
care.270 American Home Products' principal products include several popular prescription medications and
269Id. at 240
270See\American Home Products Corporation" Corporate Overview, American Home Products Website, available online
at www.ahp.com/overview.htm.
72over the counter products, including Premarin (hormone replacement therapy), Lo/Ovral (a birth control
pill), Advil, Anacin, Dimetapp, Dristan, Robitussin, Centrum, and Chapstick.271 American Home Prod-
ucts' present operating units include Wyeth-Ayerst, Whitehall-Robins (formerly A.H. Robins Company),
Cyanamid, and Fort Dodge Animal Health. American Home Products acquired A.H. Robins Company, with
its well known products { Chapstick and Robitussin { in 1989. AHP focuses its R&D on women's health,
oncology, vaccines, neuroscience, infectious disease, and hemophilia. The Chairman, President, and Chief
Executive Ocer of American Home Products is John R. Staord. American Home Products' corporate
headquarters are located in Madison, New Jersey.272
American Home Products marketed fenuramine and Redux through its subsidiary Wyeth-Ayerst. Wyeth-
Ayerst is the pharmaceutical unit of American Home Products, and the Wyeth-Ayerst organization includes
Wyeth-Ayerst Laboratories, Wyeth-Ayerst International, Inc., and Wyeth-Ayerst Research.273 Wyeth-
Ayerst is headquartered in suburban Philadelphia and employs over 40,000 people throughout the world.274
It provides more prescription products to Americans than any other pharmaceutical company.275
While American Home Products is a well-known pharmaceutical and consumer products leader, the fen-
phen situation has led to serious problems for the company. \For generations, American Home Products
of Madison, N.J. has stocked family medicine chests with remedies that inspire trust, including Robitussin,
Preparation H, and Advil. Lately, though, some of American Home Products' most promising products have
inspired something else: lawsuits, by the thousands."276 American Home Products' stock price has fallen
signicantly as a result of the liability it faces in fen-phen suits, and when it took Pondimin and Redux of
271See Ethical Pharmaceuticals, Vaccines and Nutritionals, American Home Products Website, available online at
www.ahp.com/ahp/products.pharm.htm; See also Consumer Health Care, American Home Products Website, available online
at www.ahp.com/ahp/products/consumer.htm.
272See Frequently Asked Questions, American Home Products Website, available online at www.ahp.com/faq.htm.
273See Pharmaceutical R&D, American Home Products Website, available online at www.ahp.com/r&d pharm.htm.
274See Wyeth-Ayerst, American Home Products Website, available online at www.ahp.com/wyeth.htm.
275See Wyeth-Ayerst Laboratories, American Home Products Website, available online at www.ahp.com/wyeth labs.htm.
276Steve Sternberg, Lawsuits: Drug Development's Side Eects, USA Today, Jan 12, 2000, Health Section.
73the market it lost between $200 and $300 million as a one-time cost of the product withdrawal.277 American
Home Products has attempted to improve its nancial position by settling the valvular heart disease fen-
phen suits and ending the uncertainty surrounding its level of exposure resulting from Redux and Pondimin
liability.
Recent Problems of American Home Products
In addition to the problems associated with Pondimin and Redux, American Home Products
has had a run of high-prole problems: AHP recently recalled a new rotavirus vaccine after doctors
reported a link to serious bowel conditions in dozens of babies; AHP in August settled lawsuits
led by thousands of women who allegedly suered side eects from its Norplant implantable
contraceptive; and AHP in 1998 recalled the short term pain reliever Duract after 12 people
suered kidney failure. Sidney Wolfe of the non-prot watchdog organization Public Citizen
Health Research Group says the cascade of calamities { and how each was handled { raises serious
questions about AHP and its pharmaceutical subsidiary, Wyeth-Ayerst, and how they do business.
`Why did they have such an unprecedented number of drugs go wrong?'278
Critics suggest that American Home Products' problems demonstrate (1) The conict pharmaceutical com-
panies face when they must choose between loyalty to a possible new blockbuster drug and its responsibility
to report any side eects when they occur; (2) The weakness of the U.S. government's voluntary system
for side eect tracking279 after the FDA has approved drugs for sale; and (3) The problem of doctors writ-
ing popular prescriptions to provide personal prot280, even when there is no medical justication for the
277See American Home Products Corporation, Voluntary Recall Of Pondimin And Redux To Impact Earnings For
1997 And 1998, American Home Products Press Releases, Madison, N.J., Sept. 15, 1997, available online at
www.ahp.com/releases/ahp 091597.htm.
279It is common for side eects to emerge after drugs are approved for sale. Often sales to the public are called \Phase IV"
clinical trials, since much new information is gleaned during the initial period when the drug becomes available on a widespread
basis. The FDA says it would take more than the 5,000 people who take part in most large scale drug studies to discover
subtle side eects. The FDA's adverse event reporting system is not mandatory, and the FDA depends on drug companies to
voluntarily report adverse events. This was seen in the advisories sent out regarding fen-phen, which all included a request for
health professionals to notify the FDA's MedWatch Program or the manufacturers of Pondimin or Redux regarding valvular
heart disease or PPH. All the notices included the MedWatch phone and fax numbers. See Steve Sternberg, Lawsuits: Drug
Development's Side Eects, USA Today, Jan 12, 2000, Health Section.
280This refers to the vast amounts of doctors who were prescribing fen-phen for cosmetic weight loss. Although the literature
on Redux and Pondimin stated that it was only indicated for use in people with a BMI over 30, a great deal of Redux and
Pondimin prescriptions were written for people who did not meet this qualication. People of all weights were requesting
fen-phen in response to the national media craze surrounding the weight loss drugs. In the interview with Dr. Marnell, she
indicated that she received calls from several friends and acquaintances asking her about fen-phen. She reiterated to them that
Pondimin and Redux were only for those with a BMI over 30, but many other doctors did not adhere to this BMI limitation.
Doctors were prescribing fen-phen over the internet and Jenny Craig and Nutri-System doctors were giving out fen-phen to
74medication.281
Alleged American Home Products Wrongdoing
Failure to Report PPH/Valvular Heart Disease Risks to FDA
Much of the fen-phen litigation has brought to light alleged wrongdoing by American Home Products,
although it maintains it did not commit any such wrongdoing in its handling of Pondimin and Redux. Both
in a trial in New Brunswick, N.J. (Vadino) and in the Lovett trial in Texas, jurors heard testimony that
American Home Products had received many reports of valvular heart disease and PPH without informing
the FDA. In those trials, plaintis' lawyers \argued that American Home [Products] concealed information
from regulators, doctors and consumers about links to valvular heart disease and [PPH]".282 In the Vadino
trial, plaintis' lawyers presented evidence that American Home Products knew of over 30 cases where serious
side eects occurred in Pondimin and Redux users but never reported those incidents to the FDA.283
patients who they barely knew and who did not meet the BMI requirement. In one high prole case, the wife of the Mayor
of North Miami Beach, Patricia Ann Mishcon, suered a fatal heart attack after she had been taking fen-phen for six months
in an eort to lose ten pounds. Her prescribing doctor was an ophthalmologist who was operating a weight loss clinic. See
Caren A. Crisanti, Product Liability and the Prescription Diet Drug Cocktail, Fen-Phen: A Hard Combination to Swallow, 15
J. Contemp. Health L. & Pol'y at 243.
Note: This problem of cosmetic weight loss use was not a problem unique to fen-phen per se, it is a common problem with
`popular' drugs that Americans want even though they do not suer from the medical problem that led to the drug's development.
Viagra today is another example of this phenomenon, with doctors prescribing it over the internet and widespread use of the
drug by people who do not suer from clinical erectile dysfunction.
281See Steve Sternberg, Lawsuits: Drug Development's Side Eects, USA Today, Jan 12, 2000, Health Section.
282Edward R. Silverman, Diet Pill Jury is Dismissed as Settlement Grows Near, New Jersey Star Ledger, Oct. 5, 1999,
available online at www.nj.com/business/ledger/d28061.html
283See id.
75Frederick Wilson, one of AHP's medical monitors for Pondimin, testied that by 1994 the
company had received reports of 41 Pondimin users with potentially fatal PPH { and that
AHP did not update the drug's package insert with a warning about the problem for two
years. AHP ocials countered that the company was awaiting data from a large study on the
lung disorder. In 1995, Wilson testied, the company received reports of heart-valve problems
from Belguim. AHP experts responded that the European reports weren't alarming because
the leaks were mild and typical of those commonly found in the general population. An FDA
investigative report that emerged in the Lovett case found numerous deciencies in AHP's
adverse-event reporting in the USA.284
U.S pharmaceutical companies are required to notify the FDA quickly of serious and unexpected adverse
eects that occur in users of drugs they market. The companies \must notify the FDA regardless of whether
the eects occur in the U.S. or abroad, and whether or not they appear to be related to the drug. American
Home Products stated that after the Mayo study was released that they had known of the... Belgian cases
and six others elsewhere in Europe. AHP said it told the FDA of ten of the cases and the FDA conrms
receiving eight. AHP decided not to report all of the patients that had developed heart valve damage because
they felt the unreported cases did not t within the reporting requirements of the FDA."285 In the Vadino
trial, plaintis' attorney Sol Weiss said that \the valvular problems were evident from the beginning. Their
[AHP's] French subsidiary knew about it, and American Home Products chose to ignore it."286 American
Home Products spokespersons \conrmed reports that they were aware of the heart valve problems for
months before the FDA's warnings, stating, `we were being very cautious and working with the FDA to
determine if these [heart valve problems] were isolated incidents or whether this required a higher level of
warning."'287 Peter Bleakley, an American Home Products attorney, said that \the overwhelming majority
of people that reported problems had some kind of congenital heart disorder to begin with and the secondary
pulmonary hypertension could have been a result of their obesity, or any of the other diet cures they had
tried. There is no basis by which anyone reviewing these case reports would have seen a connection between
285Vivi Vanderslice, Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in Light of Amchem v. Windsor, 35
Cal. W. L. Rev. at 202.
286Matt Ackermann, Fen-Phen Trial Testimony: Risks Stop One Year After Use, New Jersey Law Journal, Sept. 13, 1999,
available online at www.lawnewsnetwork.com/stories.
287See Lance and Tortorich, Popular Diet Drugs Pulled From Market, 9 Loy. Consumer L. Rep. at 297.
76the drug and a valvular problem."288
Kip Petro, the attorney for the plainti Debbie Lovett in the rst fen-phen case to result in a jury verdict,
said that company memos introduced into evidence in the Lovett case \showed that American Home [Prod-
ucts] allegedly knew of people who took the drug and developed heart damage, but resisted putting warning
labels on the product"289. In addition, in the Lovett trial evidence revealed American Home Products \had
essentially paid for ghostwritten scientic papers and helped edit them to remove medical information before
publication. The drug manufacturer contracted with medical publisher Excerpta Medica, which hired ghost-
writers to cull the existing medical literature, develop a favorable spin, and assemble positive ndings into
a compendum of advantageous conclusions regarding the drug. The company then paid the original authors
for permission to list their names as authors of the new articles."290 In response to Petro's allegations
and the evidence concerning the medical research, American Home Products has claimed repeatedly that it
acted responsibly.291
The PPH Label Numbers Issue
A major issue in all PPH cases concerns the numbers of PPH cases listed on the labels of Redux and
Pondimin and whether American Home Products withheld information about new cases and failed to put
the information on the label. (See discussion below of the Washington trial in Mississippi). The 1983
Pondimin Package Insert reported two PPH cases in female patients who took Pondimin for eight months.
Internal Wyeth-Ayerst memos indicate that in 1994 Wyeth had received reports of 37 more PPH cases in
Pondimin users. In June of 1994 a high level Wyeth-Ayerst ocial recommended updating the Pondimin
288Matt Ackermann, Fen-Phen Trial Testimony: Risks Stop One Year After Use, New Jersey Law Journal, Sept. 13, 1999,
available online at www.lawnewsnetwork.com/stories.
289John Council, Fen-Phen Fight Has Just Begun, Plaintis Lawyers Say Verdict Sets the Market Rate, Texas Lawyer, Aug.
16, 1999 at 1.
290Richard H. Middleton, Jr., Our Quest For Corporate Honesty, 35-oct Trial 9 (1999).
291See id.
77label to reect the higher PPH numbers. However, nothing was done at that time.292 The label was revised
on June 20, 1996 to report the IPPHS ndings. The new label stated that a two-year international study
found that 20 out of 95 patients diagnosed with PPH had taken fenuramine and other anorexigens. The
insert also stated that the PPH risk increased when patients took anorexigens for over three months. The
insert also stated that in the majority of PPH cases patients had used fenuramine for over 12 months.293
The insert advised doctors that \treatment should be discontinued in patients who develop new unexplained
symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. These patients should be evaluated
for the etiology of these symptoms and the possible prevalence of pulmonary hypertension."294 The Redux
Physician Package Insert was also changed in 1996 to report the same ndings from the IPPHS. The same
updated PPH warnings were reported in the Redux insert as in the Pondimin insert. Plaintis in various
fen-phen suits have claimed that the Pondimin and Redux warnings up until the 1996 changes only listed
a handful of reported PPH cases at a time when AHP was aware of dozens more. The numbers issue was
brought up in the New Jersey Vadino medical monitoring class action trial. Plaintis' lawyers said that
American Home Products had received 54 adverse reports and that Redux and Pondimin had caused nine
deaths.295 The plaintis' attorney said that American Home Products \should have hired an expert to pick
up on these signals. They should have hired someone in 1995 instead of 1997 to prove there was something
wrong with this drug."296 American Home Products defense lawyer Peter Bleakley of Arnold & Porter
said of this issue, \it's true that Wyeth-Ayerst considered changing the numbers. I wish that there was a
satisfactory reason for why it wasn't done in a timely fashion."297 In his testimony at the Vadino trial, Dr.
292See L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
293See In re: PA Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation No. 9709-3162 (Pa.
C.1st 1999) American Home Products Exhibits 13, 14, and 16.
294Id.
295See Matt Ackermann, Fen-Phen Lawyers Stick to Texas Formula, : As New Jersey Trial Continues, A Similar Class-Action
Suit is Dismissed in California, New Jersey Law Journal, Aug. 23, 1999.
296Id.
297Bob Van Voris, A Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
78Marc Deitch, former senior Vice President of Medical Aairs at Wyeth Laboratories, said \I'm not saying
we shouldn't have changed the number. We should have. It was a mistake, and I am taking responsibility
for it."298
Black Box Warning in Physician's Desk Reference Issue
There was also discussion over whether there should have been a \black box" warning in the Physician's Desk
Reference (\PDR") for Pondimin and/or Redux. In Vadino, plaintis' counsel presented a July 1996 report
from Sophia Bayawakeh, a Wyeth marketing analyst, that said that a black box warning in the PDR could
cut Pondimin and Redux sales by up to 50%. That marketing report was given to Carrie Smith Cox, vice
president of women's health care at Wyeth. Carrie Smith Cox was the head of marketing for Pondimin and
Redux from 1995 until 1997. When plaintis' counsel called Smith Cox as a witness in the Vadino trial, she
said that she did not read the report from Bayawakeh and that she generally only read half of the material
that came to her attention.299 However, Smith Cox wrote a memo to her supervisors in November of 1995
that said that a black box warning for Pondimin and/or Redux would be an \extremely strong negative that
needed to be defused from day one... as you know this is probably the biggest single factor remaining to
determine the future sales performance of the product[s]."300 These memos were presented in the Vadino
trial. Vadino plaintis' counsel said that a black box warning in the PDR would have alerted doctors to the
risk of heart and lung problems and deterred prescriptions.301
FBI Investigation
American Home Products also became involved in a federal investigation surrounding the approval of Redux.
298Matt Ackermann, Fen-Phen Lawyers Stick to Texas Formula: As New Jersey Trial Continues, A Similar Class-Action




79The FBI interviewed FDA employees about Redux's approval, according to Wall Street Journal reports.302
The FBI was attempting to determine if American Home Products informed the FDA of all the information
it had regarding adverse Redux reactions.303 In 1999, The New Jersey Star-Ledger reported that \the FBI
and the FDA's own Oce of Criminal Investigation are examining the handling of the two drugs".304 The
FDA/FBI investigations were related to the Michael Weintraub/Trevena weight loss clinic aair in Florida.305
A lawyer with a rm that represents AHP downplayed the investigation, stating that \I can tell you, as a
former prosecutor, agents can look into anything they want, it doesn't have to be substantial. Agents can
take phone calls, respond to letters, and follow up on leads that don't lead to any action."306
Spoilation Sanctions For E-Mail Tapes in Linnen Trial
In the Linnen wrongful death trial in Massachusetts, which later settled, American Home Products faced
sanctions for destroying e-mail evidence. Judge Raymond Brassard agreed to give a spoilation instruction
when the case was tried. He was to charge the jury that it may infer that e-mails destroyed by American
Home Products contained unfavorable evidence for the defense. American Home Products made backup
tapes of employee e-mails each day, and it periodically re-used those tapes after retaining them for a period
of time. After plaintis' lawyers requested the tapes, American Home Products failed to cease re-using the
old tapes, and some e-mail tapes were lost. American Home Products did nd over 1000 backup tapes when
depositions were nearly complete, over one and a half years after plaintis' lawyers had requested them.
302See Business-Watch Corporate Brief, Natl. L.J., Sept. 20, 1999 at B4.
303See Matt Ackermann, Fen-Phen Trial Testimony: Risks Stop One Year After Use, New Jersey Law Journal, Sept. 13,
1999, available online at www.lawnewsnetwork.com/stories.
304Edward R. Silverman, Diet Pill Jury is Dismissed as Settlement Grows Near, New Jersey Star Ledger, Oct. 5, 1999,
available online at www.nj.com/business/ledger/d28061.html
305See Kris Huntley, Fen-Phen King Turns Tables On Drug Maker: Once a Promoter and User of the Weight-Loss Drug
Combination, John Trevena Has Filed a Civil Suit Against Drugmaker Wyeth-Ayerst Laboratories, Inc., Accusing It of Fraud,
St. Petersburg Times, Oct. 10, 1999, Business Section.
306Matt Ackermann, Fen-Phen Trial Testimony: Risks Stop One Year After Use, New Jersey Law Journal, Sept. 13, 1999,
available online at www.lawnewsnetwork.com/stories.
Statement of Mark Farley, a partner with Gibbons, Del Deo, Dolan, Gringer & Vecchione. Farley was a former U.S. Attorney
in Newark who worked on health fraud cases for eight years. See id.
80Judge Brassard also ordered American Home Products to pay the plaintis' legal costs concerning the e-mail
problem and for the restoration costs for some of the backup e-mail tapes. American Home Products issued
a statement concerning Judge Brassard's ruling claiming that it had already provided over 50,000 pages
of emails to plainti's lawyers. Plaintis' lawyers in the Linnen case expressed their \delight" with Judge
Brassard's ruling. The spoilation instruction never came to bear since the Linnen case settled without ever
going to the jury, but it will likely be an issue in future PPH trials.307
American Home Products Financial Situation
Failed Merger With Warner-Lambert
On November 4, 1999, AHP announced that it had entered into a merger agreement with Warner-Lambert
in what was to be a friendly merger of equals. The merger would create the world's largest pharmaceutical
and consumer health products company with pro forma sales of $26 billion and one of the industry's largest
R&D budgets of almost $3 million. The new company was to be called AmericanWarner Inc. The new
company would have the blockbuster drugs Lipitor, a $3.6 billion anti-cholesterol drug, and Premarin, a
$1.8 billion hormone replacement therapy. It would also have several well known consumer health brands,
including Advil, Listerine, Sudafed, Lubridern, Neosporin, and Preparation H. The merger of equals trans-
action was unanimously approved by both American Home Products' and Warner-Lambert's Boards of
307See Bob Van Voris, Spoilation Sanctions for Fen-Phen Maker: American Home Products Destroyed E-Mail Backup Tapes,
Natl. L.J., July 5, 1999 at A4.
Note: The proposed Settlement Agreement does not cover PPH claims, so barring settlements, PPH trials will still occur and
the destroyed AHP e-mails will continue to pose a problem. AHP concedes the emails were destroyed but asserts that the
plaintis suered no real harm as a result of the destruction, while Judge Brassard's ruling indicates that the court would allow
the jury to infer that the destruction did cause harm to the Linnen family. Michael R. Overly, an electronic discovery expert
at Foley & Lardner in Los Angeles, said that e-mails are often extremely valuable to plaintis, since people tend to express
thoughts and emotions in e-mails that they would not write down in a formal memorandum. See Bob Van Voris, Plaintis Say
Firm Hid Data on Fen-Phen: E-Mails, Tapes Are at Issue in Mass. Suit Over Woman's Death, Natl. L.J., May 31, 1999 at
B1.
81Directors. Shareholders of American Home Products and Warner-Lambert would each own approximately
50% of AmericanWarner. AmericanWarner was expected to achieve higher earnings growth than either
company could expect by itself. The merger was expected to close in the second quarter of 2000. It would
be subject to antitrust clearance, American Home Products and Warner-Lambert shareholder approval, and
certain other conditions.308 Amid rumors that AHP was in discussions with Pharmacia & Upjohn and that
the Warner-Lambert merger would not proceed, AHP issued a press release on December 10, 1999 stating
that AHP was fully committed to the completion of that merger and that it would \create enormous near
and long-term value for our shareholders."309
However, the merger never occurred and American Home Products became embroiled in litigation with Pzer
and Warner-Lambert over the merger situation. The Warner-Lambert merger agreement was eventually
terminated and at the present time American Home Products remains an independent company. On February
7, 2000 an American Home Products press release conrmed that the merger agreement with Warner-Lambert
Company was terminated in accordance with its terms. The merger agreement provided for American Home
Products to receive $1.8 billion in connection with the termination, all litigation among American Home
Products, Warner-Lambert, and Pzer Inc. was discontinued, and American Home Products' option to
purchase Warner-Lambert shares was rescinded. American Home Products CEO John Staord stated,
308See American Home Products Corporation, Warner-Lambert and American Home Products to Merge, Creating World's
No. 1 Pharmaceutical and Consumer Health Products Company, American Home Products Press Releases, Madison, N.J.
and Morris Plains, N.J., Nov. 4, 1999, available online at www.ahp.com/releases/ahp 110499.htm.
309American Home Products Corporation, AHP Remains Committed to Completion of Announced Warner-Lambert Company
Merger-of-Equals Agreement, American Home Products Press Releases, Madison, N.J., Dec. 10 1999, available online at
www.ahp.com/releases/ahp 121099.htm.
82While we regret that we were not able to complete the transaction, we understand the decision
of the Warner-Lambert board to support the alternative transaction... the termination of our
agreement brings to an immediate close the distracting and acrimonious litigation among the
companies and allows us to focus on our growing health care business. AHP has one of the
best pipelines in the pharmaceutical industry and we look forward to continuing to develop and
market our outstanding new products and moving forward in what promises to be an excellent
year for growth for our Company in 2000.310
Securities Litigation against American Home Products Resulting From the Fen-Phen Aair
In Oran v. Staord, investors in 1999 brought a Rule 10(b)(5) securities fraud claim against American Home
Products and several American Home Products executives. Judge Politan of the U.S District Court in New
Jersey dismissed the case with prejudice. Investors claimed that American Home Products and several of its
insiders misrepresented and omitted facts concerning Redux and valvular heart disease in patients using the
drug. The plaintis alleged that the defendants misled the investing public to believe that Redux was safe
and would continue to generate large prots for American Home Products.311
In order to sustain a 10(b)(5) claim, any undisclosed information must be material. Material means that
there must be a substantial likelihood that, under all the circumstances, the omitted fact would have assumed
actual signicance in the deliberations of the reasonable shareholder in whether to invest in that particular
corporation.312 Based on the idea of an ecient market, any information that alters the corporation's share
price is considered material.313 If a company's eventual disclosure of the information at issue had no eect
on the company's stock price, that information is immaterial as a matter of law.314 And, if the information
is not material, it is not actionable in a 10(b)(5) claim.315
The Oran plaintis alleged that American Home Products knew of the valvular heart disease associated with
Redux long before it publicly disclosed that information on July 8, 1997. However, during the four days
311See Oran v. Staord, 915 F.Supp. 2d 906 (D. New Jersey 1999).
312See In re Westinghouse Securities Litigation, 90 F.3d 696, 714 (3d Cir. 1996).
313See In re Burlington Coat Factory Securities Litigation, 114 F.3d 1410, 1425 (3d Cir. 1997).
314See id.
315See id.
83following the announcement of Redux's problems, American Home Products' share price rose by $3.00. The
share price did not begin to experience a downturn until September 15, 1997, when American Home Products
announced it was withdrawing Redux from the market. Therefore, the Oran court found the medical data
disclosed by American Home Products on July 8, 1997 to be immaterial as a matter of law.316 The court
refused to hold that \a pharmaceutical company owes a greater duty to disclose adverse medical data to the
investing public than it owes to the FDA during a drug's approval process" and found that American Home
Products' failure to disclose the adverse reaction reports to investors until July 8 was not actionable.317
The plaintis also made claims that AHP continued to mislead the investing public after it made the July
8 disclosure by making the statement that the medical data was \limited and therefore inconclusive". The
court held that this statement was too vague to be actionable, that a reasonable investor would not rely on
such a vague statement, and that it was not false at the time it was made since there was no systematic
study of Redux and valvular heart disease and no conclusive nding that the drug denitely caused the valve
problems. The plaintis also claimed that American Home Products continued to mislead the investing
public after the July 8 statement by failing to reveal additional European ndings and adverse reaction
reports. The court held that those facts would not have added anything to the July 8 disclosure and would
not have signicantly altered the total mix of information in a way that a reasonable investor would nd to be
relevant. The plaintis also alleged that American Home Products misled the investing public about the FDA
approval process, because American Home Products suggested that it had disclosed to FDA all information
it had regarding the safety of Redux.318 The court found that American Home Products' statements to
the investing public about Redux's FDA approval did not suggest that FDA approval \was based upon a
review of every existing piece of relevant medical data. At best, the statements recited in the Complaint
imply only that the FDA conducted a systematic and thorough review and concluded that Redux was safe
316See Oran v. Staord, 915 F.Supp. 2d 906 (D. New Jersey 1999).
317Id.
318See id.
84and eective when used as a weight loss drug."319 The court also noted that the plaintis did not claim
that American Home Products breached any of its obligations to report to the FDA, and they did not claim
that the additional information/studies at issue would have changed the FDA's decision on whether or not
to approve Redux. The court found it most important that the plaintis did not state why a reasonable
investor in making the decision whether to buy or sell American Home Products shares would be concerned
about these particular aspects of the FDA's Redux approval.320 The court concluded that \AHP did not
materially mislead the investing public by failing to come forward with the reports of valvular heart disease
prior to July 8, 1997; nor did AHP mislead the public by failing to disclose the specic medical data that
formed the basis of its July 8 announcement; nor did the July 8 disclosure become materially misleading as
a result of AHP's failure to make any additional or subsequent disclosures."321
The Relationship of Pondimin and Redux and the Proposed Settlement to the American Home
Products Stock Price
American Home Products stock suered from the fen-phen situation and the uncertainty surrounding the
thousands of suits led against American Home Products and its subsidiaries. On August 6, 1999, when the
Lovett verdict of $23 million came down against the defense, American Home Products' stock price dropped
by 12%.322 \In the past six months [from October, 1999], diet-drug suits have contributed to a steep decline
in AHP's value. From a 52-week high of $70.25 a share on April 13, the stock hit a low of $38.50 on Sept.
9, a 45% drop."323
The impact of fen-phen liability on its stock price was a driving force in American Home Products' desire




322See ob Van Voris, A Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
323Donna Shaw, Settlement Reached in Diet Drug Lawsuits, Philadelphia Inquirer, Oct. 8, 1999, at A1.
85because the diet-pill litigation, as well as setbacks involving other products and dierent business units,
have sent its stock plunging nearly 40% since April."324 When American Home Products was certain that
a settlement would be announced in the very near future, it invited securities analysts and money managers
to a presentation in New York on \the New American Home Products."325
Between January and May of 1999 several American Home Products insiders cashed in many of their stock
options and sold large number of shares for prots that ranged from $1.4 million to $7.3 million per person.
American Home Products claimed that they were routine transactions and that executives and other high
level ocials had made similar transactions in years past. American Home Products also noted that the
amount of shares traded were a small fraction of total shares held by top executives.326 \Alex Zisson, an
analyst with investment rm Hambrecht & Quist, agreed that the insider stock sales appeared routine, and
he noted that executives of rms cash in options and sell stock regularly. Any time there is disappointment
afterward, people go back and point their nger."327 In contrast, one plaintis' attorney in Florida character-
ized the insider selling in the following manner: \I've seen it time and again. In an eort to instill condence
in investors and stabilize stock prices, corporations facing potentially massive litigation repeatedly downplay
the seriousness of the threat posed by the litigation; then, when the threat becomes too big to ignore, the
corporate big-wigs sell o large chunks of their stock before the corporations are forced to fess up."328
Whatever the true reason for the insider selling, American Home Products has made great strides towards
stemming the tide of fen-phen liability with the Settlement Agreement. While it still will face PPH suits even
if the Settlement is given Final Judicial Approval and American Home Products decides not to terminate
the agreement, American Home Products will dispose of the over 4,000 valvular heart disease suits that
324Edward R. Silverman, Diet Pill Jury is Dismissed as Settlement Grows Near, New Jersey Star Ledger, Oct. 5, 1999,
available online at www.nj.com/business/ledger/d28061.html.
325Id.
326See Susan Spielberg, Executives Cashed In American Home Stock, Philadelphia Inquirer, Sept. 11, 1999, Business
Section.
327Id.
328Insider Selling Reects on True Scope of American Home Products' Diet Drug Liability, PR Newswire, Sept. 7, 1999,
Pensacola, Florida, available online at http://leflaw.net/fenphen/insider9/99.htm.
86were negatively inuencing its share price. At one point American Home Products was denying analysts
information on the amount of liability insurance it had to cover potential verdicts, and there were reports
from analysts that AHP may face resistance from their insurers over fen-phen liability.329 The Settlement
has dramatically changed that negative situation and things are looking more positive for American Home
Products at the present time.
In fact, many analysts see American Home Products' stock price today as undervalued and see the company
as a prime takeover target. After the Settlement was announced, Business Week ran a story called \The
Cloud Over American Home Products Dissipates", which stated that:
[t]hanks to its proposed $4.8 billion settlement over fen-phen, investors are looking at the company
again. It's rare that Wall Street is delighted to discover that a company's gross earnings will be
reduced by nearly $5 billion over the next few years. But more champagne than tears owed
among analysts and money managers who follow American Home Products wen it announced just
such a development on Oct. 7 [1999]. The reason for their joy was that $4.8 billion is going to
pay o plaintis who claimed that a cocktail of AHP drugs... had caused heart problems. It isn't
unusual for such class actions to take years, if not decades, to settle. But AHP has reached an
agreement less than two years after the rst reports of the problem.330
Analysts have noted that the Settlement was for signicantly less than American Home Products could have
had to pay, as well as the presence of many promising drugs in American Home Products' pipeline. However,
they have also noted that the Settlement has not yet received Final Judicial Approval and that American
Home Products still has the right to walk away if there are too many opt-outs. However, at this time \AHP
has the upper hand. If it comes to lots of individual lawsuits, most of the plaintis will be treading on
legal thin ice, since few of them have actually suered signicant medical problems. Now that the specter
of litigation is less ominous, analysts are enthusiastic about the stock."331 While at one point the fen-phen
problem was very damaging to American Home Products' share price and adversely impacted the proposed
merger of equals with Warner-Lambert, that picture appears to have changed at the present time. AHP is
329See id.
331Id.
87doing well in terms of its current drug sales and has been doing well in the vaccine business as well.332 \Now
that the legal situation is clearing, many companies would love to own AHP. To make sure they ask nicely,
the company's board passed a poison-pill provision on Oct. 8 [1999] that will make a hostile takeover more
dicult. Whether AHP is acquired or goes it alone, no one is disputing that the stock looks better now than
it has in months. Although the company's third-quarter earnings, which will be announced on Oct. 18, will
sink to high heaven because of the settlement write-o, by next year AHP could be smelling like a rose."333
Litigation with Interneuron
On Jan 24, 2000, Interneuron Pharmaceuticals, Inc. led a complaint seeking damages against American
Home Products in Superior Court of the Commonwealth of Massachusetts, Middlesex County. The complaint
alleges that American Home Products and Wyeth-Ayerst (American Home Products' subsidiary) withheld
and concealed information from Interneuron on possible health risks associated with Redux. Interneuron
claimed that that safety information was essential for Interneuron to determine the safety of dexfenuramine
(Redux), which was developed by Interneuron and marketed by American Home Products. While Pondimin
(fenuramine) was marketed only by American Home Products, Redux was marketed by American Home
Products and co-promoted by Interneuron. Interneuron's complaint seeks treble damages and attorney's
fees. Such damages are permissible under the Massachusetts law for knowing and willful deceptive acts and
practices, fraud and misrepresentations. Interneuron attorneys stated that following Redux's withdrawal
from the market, over 2,000 lawsuits were led against Interneuron. An Interneuron representative said
that Interneuron would vigorously defend against each lawsuit and le a cross-claim against American Home
Products seeking indemnication for each one.334
332See id.
333Id.
334See Interneuron Pharmaceuticals Sues AHP for Fraud; Marketing Partner Withheld Critical Data Regarding Anti-Obesity
Drugs, BW Healthwire, Business Editors and Health/Medical Writers, Lexington, Mass., Jan. 24, 2000.
88THE MEDICAL MONITORING ISSUE IN THE FEN-PHEN LITIGATION
Judicial Recognition of the Claim of Medical Monitoring
Medical monitoring was rst recognized in the federal court system in Friends For All Children, Inc. v. Lockheed Aircraft Corp.,
587 F. Supp. 180, 184-188 (D.D.C. 1984). In Friends For All Children, the plaintis were Vietnamese or-
phans who had survived a plane crash that occurred during a refugee evacuation mission. They sought diag-
nostic medical exams that were necessary to determine if brain injury had occurred when the plane's cabin
suddenly depressurized. In Friends for All Children, the D.C. Circuit \armed the imposition of medical
monitoring liability on the defendant tortfeasor, in a decision widely cited by subsequent medical monitoring
cases around the country."335 Friends For All Children established the precedent for medical monitoring
claims even in the absence of physical injury.336 In Ayers v. Jackson, 525 A.2d 287 (N.J. 1987), the New
Jersey Supreme Court held that \compensation for reasonable and necessary medical expenses is consistent
with well-accepted legal principles."337 The Ayers Court stated that \[i]t is inequitable for an individual,
wrongfully exposed to dangerous toxic chemicals but unable to prove that disease is likely, to have to pay his
own expenses when medical intervention is clearly reasonable and necessary."338 In medical monitoring cases,
there is a fundamental distinction between proving that the defendant's wrongdoing caused the injury versus
proving that the defendant's conduct caused the need to monitor for the presence of an injury.339 The U.S.
Court of Appeals for the Third Circuit claried the distinction in In re Paoli R.R. Yard PCB Litigation, 916
335Elizabeth J. Cabraser and Fabrice N. Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product
Liability Litigation, American Law Institute { American Bar Association Continuing Legal Education Course of
Study, July 22, 1999, at 18.
336See id.
337Ayers v. Jackson, 525 A.2d 287, 309 - 312 (N.J. 1987).
338Id. at 312.
339See Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation,
American Law Institute { American Bar Association Continuing Legal Education Course of Study, July 22, 1999,
at 18.
89F.2d 829,850 (3d Cir. 1990), stating, \thus, the appropriate inquiry is not whether it is reasonably probable
that plaintis will suer harm in the future, but rather whether medical monitoring is, to a reasonable degree
of medical certainty, necessary in order to diagnose properly the warning signs of disease".340 The court in
Friends For All Children held that an injunction compelling defendants to pay for medical monitoring is a
proper use of a court's equitable powers. Additionally, medical monitoring awards can be set up in the form
of a court supervised fund in place of giving money directly to plaintis to pay for their medical expenses.341
The California and Pennsylvania Supreme Courts have expressed a preference for a judicially supervised
fund for medical screening as opposed to lump sum damages to the plaintis.342
Medical Monitoring Claims of Fen-Phen Plaintis
The medical monitoring fen-phen plaintis are currently claiming that leading public health organizations
hare urged fen-phen users to get medical examinations, including echocardiograms in certain cases (see above
discussion on fen-phen health problems). The plaintis have moved for medical monitoring class certica-
tions, asserting that \AHP should pay the quantiable costs of periodic medical examinations necessary to
detect the onset of heart and lung disease, because it is through their wrongful actions that plaintis have
been made susceptible to such disease."343 Medical monitoring has the potential to dramatically increases
the tortfeasor's costs, since the tortfeasor is no longer solely liable for only the exposed person who becomes
sick but also to some degree to all exposed individuals. More sick plaintis will become aware of their
conditions and the drug company or other tortfeasor will be liable for those problems, which it in fact paid
340In re Paoli R.R. Yard PCB Litigation, 916 F.2d 829,835 (3d Cir. 1990).
341See Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation,
American Law Institute { American Bar Association Continuing Legal Education Course of Study, July 22, 1999,
at 18.
342See id. at 22.
343Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation, Amer-
ican Law Institute { American Bar Association Continuing Legal Education ALI-ABA Course of Study, July 22,
1999, at 18.
90to discover.344
Elements of a Medical Monitoring Claim
The following are the substantive elements required for a medical monitoring claim: \(1) signicant expo-
sure to a proven hazardous substance; (2) signicant resulting risk of contracting a serious latent disease;
(3) signicantly increased risk of disease as compared to the general population; (4) the existence of eective
monitoring procedures; (5) reasonable necessity for monitoring, including endorsement by a qualied physi-
cian; (6) proof that the monitoring is dierent from regularly expected care; and (7) demonstrated clinical
value in the early detection and diagnosis of the disease."345
Fen-Phen Plaintis and the Medical Monitoring Claim Elements
Most of those substantive elements have been satised by the fen-phen plaintis. The rst element, signicant
exposure to a proven hazardous substance, brings up the causation problem. Causation is not certain, but
the data from the FDA and the Mayo Clinic give plaintis a strong foundation for the claim that Redux
and Pondimin are proven hazardous substances in terms of valvular heart disease causation. AHP will argue
that valvular heart disease is not a serious problem and that even if Redux and Pondimin caused the higher
incidence of valvular heart disease, that does not make Redux and Pondimin proven hazardous substances.
As for the second element, signicant resulting risk of contracting a serious latent disease, plaintis can use
data from the Mayo Clinic of a 30% chance of getting valvular heart disease after taking fen-phen as opposed
to less than 5% in the general population. This data also supports the third element, a signicantly increased
risk of disease as compared to the general population. For the fourth element, existence of eective monitoring
344See Matt Ackermann, In Fen-Phen Trial, the Uninjured Sue for Preventative Maintenance, The New Jersey Law Jour-
nal, Aug. 16, 1999.
345Id at 12.; See also Potter v. Firestone Tire and Rubber Co., 863 P.2d 795 (Cal. 1993).
91procedures, plaintis can point to modern echocardiography. For the fth element, reasonable necessity for
monitoring, plaintis can point to DHHS and American College of Cardiology Recommendations. However,
plaintis will have to face the fact that those recommendations do not provide that every fen-phen user should
have an echocardiogram, only those with symptoms or who may be at risk for bacterial endocarditis.346 For
the sixth element, proof that monitoring is dierent from regularly expected care, plaintis can again look
to DHHS and ACC recommendations, which go above what is recommended for the general population.
Plaintis may have trouble with the seventh element, requiring demonstrated clinical value in the early
detection and diagnosis of the disease. The fact is that it is unclear at the present time exactly what health
problems valvular heart disease causes and how it impacts a person's ability to live a long and normal life.
In some cases valvular replacement is needed, but in other cases valvular regurgitation does not seem to
pose any day to day health problems aside from the threat of bacterial endocarditis during certain medical
procedures. For PPH claims this would be an easy element to satisfy since early detection of PPH can be
very benecial to PPH patients. However, the facts are not so clear with valvular regurgitation, and the
medical monitoring classes are all seeking medical monitoring for valvular heart disease problems. Overall,
on the substantive elements for medical monitoring claims, the plaintis have strong arguments in their
favor. The proposed Settlement Agreement reects this, as it allows for a large sum for medical monitoring
and echocardiograms for each patient who was exposed to Redux or Pondimin for over 61 or more days,
which goes beyond what was recommended by DHHS and the ACC.
States That Have Recognized Medical Monitoring Claims and Certied Medical Monitoring
Classes in Fen-Phen Litigation
While the fen-phen plaintis have strong claims on each of the elements of a medical monitoring claim as
346American Home Products Attorney Peter Bleakley focused on this fact, stating that no major health organization called
for a monitoring program like the one envisioned by the asymptomatic medical monitoring plaintis. See Bob Van Voris, A
Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
92listed above, not all states recognize medical monitoring as a cause of action independent of a physical injury,
and not all states will certify medical monitoring classes in fen-phen litigation.347 Judge Bechtle certied a
federal medical monitoring class in the multi-district litigation on August 29, 1999.348 Texas, Illinois, Ken-
tucky, New Jersey, Pennsylvania, Washington, West Virginia, Florida, and New York, and Montana have
also certied medical monitoring classes as well.349 The issue is being litigated in other states as well, and
some have refused to certify medical monitoring classes.
Manhattan Supreme Court Justice Helen E. Freedman certied a class of plaintis seeking medical mon-
itoring because of their Redux/Pondimin exposure. Justice Freedman certied the class of asymptomatic
plaintis in Cunningham v. American Home Products, and the class consisted of approximately 1 million
NY consumers who took fen-phen and ingested either Pondimin or Redux. The plaintis claimed that ex-
posure to Pondimin and Redux put them at increased risk for valvular heart disease and PPH. They further
claimed that the sellers and manufacturers of fen-phen defectively designed Pondimin and Redux and mar-
keted them while they knew or should have known about the health risks they posed. None of the plainti
class members had valvular heart disease at the time of class certication. American Home Products denies
that Redux and Pondimin increase risks of heart problems. Justice Freedman was the eighth state judge to
certify a medical monitoring class in fen-phen litigation. She held that New York case law stated or implied
that under proper circumstances New York would recognize a medical monitoring claim. Justice Freedman
stayed the New York action because all of the New York plaintis are included in the national multi-district
347While not all states recognize medical monitoring as a claim independent of a physical injury, Judge Arthur Spiegel of
the Southern District of Ohio wrote a series of inuential opinions in the Telectronics defective pacemaker lead wire litigation
where he \conducted a comprehensive evaluation of the laws of all fty states and concluded that all states would recognize
the monitoring remedy because the sound policy arguments in favor of medical monitoring, as well as the legal doctrines of
avoidable consequences and recovery of future medical expenses, would persuade the states which have not yet addressed the
issue to arrive at the same conclusion as those states that have, i.e., that medical monitoring is a permissible cause of action or
element of damages." Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability
Litigation, American Law Institute { American Bar Association Continuing Legal Education ALI-ABA Course of
Study, July 22, 1999, at 12.
348See In re Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Jeers v. American Home Products Corporation,
No. CIV. A. 98-20626 1999, Memorandum and Pretrial Order No. 865, U.S. District Court for the Eastern District of Penn-
sylvania, Aug. 26, 1999, WL 673066 (E.D. Pa.).
349See id.
93case in the Eastern District of Pennsylvania before Judge Bechtle. However, the Justice Freedman's decision
was signicant because until her ruling it was not clear whether New York recognized a pre-injury claim for
medical monitoring.350
Texas was the rst state to certify a medical monitoring class of fen-phen plaintis on October 14, 1998.
Judge Fred Edwards of the 9th District of Texas certied a class seeking medical screening for all Tex-
ans who took Pondimin or Redux for 60 days or more.351 The class excludes those who already led
personal injury suits for injuries they allegedly suered as a result of taking fen-phen. Approximately
600,000 Texans are in that medical monitoring class.352 In New Jersey, class certication for a medi-
cal monitoring class was initially denied. However, it was later certied by Judge Marina Corodemus
in Vadino et al v. American Home Products Corporation et al. on January 25, 1999.353 The class ac-
tion trial in New Jersey was suspended by Judge Corodemus because of the proposed Settlement Agree-
ment. In Pennsylvania, Judge Stephen Levin certied a medical monitoring class of asymptomatic Re-
dux and Pondimin exposed state residents on March 12, 1999. In West Virginia, a state circuit court
certied a class of approximately 40,000 asymptomatic plaintis who were exposed to Pondimin or Re-
350See Michael Riccardi, Class Status Granted in Fen-Phen Suit, New York Law Journal, Sept. 17, 1999, available online
at www.lawnewsnetwork.com/stories/A5881-1999Sep16.html.
351See Texas Fen-Phen Class is Certied, Natl. L.J., Oct. 26, 1998 at A8.
352See Fen-Phen's Test Case, Texas Lawyer, Oct. 19, 1998 at 3.
353Judge Corodemus's opinion lists several equitable reasons justifying medical monitoring class treatment for diet drug users.
American Home Products claimed that it would be inequitable to hold them responsible for medical monitoring because then
they would be liable for determining if the class member suered any harm. However, there are strong policy reasons in favor of
holding American Home Products liable for medical monitoring costs. American Home Products would only have to pay medical
monitoring if the plaintis actually established the liability of American Home Products, i.e. if they proved that American
Home Products wrongfully concealed the risks of valvular heart disease associated with Redux and Pondimin. Once liability is
established, a strong policy argument can be made that American Home Products should assume the responsibility for these
costs, which American Home Products may be better able to absorb than the tort victim. See Cabraser and Vincent, Class
Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation, American Law Institute { American
Bar Association Continuing Legal Education ALI-ABA Course of Study, July 22, 1999, at 12. The Ayers court in
New Jersey, which was inuential in rst recognizing pre-symptomatic medical monitoring, stated that \Allowing recovery for
such [medical screening] expenses avoids the potential injustice of forcing an economically disadvantaged person to pay for
expensive diagnostic examinations necessitated by another's negligence." Ayers v. Township of Jackson, 525 A.2d 287, 311
(N.J. 1987). The policy reasons may be particularly strong in pharmaceutical drug liability cases like the fen-phen litigation,
where exposure to dangerous drugs makes \prompt protection... and treatment essential to prevent or ameliorate injury."
Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation, American
Law Institute { American Bar Association Continuing Legal Education ALI-ABA Course of Study, July 22, 1999,
at 27.
94dux in Birch v. American Home Products. In Washington state, Judge Richard J. Shroeder certied a
medical monitoring class on October 16, 1998 in St. John v. American Home Products. In Illinois, Cir-
cuit Judge Ellis E. Reid certied a class dened as Illinois residents who purchased and took Pondimin
or Redux in Illinois and who had or would undergo the medical screening procedures recommended by
DHHS and the Illinois Department of Pubic Health. The Illinois medical monitoring class specically ex-
cluded any plaintis who were diagnosed with PPH, valvular regurgitation, or any other illness [allegedly]
caused by Pondimin or Redux ingestion. In Kentucky, Judge Joseph Bamberger certied a medical mon-
itoring class for certain exposed Kentucky residents in Guard, et. al. v. A.H. Robins Co., Inc.354 Florida
certied a medical monitoring class in Petito v. A.H. Robins Co. on December 22, 1999. The trial court
had held that Florida did not recognize a pre-injury medical monitoring claim, but the appellate court
reversed that decision.355 Montana certied a statewide medical monitoring class on February 2, 2000 in
Lamping, et al. v. American Home Products Inc., et. al. Missoula County District Court Judge Ed McLean
found that the use of Redux and/or Pondimin carried a statistically high risk of heart damage and that the
risk warranted medical monitoring class certication. At the time the plaintis in Montana led their com-
plaint, Montana did not recognize pre-injury medical monitoring.356
All of the above decisions follow Friends for All Children \in analyzing medical monitoring as a discrete eq-
uitable claim, best implemented in multiple exposure cases through the pragmatic and inherently equitable
remedy of judicially supervised relief, rather than piecemeal or lump sum damages."357
354See id. at 10-11.
355See Legal News: Medical Monitoring, 18 Products Liability Law & strategy 8 (1999).
356See Montana Judge Certies Medical Monitoring Class, Citing High Risk of Injury, Mealey's Litigation Report Fen-
Phen/Redux, available online at www.mealeys.com/fen.html.
Note: On January 10, 2000, Judge Richard G. Blane II in held in Luce, et. al v. Gate Pharmaceuticals, et. al that although Iowa
does recognize medical monitoring under proper circumstances, Pondimin and Redux do not cause the latent eects that require
certication of a medical monitoring class. See No Latent Injury Found, Mealey's Litigation Report Fen-Phen/Redux,
available online at www.mealeys.com/fen.html.
357Cabraser and Vincent, Class Certication of Medical Monitoring Claims in Mass Tort Product Liability Litigation, Amer-
ican Law Institute { American Bar Association Continuing Legal Education ALI-ABA Course of Study, July 22,
1999, at 11 - 12.
95Whether or not state courts certify medical monitoring classes and whether state law supports medical
monitoring claims is critical in the multi-district litigation. Judge Bechtle, the MDL judge in Philadelphia,
has \dropped from the case the claims of residents of states where medical monitoring relief is barred."358
Signicantly, California courts have rejected certication of medical monitoring classes.359
THE MULTI-DISTRICT LITIGATION { MDL 1203
Mass Tort Case Consolidation { History and Justications
Mass tort cases are often consolidated for pretrial proceedings. This has been the case with asbestos cases,
which are before Judge Charles Weiner of the Eastern District of Pennsylvania, silicone gel breast implant
cases before Judge Sam Pointer of Alabama, and Norplant cases before Judge Richard Schell of the Eastern
District of Texas.360 Traditionally, mass disasters such as plane crashes, explosions, site contaminations, or
oil spills were conned to one area, where a single judge in a court near the area of the mass disaster would
358Michael Ricardi, Class Status Granted in Fen-Phen Suit, New York Law Journal, Sept. 17, 1999, available online at
www.lawnewsnetwork.com/stories/A5881-1999Sep16.html.
359See id..
In Tith, et al. v. Manhattan Weight Control, et al., Judge Daniel Solis Pratt of the California Superior Court, who is pre-
siding over the California state court diet drug litigation, denied a plaintis' motion to certify a California medical monitoring
class. Judge Pratt found class certication improper because of the large number of factors unique to each plainti, like how
long they took the drugs. He said the presence of these factors presented disparate issues concerning risk and damages. Judge
Pratt found that common issues did not predominate among the proposed class of medical monitoring plaintis, which is a
requirement of California law. See American Home Products Corporation, American Home Products Media Statement On Diet
Drug Decision in California State Court Denying Class Certication, American Home Products Press Releases, Madison,
N.J., Aug. 20, 1999, available online at www.ahp.com/releases 082099.htm.
360Many state courts also consolidate cases for pretrial management. All fen-phen cases in New York have been consolidated
and assigned to the Honorable Helen A. Freedman for pretrial management. See Helen E. Freedman, Product Liability Issues
in Mass Torts { View From the Bench, 15 Touro L. Rev. 685, 687 (1999). New Jersey cases have also been consolidated
before Judge Marina Corodemus. See Paul Rheingold, Michael Coren, and Sol Weiss, Natl. L.J., Feb. 22, 1999, at C2. Texas
did not consolidate its fen-phen cases before a single judge for pretrial management, although Rule 11 of the Texas Rules of
Judicial Administration allow statewide consolidation for pretrial management in cases that have common issues of fact or law.
American Home Products was in favor of the Texas consolidation, while plaintis attorneys were not, claiming that it was a
tactic to delay discovery going on in various areas of the state. A judge was appointed for pretrial management in each of the
nine administrative regions of Texas, but there is no statewide consolidation. See No Fragmenting Fen-Phen, Texas Lawyer,
July 13, 1998 at 3.
96manage the cases.361 However, \[d]uring the last twenty-ve years, a new type of mass tort, often national
in scope, has emerged. In these cases, plaintis have claimed that toxic substances, toxic pharmaceuticals
or defective devices have been put into the stream of commerce causing harm either in the short or long run
to individuals to either ingest the drug, are exposed to the substance, or are implanted with the device."362
In such cases, \aggregation of mass tort cases have become the norm in many jurisdictions."363 Advantages
to consolidation include: (1) The judge handling the case develops expertise on the matter; (2) Rulings are
more likely to be consistent; (3) Management is more ecient { usually parties develop a case management
order allowing for uniform pleadings, interrogatories, and approaches to discovery; (4) Consolidation facil-
itates exploration of alternative dispute resolution, special masters, and settlement negotiations; and (5)
Consolidation allows the judge to coordinate with other federal judges and state judges in other jurisdictions
with similar cases for ecient disposition of cases. One disadvantage of consolidation is that the increased
eciency may encourage additional lings and therefore provide a welcoming environment for weak cases.364
Another aspect of consolidation is that \a mass tort judge's perspective may dier from a judge viewing
cases individually. A judge who has many cases is more likely to consider the ramications of particular
ruling on the entire litigation. This may even include the potential for bankruptcy and or the likelihood of
increased insurance coverage. On the other hand, appellate courts, faced with appeals on individual cases,
tend to look at the individual case without considering the impact of a particular ruling on the litigation as
a whole."365
Consolidation of the Diet Drug Litigation Into MDL 1203 Before Judge Louis Bechtle
The fen-phen litigation has been consolidated like the Norplant, asbestos, and silicon gel breast implant
361See Helen E. Freedman, Product Liability Issues in Mass Torts { View From the Bench, 15 Touro L. Rev. 685 (1999).
362Id. at 685 { 686.
363Id. at 686.
364See id. at 687 { 689.
365Id. at 689.
97cases. \On December 10, 1997, the Judicial Panel on Multidistrict Litigation named Senior U.S. District
Judge Louis Bechtle of the U.S. District Court for the Eastern District of Pennsylvania to oversee a newly
created MDL for fenuramine, phentermine, and dexfenuramine litigation. Judge Bechtle has extensive
experience overseeing consolidated litigation"366
This decision came about after fen-phen plaintis lawyers in September of 1997 led an with the Judicial
Panel on Multi-District Litigation seeking to consolidate all of the fen-phen suits for pretrial proceedings.
The Judicial Panel on Multidistrict Litigation ordered that consolidation on December 10, 1997, pursuant
to 28 U.S.C. x 1407. All suits currently led and any future lawsuits were to be handled by U.S. District
Judge Louis Bechtle in the Eastern District of Pennsylvania. Since the consolidation, the MDL court has
received over 1000 actions as part of MDL 1203.367
In February of 1998 Judge Bechtle selected nine well known litigators to form a committee to coordinate all
pretrial stages of the litigation, and in May of 1998 he appointed defense liaison counsel for retailers, diet
centers, and physicians in the MDL. He had the responsibility for class certication. Once the cases have
nished pretrial proceedings, they will be returned to the federal courts where they were originally led.368
Disadvantages of MDL Consolidation and the Fen-Phen Fast Track
While consolidation has led to increased eciency and facilitated settlement negotiations, there are also
some serious downsides to putting all the cases in an MDL. \There are two large inequities that can occur
in mass litigation, in view of many lawyers and judges. One is that people who are not seriously injured can
366Evans and Kerner, A Primer on Fen-Phen Litigation: Allegations and Defenses, 65 Def. Couns. J. at 357.
Judge Bechtle has over 15 years experience handling complex multiparty litigation. He was the MDL judge for the 1,357 cases
that stemmed from the 1980 re at the MGM Grand Hotel and Casino in Las Vegas. See Nation's Fen-Phen Cases Consolidated
in Philly, Natl. L.J., Dec. 29, 1997, at B2.
367See In re Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Jeers v. American Home Products Corporation,
No. CIV. A. 98-20626 1999, Memorandum and Pretrial Order No. 865, U.S. District Court for the Eastern District of Penn-
sylvania, Aug. 26, 1999, WL 673066 (E.D. Pa.).
368See Vivi Vanderslice, Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in Light of Amchem v. Windsor,
35 Cal. W. L. Rev. at 214 { 215.
98clog the system for years. The other is that people with serious injuries can be overlooked in the clamor
and the throng and be shortchanged on court attention and, ultimately, on compensation."369 There has
been a fear in the fen-phen litigation that more serious cases may get lost amidst the sheer volume of claims
before Judge Bechtle. Many plaintis' lawyers fear the MDL will slow the progress of their cases. The MDL
can also aect the progress of state cases. \[A]lthough Judge Bechtle has no formal power over the conduct
or scheduling of state court cases, state judges typically coordinate their cases with an ongoing MDL to
avoid duplication of eorts. In eect, the MDL can act as something like a pace car, slowing or speeding
the progress of state court cases, depending on how the MDL has handled."370 In addition, \a handful of
plaintis with life-threatening conditions worry the MDL means they may not live long enough to get their
day in court."371 While having plaintis die before their trials occur is a personal tragedy for the plainti
who never got their day in court, \[h]umanitarian concerns aside, there are cold strategic reasons plaintis'
lawyers prefer to try a case before the plainti dies. For one, jurors are likely to award more money to a
sympathetic live plainti than to the memory of a dead one."372
The problem of extremely sick plaintis trapped in the MDL was exemplied in the case of Carol Aserinsky,
who developed PPH after she took fen-phen. Ms. Aserinsky is in very serious condition and her prognosis is
very poor.373 Her case was originally assigned to federal Judge Marvin Katz in Philadelphia. If the case had
stayed with Judge Katz it would have been ready for trial in June, 1998. However, the case was consolidated
into MDL-1203 in December of 1997. Her attorney, Daniel Thistle, led a motion for remand to state court,
which Judge Bechtle denied on June 29, 1999.374 Thistle also made several requests to get Aserinsky's case
369L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
370Bob Van Voris, Fen-Phen Victims May Die Before MDL Ends: Federal Judge is Considering Creating a Fast Tract For
Most Seriously Ill Plaintis, Natl. L.J., Feb. 23, 1998 at A7.
371Id.
372Id.
373Aserinsky is housebound, she is on a waiting list for a double lung transplant, she is connected to oxygen at all times, and
an IV implanted in her chest delivers medicine directly to her heart 24 hours a day. See L. Stuart Ditzen, In Mass Litigation,
The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
374See In re: Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Carol and Armound Aserinsky v. Wyeth Laboratories, Inc., et al.,
WL 554608 (E.D. Pa. 1999).
99sent back to Judge Katz. His requests were all denied, as was an appeal to the Third Circuit. However,
Judge Bechtle expressed concern about this problem and took action to separate the most serious cases
from the mass of other cases comprising MDL 1203.375 In February of 1999 Judge Bechtle asked the lead
plaintis' lawyers how many plaintis were claiming serious diagnosed injuries. The answer was eleven cases,
less than one percent of all federal cases. Judge Bechtle wanted to ensure that those serious cases were not
lost amidst all the other cases in MDL 1203. Judge Bechtle set up a fast track to expedite the serious cases
and send them back to the districts where they were led for trial. Aserinksy's case was at the top of that
list of serious cases and it went back to Judge Katz.376
People with serious medical problems like Carol Aserinsky are at one end of the spectrum of diet drug
plaintis, and people without any present medical problems in the medical monitoring suit are at the other.
This will necessarily create tension when all those cases are put together in front of a single judge in an MDL
consolidation. However, Judge Bechtle has shown that he is aware of the problem and has acted to solve it
with the creation of the fast track for seriously ill patients. Therefore, MDL 1203 is taking advantage of the
benets of consolidation while attempting to eliminate its most major downside, making it an overall plus
in the diet drug litigation as a whole.
CLASS ACTION LAWSUITS AND THE ISSUE OF CLASS CERTIFICATION
Class Action Description and the Requirements of Federal Rule of Civil Procedure 23.
375As of November 22, 1999, over 800 lawsuits had been consolidated in MDL 1203. If those cases were stacked on top of one
another, they would rise 60 feet up, as tall as a six-story building. If all the state lawsuits were added to that stack, it would
be double to triple that height. \In mass litigation, the serious cases can get lost." L. Stuart Ditzen, In Mass Litigation, The
Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
376See id.
100A class action is a lawsuit where \claims and rights of many people are decided in a single court proceeding
brought by representative plaintis. Class actions avoid the necessity for hundreds, or even thousands, of
people to le similar individual lawsuits, enable the court system to resolve these claims in a more ecient
and economical way, and seek to assure that people with similar claims are similarly treated. In a class action,
the court has a responsibility to assure that prosecution of the class claims by the Class Representatives and
Class counsel is fair."377
To be certied as a class, an action must rst satisfy the requirements of Federal Rule of Civil Procedure
(\FRCP") 23(a). The four requirements of FRCP 23(a) are: \(1) the class is so numerous that joinder of
all members is impracticable, (2) there are questions of law or fact common to the class, (3) the claims
or defenses of the representative parties are typical of the claims or defenses of the class, and (4) the
representative parties will fairly and adequately protect the interests of the class. Thus, Rule 23(a) requires
numerosity, commonality, typicality and adequacy of representation."378 An action for class certication
must also satisfy the requirements of FRCP Rule 23(b)(2). Rule 23(b)(2) requires \rst, that the defendant
is alleged to have acted in some uniform way toward the class that would make relief appropriate, and
second, that the injunctive relief requested is applicable to the entire class."379 Finally, an action for class
certication must satisfy the requirements of FRCP 23(b)(3), which requires that \questions of law or fact
common to the members of the class predominate over any questions aecting only individual members,
and that a class action is superior to other available methods for the fair and ecient adjudication of the
controversy"380 When he certied the nationwide Jeers medical monitoring class, Judge Bechtle found that
377Ocial Court Notice of Nationwide Diet Drug Class Action Settlement: In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593.
378In re Diet Drugs (Phentermine, Fenuramine, Dexfenuramine) Products Liability Litigation, Jeers v. American Home Products Corporation,
No. CIV. A. 98-20626 1999, Memorandum and Pretrial Order No. 865, U.S. District Court for the Eastern District of Penn-
sylvania, Aug. 26, 1999, WL 673066 (E.D. Pa.).
379Id.
380Fed. r. civ. p. 23(b)(3).
101the medical monitoring claims of asymptomatic fen-phen plaintis were proper for class treatment under
the requirements of FRCP 23(a), FRCP 23(b)(2), and FRCP 23(b)(3). Judge Bechtle also found that all of
those requirements were met when he granted provisional certication to the Brown nationwide settlement
Class.381
Class Action Lawsuits in the Fen-Phen Litigation
Individual and class action lawsuits were led against American Home Products concerning fen-phen use,
alleging injury as a result of ingestion of Pondimin and/or Redux or potential injury requiring medical mon-
itoring. All federal diet drug cases were transferred to MDL 1203 before Judge Bechtle, and one of those
cases, Brown v. American Home Products Corporation, was provisionally certied in a nationwide class ac-
tion. The plainti in Brown seeks injunctive relief and compensatory damages. American Home Products
has asserted that it is not liable to the plainti's class in any manner. Judge Bechtle also certied a na-
tionwide medical monitoring class in In re Diet Drug Products Liability Litigation (Jeers v. AHP), MDL
Docket No. 1203.382
There are ve subclasses within the larger Brown settlement class. These subclasses include: (1) Subclass
1(A) { Diet drug recipients who took Pondimin and/or Redux for 60 days or less and have not been diagnosed
with FDA Positive regurgitation by an echocardiogram performed between the start of the diet drug use
and September 30, 1999; Subclass 1(B) { Diet drug recipients who took Pondimin and/or Redux for 61 or
more days and have not been diagnosed with FDA Positive regurgitation by an echocardiogram performed
between the start of the diet drug use and September 30, 1999; (3) Subclass 2(A) { Diet drug recipients who
took Pondimin and/or Redux for 60 days or less and have been diagnosed with FDA Positive regurgitation
381See Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593.
382See id.
102by an echocardiogram performed between the start of the diet drug use and September 30, 1999; (4) Subclass
2(B) { Diet drug recipients who took Pondimin and/or Redux for 61 or more days and have been diagnosed
with FDA Positive regurgitation by an echocardiogram performed between the start of the diet drug use and
September 30, 1999; and (5) Subclass 3 { Diet Drug recipients who have been diagnosed with mild mitral
regurgitation by an echocardiogram performed between the start of the diet drug use and the end of the
screening period but who have not been diagnosed with FDA Positive regurgitation between the start of
the diet drug use and the end of the Screening Program. Each subclass also includes all representative and
derivative claimants whose claims are based on their personal or legal relationship with the diet drug user
identied in each subclass.383
Class Certication in the Fen-Phen Litigation and the Supreme Court Amchem Decision
The class certication for settlement purposes in the fen-phen MDL was impacted by the Supreme Court
case of Amchem Products, Inc. v. Windsor, which tightened up the requirements for class certication.
The proposed settlement class in Amchem consisted of persons who had manifested physical injuries due
to asbestos exposure and also those who had not yet manifested any injuries but who had been exposed
to asbestos. The Supreme Court held that the proposed settlement class had to meet FRCP Rule 23
requirements and that the court would also have to consider the adequacy of the settlement. The court
found that the Amchem proposed class did not meet Rule 23's requirements for certication, since it did
not meet the commonality requirement or the adequacy of representation requirement.384 The court found
that \the goal of class members who were currently injured and needed immediate payment conicted with
the interests of exposure only plaintis in ensuring an ample, ination protected fund for the future."385
383See id.
384See Vivi Vanderslice, Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in Light of Amchem v. Windsor,
35 Cal. W. L. Rev. at 199 { 204.
385Id. at 209.
103Amchem presented the issue of maintaining present and future injuries in the same case.
Judge Bechtle did provisionally certify the Brown settlement class in the fen-phen litigation, so the Amchem
concern did not come to bear. He still has to give Final Judicial Approval386 to the Settlement, and
there the Amchem concerns may become important. However, the fen-phen Settlement addresses many of
Amchem's concerns in its structure. It is critical to note that the Supreme Court acknowledged the fact
that in Amchem there was no subclass division. In Amchem, \the Supreme Court indirectly encouraged the
use of subclasses... to ameliorate the potential intra-class conicts of interest between present and future
claimants."387 The court in Amchem stated: \where dierences among members of a class are such that
subclasses must be established, we know of no authority that permits a court to approve a settlement without
creating subclasses."388 The class in the fen-phen litigation is divided into 5 subclasses with separate counsel
for each. (See detailed discussion of the Settlement below).
In Amchem the court also noted the issue of conicts of interest among class members, particularly presently
injured plaintis who desire payments as soon as possible versus plaintis facing future injury who want to
preserve money for possible later payments. This is also less of a problem with the fen-phen Settlement, since
its provisions for future and present injuries are divided clearly into Fund A and Fund B. Also, while American
Home Products will have to pay out a large sum in the Settlement, it is not an amount that threatens to
bankrupt American Home Products and prevent any future payments to injured diet drug users. In addition,
the Settlement prevents conict because plaintis who receive Fund A medical monitoring benets will have
the chance to qualify for Fund B payments if they later become sick. The money has been set aside for both
types of plaintis today, so that the future injured are not in conict with the presently injured. All can be
386Judge Bechtle's decision on whether to grant Final Judicial Approval to the Settlement will be reviewed by the U.S. Court
of Appeals for the Third Circuit. See Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Frequently Asked Questions,
available online at www.dietdrugsettlement.com.
387Ryan Kathleen Roth, Mass Tort Malignancy: In The Search For A Cure, Courts Should Continue To Certify Mandatory,
Settlement Only Class Actions, 79 B.U. L. Rev. 577 (1999).
388Amchem Products, Inc. v. Windsor, 521 U.S. 591, 627 (1997).
104sure they will receive compensation.389
Judge Bechtle did provisionally certify the settlement class in Brown, and one of the issues to be determined
in the Fairness Hearing to be held on May 1 { 5, 2000 will be whether that class shall remain certied.390
In all likelihood, the class will remain certied. This is because of the clear division of the class into ve
subclasses, the provision of separate counsel for each subclass, the exibility for class members to change
to a dierent subclass if their position changes, the separation of money into Fund A and Fund B, and the
construction of safeguards to ensure a minimum of intra-class conicts of interests.
THE PROPOSED SETTLEMENT AGREEMENT
Plaintis and [American Home Products] defense lawyers391 negotiated a Settlement Agreement in Oc-
tober of 1999. Judge Bechtle gave preliminary approval to the Settlement on November 24, 1999.392 The
proposed settlement is subject to a Fairness Hearing and Final Judicial Approval. 393
Members of the Brown Settlement Class
The Settlement includes all individuals who are members of the class that was provisionally certied in
389See Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593.
390See id.
391The team of plaintis' lawyers who negotiated the [settlement] deal will have the right to petition the court for up to $429
million in attorney fees. See Fen-Phen Settlement Gets Court Approval,
Natl. L.J., Dec. 6, 1999 at B4.
392See id.
393Judge Bechtle denied certication of a $100 million Interneuron limited fund mandatory settlement on Sept. 30, 1999. Judge
Bechtle said that elements of the Interneuron settlement \went astray" from the original intent of the Advisory Committee
that wrote FRCP 23. The proposed Interneuron settlement was overall extremely dierent from the American Home Products
proposed Settlement Agreement. See Recent News, Mealey's Litigation Report Fen-Phen/Redux, available online at
www.mealeys.com/fen.html.
105Brown v. American Home Products. The Settlement is also intended to resolve the claims of members of
other diet drug class action lawsuits against American Home Products that have been certied or condi-
tionally certied. These class actions include, but are not limited to: the Jeers nationwide federal medical
monitoring class, the West Virginia statewide personal injury and medical monitoring class, the Illinois
statewide refund and monitoring reimbursement class, the New Jersey statewide Unfair and Deceptive Acts
and Practices and medical monitoring class, the New York statewide medical monitoring class, the Pennsyl-
vania statewide medical monitoring class, the Texas statewide medical monitoring class, and the Washington
statewide medical monitoring class.394
Class members are dened as all individuals who used Pondimin and/or Redux and live in the United States
or its possessions and territories. If a person meets that denition, he or she is a member of the nationwide
class that was provisionally certied in the diet drug litigation for settlement purposes only, regardless of
whether that person already has a lawsuit pending. Such persons are also class members even if they are
class members in other diet drug class actions. Persons are also class members who are derivative or rep-
resentative claimants of persons who used Pondimin and/or Redux and live in the U.S. or its possessions
or territories. Such persons include family members or \signicant others" of Pondimin/Redux users and
persons with certain legal relationships with Pondimin/Redux users such as heir, beneciary, or executor
of an estate. Persons in the above listed categories are not class members if their claims against American
Home Products or American Home Products Released parties arising out of Pondimin and/or Redux use
have been nally resolved either by judgment or by a release.395
Settled Claims and Released Parties
394See Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593.
395See id.
106Under the Settlement Agreement, in exchange for settlement benets, class members are \agreeing to re-
lease any and all claims, including assigned claims, whether known or unknown, asserted or unasserted,
regardless of the legal theory, existing now or arising in the future by any or all members of the Settlement
Class arising out of or relating to the purchase, use, manufacture, sale, dispensing, distribution, promotion,
marketing, clinical investigation, administration, regulatory approval, prescription, ingestion, and labeling
of Pondimin and/or Redux, alone or in combination with any other substance, including, without limita-
tion, any other drug, dietary supplement, herb, or botanical."396 These settled claims include but are not
limited to: all personal or bodily injury claims, claims for compensatory, punitive, and multiple damages,
loss of wages, loss of support, consumer fraud claims, wrongful death and survival actions, medical screen-
ing or monitoring, economic or business losses, and prejudgment or post-judgment interest. The \Released
Parties" include American Home Products and each of its subsidiaries, aliates, and divisions (including
A.H. Robins and Wyeth-Ayerst), American Home Products shareholders, any and all suppliers of materials,
components, or services used in the manufacture of Redux and/or Pondimin, all Pondimin/Redux distrib-
utors, and all Redux/Pondimin prescribing physicians and dispensing pharmacies (only for certain claims).
Released parties do not include prescribing physicians and dispensing pharmacies when the claims are based
on their independent negligence or culpable conduct. Les Laboratories Servier S.A. and all its aliates
and subsidiaries are not Released parties, nor are any phentermine manufacturers, sellers, or distributors.
Interneuron Pharmaceuticals is also not a Released Party. Non-Settling Defendants are barred from bring-
ing claims for contribution and/or non-contractual indemnity against American Home Products and other
Released Parties to recover payments made to class members in fen-phen litigation.397
The Settlement does not include PPH claims. Pondimin/Redux users can pursue PPH claims outside of the
Settlement, even if they did not opt-out. However, Pondimin/Redux users who do not opt out of the Settle-
396Id.
397See id.
107ment cannot pursue PPH claims in court if they received Fund B (see below) matrix compensation benets,
unless the class member was diagnosed with PPH before they had left-sided heart valve abnormalities or
endocardial brosis.398 The Settlement agreement contains a clear medical denition of PPH. The PPH
denition in the Settlement agreement is broader than the denition in the IPPHS study. The Settlement
does not provide any benets for neurotoxic injuries and all Pondimin/Redux users who do not opt-out of
the Settlement will not be able to pursue any neurotoxicity claims in court.399
Terms of the Settlement Agreement
Summary of Benets
The following is a summary of the benets provided in the Settlement agreement. The Settlement provides
for a free echocardiogram and an appointment with a doctor to discuss the echocardiogram for all people
who took Redux and/or Pondimin for 61 or more days. For people who took Redux and/or Pondimin for
60 days or less, they do not qualify for a free echocardiogram and doctor's visit but the Settlement allows
exceptions in certain cases with humanitarian or compassionate reasons or true nancial hardship. All people
who have FDA positive regurgitation will receive a cash or medical services benet for heart valve disease.
People who took Pondimin and/or Redux for 61 or more days will receive $6,000 in cash or $10,000 in heart
valve related medical services, and those who took the drugs for 60 days or less will receive $3,000 in cash
398A plaintis' rm mass e-mail designed to answer fen-phen users' questions about the Settlement says \if you decide to
opt-in to the Settlement and receive Fund B compensation for your valve-related heart injuries, you generally are precluded
from bringing a separate lawsuit against American Home Products for PPH. In the event that you decide to opt-out of the
Settlement, you may pursue any and all claims against American Home Products, including a PPH claim." Answers to
Frequently Asked Questions, Web Bulletin # 3, Fen-Phen Multistate Litigation Website, Feb. 10, 2000, available online
at http://leflaw.net/fenphen.
399See Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593 at p.9
108or $5,000 in heart valve related medical services. For those patients with serious valvular heart disease as
described in the Settlement Matrix Compensation Benets Guide, they will receive benets ranging from
$7,389 to $1,485,000, depending on their age, severity of their disease, how long they took the drugs, and
various other factors. American Home Products will also establish a fund for research and education on
valvular heart disease and establish a medical registry to track Pondimin and Redux users for research and
educational purposes
Detailed Description of Benets Under The Settlement Agreement
In more detail, the Settlement provides for the following benets:
1)
The Right To An Initial Medical Evaluation.
People who took Pondimin and/or Redux for 61 or more days and had not been diagnosed
with FDA Positive regurgitation as of September 30, 1999 have a right to receive a screening
echocardiogram. This purpose of the echocardiogram is to determine whether the patient
has FDA Positive Regurgitation. The patient will have a chance to see a qualied doctor
to discuss and evaluate the echocardiogram. People who took Pondimin or Redux for 60
days or less are not entitled to a screening echocardiogram. However, they may apply to
receive an echocardiogram and accompanying doctor's visit to evaluate the echocardiogram
if they can demonstrate compassionate and humanitarian reasons and/or true nancial hardship.
2)
109Additional Medical Services or Cash People who took Pondimin and/or Redux for 61 or more days who have been diagnosed with FDA Positive valvular regurgitation at any time from the start of their use of Redux and/or Pondimin to the end of the period for screening echocardiograms400 have a right to receive $6,000 in cash or $10,000 in heart-valve related medical services, if they have registered for benets. The heart-valve related medical services include periodic doctor visits and ongoing echocardiogram evaluations. People who have been diagnosed with FDA Positive valvular regurgitation who took Pondimin and/or Redux for 60 days or less have a right to receive either $3,000 in cash or $5,000 in heart-valve related medical services.
3)
Payment of Compensation Benets
People who took Pondimin and/or Redux for any period of time who have FDA Positive
regurgitation or mild mitral regurgitation by the end of the echocardiogram screening period
have the right to recover monetary compensation if they later develop serious valvular heart
disease within approximately the next 15 years.401 Patients with serious valvular heart disease
can recover immediately under the Accelerated Implementation Option (see below). For
patients without serious valvular heart disease at the present time, they can recover nancial
compensation if and when their disease gets worse. FIVE levels of Valvular Heart Disease are
serious enough to qualify for compensation benets under the Settlement. They are:
(1)
Severe Valvular Heart Disease without symptoms or an infection in the heart (bacterial endocarditis)
(2)
Moderate to severe Valvular Heart Disease with signs of injury to the heart
(3)
Cases where the patient has had valve repair or replacement surgery or where valve repair or replacement surgery has been recommended
(4)
Serious complications of valvular heart disease or valve-related surgery like a serious stroke
110(5)
Very serious complications of valvular heart disease or valve-related surgery like death or a heart transplant
The amount of compensation that will be paid to patients who qualify for these compensation
benets depends on several factors listed in a compensation matrix. These factors include the
severity of the patient's condition, the patient's age, whether or not the patient took Pondimin
or Redux for over 60 days, whether the patient has any other causes for valvular regurgitation
other than ingestion of Pondimin and/or Redux, and whether the class member is a derivative
or representative claimant. The minimum compensation a patient can receive is $7,389 (for a
70 { 79 year old patient with a severity level of I) and the maximum compensation a patient
can receive is $1,485,000 (for a patient 24 or younger with a severity level of V). The severity
levels from I to IV are dened medically in the \Settlement Matrix Compensation Benets
Guide for Physicians, Attorneys, and Class Members"402. There are four payment schedules
(matrices) which set forth the compensation amounts for each particular patient according to
their age at diagnosis, level of severity of valvular heart disease, and various other criteria such
as the existence of alternative reasons for the valve problems. The compensation amounts are
increased annually for ination by 2% and are subject to certain court-approved deductions
like attorneys' fees and costs. The spouses, children, \signicant others" and certain legal
representatives of persons who ingested Pondimin and/or Redux may also receive compensation
payments under the Settlement. If a patient's medical condition worsens to a more serious level
of valvular heart disease that would qualify them for a higher compensation benet, the patient
has the right to \step up" to a higher compensation level.
4)
111Prescription Cost Refunds
All patients who took Pondimin and/or Redux have a right to receive a refund of $30 per
month for Pondimin and $60 per month for Redux. If the patient took Redux and/or Pondimin
for 61 or more days, there is a $500 refund limit per person. In addition, if the patient took
Redux and/or Pondimin for 61 days or more, the availability of refunds depends on whether
Settlement funds remain after providing other benets.
5)
Reimbursement For Certain Echocardiogram Costs
If the patient had an echocardiogram after they started taking Pondimin and/or Redux, the
patient may qualify for repayment of the cost of that echocardiogram. This benet will only be
available if sucient Settlement funds remain after providing benets to other class members,
except for refund benets for class members who used Pondimin and/or Redux for 61 or more
days.
6)
Medical Research and Registry
112The Settlement provides for American Home Products to sponsor medical research relating to
cardiovascular disease. The Settlement establishes a fund, not to exceed $25 million, for medical
research and education for the benet of all class members. A registry will be maintained to
track people who took Pondimin and/or Redux and to perform medical research. Provisions
in the Settlement Agreement assure that each class member's identity in the registry is kept in
condence.403
Opting-Out, Registration, and the Accelerated Implementation Option
As discussed above, Judge Bechtle provisionally certied the nationwide Settlement Class under FRCP 23(a),
23(b)(2), and 23(b)(3) for settlement purposes only. Therefore, all persons who took Pondimin and/or Redux
are automatically members of the Settlement class if they do not opt out of the Settlement by sending in
the \orange opt-out form" by March 30, 2000. Pondimin/Redux users could also opt out by writing a letter
to the court. If Pondimin/Redux users do not opt out, their rights will be determined by the Settlement
and they will be bound by its terms if it is approved. Diet drug users who do not opt out will be bound
by the Settlement and will not be able to pursue any settled claims against American Home Products and
other released parties, except in cases where the patient can exercise an intermediate or back end opt out.
An intermediate opt out opportunity exists if the patient did not know they had an FDA Positive condition
by September 30, 1999 and found out that they did have FDA positive regurgitation by the end of the
Settlement's screening program. A back end opt out opportunity exists when patients did not know that
they had a condition that would allow them to receive Matrix compensation benets before the opt-out
deadline but developed one at a later date. If the Pondimin/Redux user decides to opt out of the Settlement
through a back end or intermediate opt out, their claims will not be barred by the statute of limitations.
In back end or intermediate opt out cases, Pondimin/Redux users will not be able to recover punitive
113or multiple damages against American Home Products.404 In order to collect compensation or receive
medical monitoring, Pondimin/Redux users who do not opt out and want to participate in the Settlement
must register for Settlement benets. Pondimin/Redux users who are participating in the Settlement can
choose to proceed by registering for benets under the \blue form" registration or they can choose to receive
benets immediately by lling out the \pink form" and taking advantage of the \Accelerated Implementation
Option".
Pondimin/Redux users who do not want to presently opt-out but who may want to opt-out later through a
back-end opt out or intermediate opt-out should proceed through the blue form registration. By registering
for Settlement benets by lling out the blue form sent to Pondimin/Redux users, the patient will receive
Settlement benets only if the Settlement receives nal judicial approval. Pondimin/Redux users who know at
the time of registration that they have serious valvular heart disease and are entitled to Matrix compensation
payments do not have the option of a later intermediate or back end opt out.
Pondimin/Redux users who wish to participate in the Settlement can also proceed by taking part in the
Accelerated Implementation Option. The Accelerated Implementation Option sets the Fen-phen Settlement
apart from most other settlement agreements. In most other class action settlements class members must
wait until nal judicial approval of the settlement to receive benets. If nal judicial approval is not granted,
then class members will not receive settlement benets. The fen-phen Settlement is very dierent because
Pondimin/Redux users may accept the Accelerated Implementation Option (\AIO") and receive Settlement
benets quickly, irrespective of whether the Settlement receives nal judicial approval. AIO participants do
not have to wait until the completion of the court approval process in order to receive benets, nor do they
risk not receiving any Settlement benets if the Settlement never receives nal judicial approval. In order
404The fact that those who opt out at future points are barred from seeking punitive damages is a source of contention among
many plaintis' lawyers. See Arian Campo-Flores, A Fen-Phen Fix { Big Suits: Top of the Docket Vadino et. al. v. AHP,
The American Lawyer, Nov. 1999.
114to participate in the AIO, Redux/Pondimin users must give up their right to opt-out of the Settlement and
also give up their rights to object to the Settlement. Any persons who want to join the AIO must ll out
the pink AIO form by April 29, 2000.
The Fairness Hearing and Objecting to the Settlement Agreement
While he did give preliminary approval, Judge Bechtle has not given nal approval to the Settlement, and a
fairness hearing is scheduled for May 1-5, 2000 in the Courthouse in Philadelphia. The fairness hearing will
be held to assist Judge Bechtle in deciding whether to approve the Settlement and to make it eective for
all those Pondimin/Redux users who did not opt out or accept the AIO. Pondimin/Redux users can appear
through an attorney or in person as long as they did not opt out or accept the AIO. The purpose of the
Fairness Hearing is to determine if the Settlement class should remain certied, if the proposed settlement is
fair, reasonable, and adequate, and to consider any other matters that the court determines are appropriate.
The court can continue the Fairness Hearing on additional dates, without giving further notice to class
members. Persons who wish to speak at the hearing should request time to do so in writing and that request
must be postmarked by March 30, 2000. An attorney may appear on behalf of a class member at the hearing.
Those class members who do not wish to object do not need to appear or le any papers. Class members can
also submit written comments in support of or in objection to the Settlement. Such written comments must
have been postmarked by March 30, 2000, or the objection will not be considered by the court in deciding
whether to grant approval to the Settlement. If a settlement class member does not mail an intention to
appear or a written comment by the set deadline, that class member shall have waived his or her right to
object and will be permanently barred from objecting to the proposed Settlement. 405
405All of the information in the sections on \Opting-Out, Registration, and the Acceler-
ated Implementation Option" and \The Fairness Hearing and Objecting to the Settlement Agree-
ment" come from the Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593 (in its entirety).
115Payment of Settlement Benets by American Home Products
The Settlement Agreement provides for American Home Products to put money in a Settlement Trust.
The Trust will put money into two separate funds, Fund A and Fund B. Fund A and Fund B will be used
to pay for Settlement benets for class members as well as for administrative costs and certain attorneys'
fees. American Home Products has already started putting money into Fund A and Fund B and it will
continue to put money into the Funds for 16 years, as is necessary. American Home Products must pay
into the Funds $1.85 billion within the next three years, and it may pay into the Funds as much as $4.83
billion, which is $3.75 billion in present value. Any payments into the Funds over the initial $1.85 billion
will be paid in only as necessary as determined by the amount of class members who register to receive
benets. The payments above the initial $1.85 billion are subject to annual maximum amounts and these
maximums will be adjusted to account for individuals who opt-out and for individuals who subsequently
receive payments from American Home Products as a result of judgments or settlements. Fund A will be
used for Pondimin/Redux refunds, medical monitoring costs, reimbursement for certain privately-obtained
echocardiograms, additional medical services and cash payments made to class members, medical research
and education costs, costs of the tracking registry, administrative costs (including mailing/publication of
the Class Notice), and attorneys fees relating to the benets provided by Fund A (paid by American Home
Products into a separate escrow account). Fund B will be used for matrix compensation benets to class
members with serious heart disease as described in the Settlement Agreement, certain attorneys' fees related
to the matrix compensation payments, and administrative costs (including mailing and publication of the
Class Notice).406 American Home Products will record a charge of $4.75 billion pretax (aftertax $3.29
billion), which comes to $2.51 per share, to provide for expected payments to Fund A and Fund B, for other
406See id.
116fen-phen related judgments and settlements, and legal costs.407
Termination of Settlement Agreement
American Home Products has the option to terminate and withdraw from the Settlement Agreement within
30 days from March 30, 2000. The decision to terminate and withdraw is to be made at the discretion
of American Home Products, if it determines that too many Redux/Pondimin users have opted out of the
Settlement Agreement. If American Home Products decides to withdraw, it is still bound by all individual
agreements entered into when Redux/Pondimin users accepted the AIO.408
The Settlement will also be terminated if it does not receive Final Judicial Approval.409 If Final Judicial
Approval is denied, American Home Products will still be bound by individual agreements entered into by
diet drug users who accepted the AIO.410
Settlement Criticisms
The fact that American Home Products can terminate and withdraw from the Settlement if it determines
there have been too many opt-outs leads to a discussion of the extensive criticism of the Settlement by
407See American Home Products Corporation, American Home Products Announces Diet Drug Settlement Plan, American
Home Products Press Releases, Madison, N.J., Oct. 7, 1999, available online at
www.ahp.com/releases/ahp 100799.htm.
408See Ocial Court Notice of Nationwide Diet Drug Class Action Settlement:
In re Diet Drugs (Phentermine/Fenuramine/Dexfenuramine) Products Liability Litigation, Sheila Brown, et al. v. American Home Products Corporation,
Civil Action NO. 99-20593.
409Law Professor John Coee, Jr. said Judge Bechtle is likely to approve the Settlement, although his decision will be
reviewed by the Third Circuit and may be reversed on appeal. Professor Coee said that the Third Circuit has \in the past
taken a very close look at class action settlements." See Arian Campo-Flores, A Fen-Phen Fix { Big Suits: Top of the Docket
Vadino et. al. v. AHP, The American Lawyer, Nov. 1999.
AHP lawyers expressed the view that Judge Bechtle would approve the Settlement and that his decision would be upheld by
the Third Circuit. They also said they thought that most class members, especially those who were well-informed, would accept
the Settlement. One AHP attorney characterized the Settlement as \fair, exible, and generous" and said that \once claimants
and their counsel have a chance to consider the benets of the settlement, I believe that many will prefer those benets to a
lengthy and uncertain course of litigation." Id.
410See Important Notice on the Proposed Class Action Settlement/A Class Member's Guide to the Diet Drug Litigation
Settlement.
117plaintis' lawyers around the country. Many plaintis' lawyers have praised the medical monitoring benets
of the Settlement and the Fund A provisions, but have sharply criticized the matrix compensation benets.
Many claim that it is too dicult to qualify for matrix compensation benets and that the sums for qualifying
class members are far too small.411 Marc Bern, a New York plaintis' lawyer whose rm represents over
5,000 fen-phen plaintis, said that the Settlement is great \for healthy people who just want future medical
checkups. [however], `[f]or those people who are injured, it stinks"'.412 While Settlement payments range
from $30-$60 monthly prescription refunds to a maximum of $1.5 million for people with very serious heart
problems, attorney Bern says he does not know if there is anyone in the U.S. who would qualify for that
maximum sum.413 \To qualify for the maximum $1.5 million... a plainti would have to have taken the diet
drugs, had valve surgery and suered even more dire consequences { dying, falling into a coma or undergoing
a heart transplant".414 In addition, the $1.5 million could also only be paid to people who were 24 or younger
when they got sick.415 Attorney Bern stated that most fen-phen plaintis are middle aged women who fail
to meet that age requirement, and that medical expenses alone for most of those women exceed the amount
to which they would be entitled under the Settlement Agreement. In sum, he called it a \lousy settlement"
and said that virtually everybody I speak to says they'll opt out".416
411See Amy Westfeldt, Many Decline Diet Drug Settlement, Associated Press, Oct. 15, 1999.
412Id.
American Home Products has claimed that the website of Marc Bern's rm, Napoli, Kaiser & Bern, is endangering the
Settlement. Napoli, Kaiser & Bern's website, www.dietdrugsettlement.com, reects the rm's critical view of the Settlement.
The rm calls the site educational, while American Home Products claims the site is misleading. American Home Products
has gone to court to force the Napoli, Kaiser & Bern to make certain changes, including a change in website address. The
ocial site of the MDL is www.settlementdietdrugs.com, and American Home Products asserts that the similarities in the web
addresses is diverting visitors from the court-sanctioned site to the Napoli, Kaiser & Bern site. Marc Bern said that the rm's
site has ne print that says it is not the ocial Settlement site. He says that the rm's site's purpose was not to solicit clients,
and that it is protected by the First Amendment. The site includes an opt-out form prospective plaintis can mail to Judge
Bechtle and includes an analysis of the proposed Settlement, which the rm website labels as \totally inadequate and unfair."
Napoli Kaiser & Bern represents approximately 7,000 former Redux and Pondimin users. See Practitioner's Newswire: AHP
Goes To Court Over Law Firm Web Site, 18 Product Liability Law & Strategy 10 (2000).
After a hearing on January 14, 2000, Judge Bechtle issued a pretrial order temporarily restraining Napoli, Kaiser & Bern
from using www.dietdrugsettlement.com with respect to the orange opt-out form. See TRO continues against Law Firm's
Settlement Site, Mealey's Litigation Report Fen-Phen/Redux, available online at www.mealeys.com/fen.html.




118Bern's law rm, Napoli, Kaiser & Bern, has a website with a \fen-phen frequently asked questions" section.
In response to the question, \Do I qualify for any settlement benets", the response includes the statement
that \even when a claimant can qualify for benets, the payments being oered in some cases may not even
cover the amount of lost earnings and/or medical expenses incurred as a result of being injured. For example,
in a recent Texas case, Debbie Lovett, the jury awarded 23.5 million dollars; yet under the settlement plan
she would only receive $6000."417 The website also mentions the $150 million verdict for ve Mississippi
plaintis in Washington.418 The website says that \it is our rm's opinion that the payout leaves much to
be desired."419
Tom Pirtle, a Houston lawyer representing 3,200 fen-phen plaintis, used an example of a client who has
$2 million in medical expenses related to her valvular heart disease problem, yet would only qualify for $1
million under the Settlement terms. Pirtle said that the agreement is \a whole lot better settlement for Wall
Street than for Main Street ...[and the criteria for compensation payments] completely exclude a number
of people injured from the drug".420
Other fen-phen plaintis' lawyers in Texas joined Pirtle in his criticism of the Settlement and indicated that
they would have their clients opt out. Robert Kisselburgh, one of the lead plaintis' lawyers in the Lovett
trial, stated \I think they're absolutely kidding themselves... I mean, I don't know if it's a ploy to bring
the stock up, since it was down after our verdict, but I think they're kidding themselves if they think the
majority of people in Texas are going to take this settlement".421
417See Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Frequently Asked Questions, available online at
www.dietdrugsettlement.com.
418Both of those cases later settled for signicantly smaller amounts (see sections below on Lovett trial and Mississippi
Washington trial). See Reuters, Dallas, TX, Jury Awards $23.3 Million in Texas Fen-Phen Case, Aug. 6, 1998, available
online at www.heartinfo.org; See also Kerry Whipple, Settlement Reached in Fen-Phen Trial, The Natchez Democrat, Dec.
21, 1999, available online at www.dietdrugsettlement.com.
419Napoli, Kaiser & Bern LLP, The Fen-Phen E-Resource, Frequently Asked Questions, available online at
www.dietdrugsettlement.com.
420Arian Campo-Flores, A Fen-Phen Fix { Big Suits: Top of the Docket Vadino et. al. v. AHP, The American Lawyer,
Nov. 1999.
421Susan Borreson, Fen-Phen Plan Doesn't Thrill Texans: Most Plainti's Lawyers To Opt Out Of Settlement, Texas
Lawyer, Oct. 18, 1999, at 1. Statement of Dallas lawyer Robert Kisselburgh.
119On its website, Rheingold, Valet, Rheingold & Shkolnik, a New York plaintis rm that represents thousands
of fen-phen plaintis, says to fen-phen users:
[y]ou have probably read about a proposed class action settlement of these
cases. Almost all of our present clients are planning to take the legal step of opting
out of it. The plan does not provide any signicant payment for the great number of
persons injured by fen-phen. It does not cover PPH cases, nor does it cover many valve
regurgitation cases. It has no payment for mild leaks nor for more serious mitral and
aortic leaks unless there are serious complications. If these complications exist then
payment is made pursuant to a grid. The amounts on the grid are much lower than the
sums that our law rm and others have been able to obtain by starting suit and bringing
the cases up to trial, at which time they are settled. However, until we represent you,
we are not oering advice about whether a person should opt out or not.422
A Wyeth-Ayerst spokesman countered these criticisms with the statement that \the settlement oers a
refund program for the drugs and a rich package of medical monitoring and treatment { with signicant
compensation for those with serious valve problems. `It's a settlement for the patients... not the lawyers"'423
American Home Products General Counsel Louis L. Hoynes, Jr. said,
In designing the agreement with the plaintis' attorneys, we wanted to ensure that
the benets are attractive to the claimants and provide a strong incentive for participation.
We are condent that well-informed claimants will conclude that the range of benets of this
settlement is preferable to lengthy and uncertain litigation. The scientic studies conducted
to date and clinical experience indicate that the health of the overwhelming majority of
people who took Redux or Pondimin has not been adversely aected. The studies also show
no increased risk of valvular heart disease among persons who took the drugs for three
months or less { more than 75% of those who took the drugs. Yet this settlement provides
a quality package of benets for all individuals who used the drugs and nancial protection
in the event a person should develop serious heart valve disease.424
Settlement negotiators have responded to the barrage of plaintis' lawyers criticism by praising the settle-
ment's exibility and extensive medical monitoring benets. Christopher Placitella of New Jersey, one of
the seven plaintis' negotiators, said that \It's the most comprehensive consumer protection settlement ever
from a public health perspective".425 He said that the Settlement is unique because of its exibility, since
423Steve Sternberg, More Pain Promised In Court For AHP, USA Today, Jan 12, 2000.
425Arian Campo-Flores, A Fen-Phen Fix { Big Suits: Top of the Docket Vadino et. al. v. AHP, The American Lawyer,
Nov. 1999
120\class members can initially choose to participate in the settlement { obtaining medical tests and free visits
to the doctor { and later, if they discover a health problem or their condition worsens, withdraw from the
agreement and pursue their cases in court."426 However, those who opt out later are barred from seeking
punitive damages.427
General Consensus and Observations on the Settlement Agreement
Overall, the general consensus seems to be that plaintis attorneys are satised with the medical monitoring
provisions, which go beyond DHHS and ACC recommendations428, but are not satised with the matrix
compensation benets. Attorney Bern said that this is a result of the fact that the lawyers who negotiated
the Settlement primarily represented the clients who were not ill or who were not suering from serious
medical complications.429 While clearly not a scientic percentage, Bern estimated that approximately
25% of plaintis' lawyers in the U.S. supported the Settlement.430 The sentiment that the Settlement is
unacceptable to plaintis has been voiced around the country431 and this may have an impact on the amount
of opt-outs. If the opt-out number is too high, then American Home Products' whole purpose in entering
426Id.
427See id.
428DHHS recommended Redux/Pondimin users should be examined by their doctors and only in certain circumstances should
they have echocardiograms. \In seeking a massive echocardiogram testing program, plaintis' lawyers have gone beyond the
recommendations of the federal government and of the medical profession. The American College of Cardiology and the
American Heart Association recently issued guidelines recommending against echocardiograms for diet-drug users who showed
no symptoms of heart damage. The groups urged instead that doctors perform physical and stethoscope exams on patients and
that echocardiograms be done only for patients too obese to be diagnosed by stethoscope." In fact, doctors for the two named
plaintis in the nationwide medical monitoring class did not recommend echocardiograms for their patients. L. Stuart Ditzen,
In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
429See Amy Westfeldt, Many Decline Diet Drug Settlement, Associated Press, Oct. 15, 1999
430See id.
431See Susan R. Miller, 3.75 Billion Diet Drug Settlement Threatened By Feuding Attorneys, Miami Daily Business Review,
Jan 13, 2000 (noting that several Miami plaintis attorneys are not satised with the terms of the settlement. The article also
states that one New York plaintis' lawyer is claiming that he is getting 300 or 400 opt outs per day. The article notes that
AHP has the right to terminate the settlements if there are too many opt outs after the opt-out expiration date comes around
on March 30, 2000).
One Houston lawyer stated, \In my view, American Home Products' global settlement is now dead... a lot of people won't
go into the national settlement. If you look at that $150 million award [in Mississippi], it just shows you how angry ordinary
citizens get when they hear about these charges." David Morrow, American Home To Settle Some 1,400 Fen-Phen Suits, Dec.
23, 1999, Mealey's Litigation Report Fen-Phen/Redux, available online at www.mealeys.com/fen.html.
121into the Settlement and ending the huge threat of fen-phen litigation will be thwarted. American Home
Products may then elect to withdraw from the Settlement and only then have to pay the benets to those
class members who accepted the AIO.432
On the whole, such an outcome will be \good" or \bad" depending on where the particular plainti stands
with respect to his or her medical condition. For healthy plaintis who receive medical monitoring, the
termination of the Settlement would be a negative occurrence. However, for plaintis with valvular heart
disease, especially older plaintis, the termination of the Settlement may allow them to receive much higher
amounts of compensation than would be forthcoming according to the Settlement Agreement. For American
Home Products, a large number of opt-outs and a termination of the Settlement would be an overall negative
outcome, since it would fail to `put to bed' the threat of thousands of lawsuits that have plagued the stock
price since the fen-phen safety problems became apparent in 1997. American Home Products would be
forced to settle on a case by case basis or to try cases before juries in various state and federal courts, which
would be a costly and uncertain undertaking. John R. Staord, American Home Products CEO, said that
This Settlement provides fair and equitable terms for both diet drug claimants and American
Home Products. Settling this matter was in the best interest of those who used Pondimin or
Redux as well as of the company. We believe that this agreement is a sound way to resolve
the claims raised by diet drug users and represents a prudent course for our company. It oers
peace of mind to those who used the drugs and permits the company to move beyond the
uncertainty and distractions of litigation. We agreed to this settlement so that we can focus
on the business of making innovative pharmaceutical products. Today, we have in our research
pipeline products to help solve some of the world's most pressing health problems and this
settlement allows us to pursue and expand that eort.433
Even if American Home Products does not terminate the Settlement Agreement and it obtains Final Judicial
Approval, it still has to deal with the PPH claims that are not settled pursuant to the Agreement. Some
estimates have put liability for those claims at approximately $1 billion, and American Home Products has
432While the deadline has recently passed for opt-outs, it was a postmark deadline and the numbers are not yet available.
122already settled several PPH cases for amounts reported to range from $1.5 to $4.5 million.434 American
Home Products would have to put forth signicantly more money and eort towards individually disposing
of all the valvular heart damage cases as well. In addition, if Redux and Pondimin are later shown to cause
neurotoxicity problems in humans as well as in animals, American Home Products may also have to settle
or try a multitude of neurotoxicity claims that would be precluded by the Settlement Agreement. American
Home Products will benet immensely from a low number of opt-outs and having the Settlement gain Final
Judicial Approval. It encouraged plaintis to give up their right to object or opt-out by accepting the AIO,
and it has actively promoted and defended the Settlement Agreement. While it is yet too early to determine
the number of opt-outs, their number will have a signicant impact on the outcome of the fen-phen debacle
for American Home Products and will also have a wide-ranging eect on American diet drug users with
varying degrees of medical problems.
KEY PRIOR FEN-PHEN CASES AND SETTLEMENTS { TEXAS, MISSISSIPPI, AND THE LINNEN TRIAL/SETTLEMENT IN MASSACHUSETTS
While the settlement is the most prominent focal point of the current fen-phen legal situation, there have
been several key fen-phen cases and settlements that set the stage for the Settlement Agreement and that
may set the state for post-settlement litigation, both for PPH claims and for opt-out valvular heart disease
plaintis. If the Settlement Agreement does not receive Final Judicial Approval or if American Home
Products terminates the Agreement because of a high number of opt-outs, these cases may be of central
concern to litigators representing plaintis who ingested Pondimin or Redux. They are also critical for PPH
cases not included in the Settlement. This paper discusses the rst fen-phen case that resulted in a jury
verdict, the Lovett case in Texas, along with certain important Texas settlements. The Texas cases are
434See L. Stuart Ditzen, In Mass Litigation, The Serious Cases can Get Lost, Philadelphia Inquirer, Nov. 22, 1999, at A1.
123followed by a discussion of the Washington case in Mississippi and the settlement covering all Mississippi
fen-phen users. Also included is a discussion of the Linnen wrongful death PPH trial in Massachusetts
Texas Cases/Settlements
The Lovett Trial, Verdict, and Settlement
The Lovett case was the rst fen-phen case to end in a jury verdict. American Home Products had settled 20
cases before the Lovett case went to trial, and the company had been predicting that it would win.435 The
case was tried before a jury of eight men and four women in the courtroom of Judge Tommy W. Wallace of
Van Zandt County, Texas and the verdict was returned on August 6, 1999.436
Debbie Lovett was a 36 year old manicurist from Grand Saline, Texas. Lovett was a smoker who took
fenuramine and phentermine in combination for six months, beginning in October, 1995. Lovett sued
Wyeth-Ayerst and American Home Products, claiming that she developed leaky heart valves as a result
of her fen-phen use. Lovett had not had valve replacement surgery, although she did suer from valvular
regurgitation. Cases like Lovett's were those that American Home Products thought it would be most likely
to win, since it is hard for plaintis to prove causation and also dicult for plaintis to show that they have
suered life-altering damage as a result of fen-phen use. As one defense lawyer stated, \if you have mild
regurgitation, you can y to the moon, you can play football... it's a lab nding. It's something, but it's
435See Bob Van Voris, A Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
436See id.
124not life adjusting. That's why I think we'll be trying lots of regurgitation cases."437 Defense lawyers also
focused on the fact that Lovett had smoked for eight years, claiming that her smoking history caused her
heart problems.438 They claimed that Lovett's heart problems existed before she ever used fen-phen.439
Lovett was represented by Kip Petro and Robert Kisselburgh, two plaintis lawyers at the forefront of the
fen-phen litigation. Lovett claimed that \the manufacturer knew that fen-phen could cause damage to the
heart and did not reveal that knowledge to the public in order to maximize prots"440
The jury found that the \negligence of the defendants was the proximate cause of the plainti's injury. It...
found that the harm done to the plainti resulted from the malice of American Home Products, and awarded
a total of $23,362,000, including $20,000,000 in punitives."441 American Home Products lawyer Bob Schick
of Vinson & Elkins said \we are disappointed by today's ruling. There simply is no scientic study that has
established a causal link between the use of Pondimin and the heart problems claimed by Mrs. Lovett."442
The jury verdict was later drastically reduced in a settlement. American Home Products settled with Debbie
Lovett on September 16, 1999 for `less than 10%" of the jury award, rumored at around $2 million. Kip
Petro, an attorney for Lovett, said that the settlement \represented `more than 90%' of what he thought
437Id.
438See John Council, Fen-Phen Fight Has Just Begun, Plaintis Lawyers Say Verdict Sets the Market Rate, Texas Lawyer,
Aug. 16, 1999 at 1.
439AHP issued a press release on the Lovett trial which said that \Deborah Lovett's long-standing history of heart problems
began in 1980 when she was 17 years old. In 1990, prior to her use of the diet drugs, she was diagnosed with mitral valve
prolapse syndrome with recurrent symptomatic palpitations, a condition caused by myxomatous degeneration of the mitral
valve. In fact, her treating cardiologist, the only physician who actually examined Ms. Lovett as a patient, testied that
her heart valve problems were caused by myxomatous degeneration and not by use of fen-phen. She had this condition prior
to treatment with fen-phen, has evidence of it today and will not require surgery in the future." American Home Products
Corporation, American Home Products to Appeal Court's Ruling in Deborah Lovett v. American Home Products, American
Home Products Press Releases, Madison, N.J., Aug. 6, 1999, available online at www.ahp.com/releases/ahp 080699.htm.
440Bob Van Voris, A Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
441Lovett v. Wyeth-Ayerst Laboratories, et al, Texlaw Verdicts: Product Liability
442Reuters, Dallas, TX, Jury Awards $23.3 Million in Texas Fen-Phen Case, Aug. 6, 1998, available online at
www.heartinfo.org.
125the ultimate award would be given Texas law capping punitive damages."443 Lovett's lawyers claimed that
they entered into the settlement with American Home Products after considering Texas laws on punitive
damage caps. The settlement was reached before a judgment on the verdict was entered.444
In addition to being the rst jury verdict in fen-phen litigation, the Lovett case was also noteworthy because
of a particular defense strategy of American Home Products, namely the use of an internal FDA Memo. Leo
Lutwak, a physician and medical ocer for the FDA, wanted to testify to set the record straight about the
FDA memo, which he claimed was being mischaracterized and used in American Home Products' defense.
The December 1997 memo from Lutwak to an FDA colleague stated that Lutwak had been considering the
valvular heart disease reports from fen-phen users and that he concluded that there was no way anyone
could have foreseen the adverse valvular eects of the drugs. American Home Products lawyers read the
memo out loud to the Lovett jurors, attempting to characterize the `anyone' as anyone at all, including
anyone at American Home Products. In contrast, Lutwak states that he meant the `anyone' to mean anyone
at the FDA. Lutwak has been subpoenaed by plaintis to testify as to the true meaning of his memo, but
FDA attorneys informed Lutwak he could not do so, since agency regulations prohibit testimony by agency
employees except when authorized by the commissioner or the commissioner's representative. The FDA has
this policy in order to `stay above the legal fray' and to prevent FDA employees from spending all of their
time providing testimony in court about FDA regulated products. David Kessler, FDA Commissioner from
1991 to 1997, said that he agreed with this policy up to a certain point, but that Lutwak should be permitted
to clarify his statement to prevent the continued mischaracterization of his words. American Home Products
claimed that they did not misrepresent the comments and that Lutwak did not communicate with them to
inform them of any mischaracterization. However, as discussed above, the jury found for Lovett regardless
443Richard B. Schmitt and Robert Langreth, AHP Oer to Settle Diet-Pill Litigation May not Be Rich Enough For Lawyers,
Wall Street Journal, Fen-Phen Multistate Litigation Website, available online at http://leflaw.net/fenphen.
444See Suit Settled, Texas Lawyer, Sept. 27, 1999 at 3.
126of the use of the memo and awarded her $23.3 million. American Home Products lawyers also showed the
Lutwak memo to jurors in the Vadino class action in New Jersey, but the case never went to the jury because
of the proposed Settlement Agreement.445
Texas Fen-Phen Settlements/Other Litigation
American Home Products agreed to pay up to $6 million to settle two Texas claims with women who
claimed that fen-phen caused valvular heart damage. American Home Products agreed to pay between $2-3
million to Freda Gilmore of Dallas and Esmerelda Rocha of Alice, Texas. Some analysts claimed that the
settlement move was an attempt to increase share price and limit diet drug liability in American Home
Products' quest to complete the now-defunct merger with Warner-Lambert. The settlement with Esmerelda
Rocha was reached during a trial that had lasted three weeks. Jurors were hearing evidence about Rocha's
medical problems when the settlement was reached. Rocha, 47, took Pondimin for over a year and allegedly
developed PPH.446 \Rocha's lawyers argued her heart deteriorated to a point that she couldn't walk more
than a few feet without gasping for breath. But American Home countered that a panel of doctors couldn't
nd anything wrong with Rocha's heart."447 Gilmore also took Pondimin and claimed that doctors had
to do valve replacement surgery as a result of valvular heart damage caused by the drug. American Home
Products claimed that Gilmore's problems resulted from her history of smoking and high-blood pressure.
Her trial was set for October 20, 1999 but it was pushed ahead as plainti and defense lawyers engaged in
settlement negotiations.448
In other diet drug litigation in Texas, in April of 1999 American Home Products settled the rst fen-phen
case to go to trial one week into the plainti's presentation. The trial was occurring in the Johnson County
445See FDA Ocial Says AHP Misled Jurors about Memo, Philadelphia Inquirer, Jan 9, 2000.
446See Bloomberg, American Home To Pay Up To $6 Million In Fen-Phen Cases, People Say, Madison, New Jersey
Bloomberg Report, Nov. 16, 1999.
447Id.
448See id.
127District Court. While the exact number was not made public, the number was reported to be approximately
$500,000.449
In May of 1999, in Canton, Texas, a judge declared a mistrial after lawyers claimed they were unable to seat
an impartial jury. Lawyers said that too many of the prospective jurors had been inuenced by the media
and already concluded that the fen-phen combination was dangerous.450
Mississippi { Washington Trial and All-Mississippi Settlement
The rst fen-phen case in Mississippi to go to trial was brought by ve plaintis who claimed that Pondimin
and Redux damaged their hearts and lungs, and they claimed that American Home Products did not properly
warn them of the health risks associated with Redux and Pondimin. The trial took place in Fayette,
Mississippi, a town of less than 2,000 people. The plaintis in the Fayette trial were: Claude Pickett of
Natchez, MS, Kenya Tenner Gaines of Fayette, MS, Vinester Williams of Itta Bena, MS, Ruth Bishop
of Greenville, MS, and Brenda Hamm of Bay Springs, MS. The plaintis' lawyers claimed that all ve
were suering from either valvular heart disease or PPH, a claim which American Home Products lawyers
disputed. The ve plaintis were seeking $2 billion in damages. American Home Products attorneys claimed
throughout the entire three week trial that doctors had warned the plaintis of the health risks associated
with Pondimin and Redux, particularly the PPH risk. Plaintis claimed that American Home Products hid
knowledge about Redux's health risks when they were trying to get the FDA to approve dexfenuramine.451
Plaintis' attorney Michael Gallagher stated in his opening statement that \American Home knew Pondimin
449See Charles Ornstein, Fen-Phen Maker Settles Suit for $500,000, Dallas Morning News, Apr. 9, 1999 at A1.
450See Mistrial Declared In Fen-Phen Trial, NY Times on the Web, available online at
www.nytimescom/aponline/f/AP-Diet-Drug-Trial.html.
451See Kerry Whipple, Drug Trial Opens in Fayette, The Natchez Democrat, Dec. 1, 1999, available online at
www.dietdrugsettlement.com.
128carried the risk of heart valve disease and pulmonary hypertension. He said the company listed only four
cases of pulmonary hypertension on its warning label for the drug, although it knew about more and was
required by the FDA to include those known cases."452 To counter this claim, Dr. Marc Dietch, retired
Director of Medical Aairs for Wyeth-Ayerst, testied
that the company told the FDA as early as 1994 about more than 50 cases of pulmonary hyperten-
sion that could have been associated with Pondimin. At the time, the warning label on the drug
showed only four cases of pulmonary hypertension associated with the drug. Deitch said the FDA
never requested a label change for the drug. `What was in the label was sucient information,'
Deitch said. `Whether it was four cases or 10 cases or 15 cases. `It made no sense to put a number
in' because not enough research had been done as to the association of the drug to the disease...
[t]he label was eventually changed, Deitch said, because `we changed it on our own'.453
To support their claims, the plaintis brought in expert witness Dr. Lemuel Moye, a general causation expert,
who testied that Redux and Pondimin did cause valvular heart disease and PPH. Dr. Moye said during
the trial that American Home Products knew of the dangers of Redux and Pondimin and that they failed to
inform the public, the FDA, or the medical community. The defense brought in expert witness Dr. Marcus
Stoddard, a cardiologist who claimed that the plaintis were not sick and that even if they were he could
not link any valvular heart disease to the plaintis' use of Pondimin and Redux. Dr. Stoddard suggested
that a secondary cause may be at fault in the valvular heart disease occurrences among fenuramine and
dexfenuramine users.454
The jury in Fayette deliberated for two hours and returned with a verdict of compensatory damages of $30
million for each plainti. Plainti and defense lawyers then gave their arguments for punitive damages.
However, following those arguments, plainti and defense lawyers worked out a settlement agreement. Judge
Lamar Pickard then dismissed the $150 million verdict. The settlement was stated to be approximately $350
452Id.
454See id.
129million, which would cover virtually all of the fen-phen cases in Mississippi.455 American Home Products did
not admit any wrongdoing and it maintained that the majority of people who took Redux and Pondimin have
not experienced any adverse health eects { including the Mississippi plaintis.456 One plainti, Vinester
Williams of Itta Bena, called the trial \stressful" and \depressing" and said that \it's very hurtful to know
you've been harmed and someone's telling you there's nothing wrong with you".457 The Fayette trial was
considered extremely important because at the time, analysts considered that the Warner-Lambert merger
may have been jeopardized by a large verdict.458.
American Home Products told stock analysts concerned about the verdict and its impact on American Home
Products' stock price and Warner-Lambert merger that the Mississippi legal environment was `anything but
ordinary'. American Home Products also noted that many of the cases led in Mississippi were from plaintis
who resided in other far-away states.459
Massachusetts Linnen Wrongful Death Trial/Settlement
Mary Linnen, a computer designer in Boston, died in 1997 at the age of 30 from PPH. Mary Linnen had
taken fenuramine and phentermine in order to lose weight for her upcoming wedding. She took Pondimin
for 24 days in April of 1996. Eleven days after she began treatment, Mary Linnen complained that she
455See Kerry Whipple, Settlement Reached in Fen-Phen Trial, The Natchez Democrat, Dec. 21, 1999, available online at
www.dietdrugsettlement.com.
456AHP issued a press release on the Mississippi Settlement that read as follows: \American Home Products Corporation
conrmed today that it has reached a resolution of substantially all of the diet drug cases pending in the state of Mississippi.
The resolution was reached this evening [Dec. 21, 1999] following discussions with counsel for the plaintis in the case of
Washington et al v. American Home Products Corporation and with the assistance of Judge Lamar Pickard, who presided
over the trial. Judge Pickard has vacated the judgment for compensatory damages awarded earlier today in the Washington
case and has entered a directed verdict dismissing plaintis' claims for punitive damages. The terms of the settlement of the
Mississippi litigation are condential." American Home Products Corporation, American Home Products Corporation Conrms
Resolution of Substantially All Mississippi Diet Drug Cases, American Home Products Press Releases, Madison, N.J., Dec.
21, 1999, available online at
www.ahp.com/releases/ahp 122199a.htm.
457Kerry Whipple, Settlement Reached in Fen-Phen Trial, The Natchez Democrat, Dec. 21, 1999, available online at
www.dietdrugsettlement.com.
458See Kerry Whipple, Drug Trial May Aect More Than Plaintis, The Natchez Democrat, Dec. 11, 1999, available
online at www.dietdrugsettlement.com.
459See David Morrow, American Home To Settle Some 1,400 Fen-Phen Suits, Dec. 23, 1999, Mealey's Litigation Report
Fen-Phen/Redux, available online at www.mealeys.com/fen.html.
130was experiencing shortness of breath. She died 10 months later from PPH. Her parents brought suit against
American Home Products, claiming that the company knew that fenuramine caused PPH in other Pondimin
users.460 In opening arguments in the trial, one of the lawyers representing Mary Linnen's family stated that
\American Home ocials `knew the drugs were killing people in the U.S. and Europe and stayed silent...
the motive for this was prot, pure and simple. That money is the reason Mary Linnen is dead today."461
The Linnen suit was the rst wrongful death suit to be tried before a jury (although it eventually settled).462
American Home Products lawyers claimed that there was no concrete evidence linking Linnen's PPH to her
use of Pondimin. Linnen's family claimed that by April 1996, when Mary Linnen was prescribed fen-phen
in Massachusetts, American Home Products already had reports of over 60 Pondimin users who developed
PPH, yet the company resisted updating Pondimin's warning label for fear it would decrease sales.463 One
of the Linnen family lawyers said that \American Home was marketing Pondimin to the public at a time
when it knew it had a deadly side eect."464 American Home Products countered by stating that it did not
ever market fen-phen or promote the diet drugs together, but rather sales of Pondimin increased as doctors
read favorable studies about the fen-phen combination. An American Home Products attorney stated that
\Because Linnen's PPH progressed so quickly, its likely she already had the disease when she started taking
Pondimin... the 5 foot 3 inch, 190 pound woman was worried that her inability to lose weight signaled she
had other medical problems... this was not a cosmetic issue."465
460See News This Week, Ticker, Natl. L.J., Feb. 7, 2000, at A4.
461Id.
462The case was also noteworthy because of a particular \jury innovation" used by Judge Brassard. Judge Brassard allowed
the lawyers to address the jurors directly at dierent stages in the trial, a technique called \interim commentary" or \interim
summation". It was the rst time the technique was used by any Massachusetts judge. Judge Brassard also provided pictures
of the witnesses to the jurors to help them connect the testimony in their notes to their memory of that testimony. Judge
Brassard used these techniques because he thought the case was going to last six to eight weeks. The case settled after seven
days. See Elizabeth Amon, Shaking Up Juries, State By State - In Vogue: Juror Notes, Chats by Panel, Interim Summations,
Natl. L.J., Feb. 14, 2000, at A14.
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massachusetts Bloomberg Report, Jan. 18, 1997.
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131American Home Products and Mary Linnen's family announced a settlement on January 27, 2000. The
details were not made public, but the Wall Street Journal reported the amount to be approximately $10
million.466 \The Boston Herald quoted led plainti attorney Alex MacDonald... as saying the settlement
was the largest wrongful death recovery in state history. The Herald said that would make the settlement
higher than $7 million."467 American Home Products indicated that much of the settlement sum would be
used to fund a research foundation for PPH treatment and research. The fund will bear the name of Mary
Linnen. The statement American Home Products issued in connection with the settlement did not admit
any wrongdoing on the part of American Home Products that played a role in Mary Linnen's death.468 The
joint press statement said that \the parties are pleased to settle this matter and are especially pleased to be
able to commemorate the name of Mary J. Linnen [in the research foundation]."469
While the Linnen case settled and American Home Products did not admit any wrongdoing, \one news
report quoted juror Bill Reed as saying that a majority of the jurors were leaning towards a plainti verdict
as a `wake-up-call' to AHP. The report said the juror said, `a billion dollars for them would have been
nothing."470 Other PPH cases have also resulted in verdicts for the plaintis. PPH claims are not covered
in the proposed Settlement and other Linnen-type cases may result in large plaintis' verdicts against
American Home Products. In addition, the Linnen case produced the noteworthy rulings excluding Linnen's
phentermine experts and sanctioning Wyeth-Ayerst for the e-mail backup tape destruction.471
466See Mealey's Litigation Report Fen-Phen/Redux, Vol. 3, Issue #4, Feb. 2000, available online at
www.mealeys.com/fen.html
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468See News This Week, Ticker, Natl. L.J., Feb. 7, 2000, at A4.
469American Home Products Corporation, AHP Joint Press Statement, American Home Products Press Releases, Cam-
bridge, Mass., Jan. 27, 2000, available online at www.ahp.com/releases.ahp 012700.htm.
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132PART IIIA MAJOR LESSON WE CAN TAKE AWAY FROM THE FEN-PHEN EXPERIENCE AND AN ASEESSMENT OF THE LIKELY OUTCOME OF THE FEN-PHEN LITIGATION
The above discussion sets forth a description of the medical and legal aspects of the fen-phen diet drug
experience. It has provided numerous lessons in terms of medical knowledge and in products liability liti-
gation.472 However, its one of its most critical lessons has to do with the special situation of obesity drugs
in modern American society. Due to background circumstances, the FDA should take a simple step that
would prevent another widespread experience of the use of weight-loss drugs for cosmetic purposes. Obesity
drugs have a purpose and a place, and fen-phen's most major lesson is that we have to limit that place in
a way that was not done with Redux and Pondimin. O-label use for prescription diet drugs should not be
permitted, although o-label use should be permitted for non-obesity drugs because of its inherent benets
in medical innovation.
A MAJOR FEN-PHEN LESSON
The Need For Diet Drugs in Certain Situations to Treat Clinically Obese Individuals
Obesity is a serious concern in America and it leads to numerous associated medical problems. Obesity
472The fen-phen experience also arguably raised concerns about the way adverse drug reactions are reported to the FDA.
However, whether or not the way the structure of U.S. adverse reaction reporting is at fault for the fen-phen problem depends
on whether or not American Home Products acted responsibly in reporting adverse reactions. As this paper has discussed several
times, there is a dispute between plainti and defense lawyers over whether American Home Products acted irresponsibly and
failed to report or warn of Redux and Pondimin adverse reactions. If American Home Products failed to follow the procedures
in place, then the lesson is that drug companies should face harsher sanctions for disregarding those procedures. American
Home Products has faced serious repercussions in the form of thousands of lawsuits, monetary liability, and legal fees. Because
the alleged wrongdoing of American Home Products is an issue that has yet to be denitively resolved (and this paper has
presented both sides) it is dicult to concretely determine how the FDA reporting structure would need to be changed to
prevent another fen-pen. Preventing another fen-phen where widespread use of risky drugs for a nonexistent disease would be
better addressed by prohibiting o-label use for diet drugs.
133aects 33% of American adults. Obesity in America needs to be treated, and a proven way of losing weight
is reducing caloric intake while engaging in a daily program of physical activity. The U.S. Department of
Health and Human Services recommends that:
A person who is less than 20% overweight should begin a life-long program of moderate
physical exercise, such as brisk walking for 30 to 45 minutes, on most days of the week. Reg-
ular moderate physical activity is likely to improve weight control and will also strengthen
the heart. Overweight persons should also begin to make moderate and life long changes in
their food choices and eating practices, including reducing the total amount of calories they
eat and ensuring that their diet is low in saturated fat and rich in fruits and vegetables.
Persons who have a signicant weight problem are advised to consult their physician to
develop a strategy that is individualized for them. There are a number of options available
that a physician can discuss with the patient.473
While a caloric reduction and exercise program would be the logical road to travel, it is not the road most
Americans wish to follow. Americans are looking for a pill to take that will allow them to lose weight
without summoning the discipline required for a serious diet and increased exercise. In the interview with
Dr. Marnell, she indicated that patients would come to her and say that \nothing works" and that they
had \tried everything". Reducing caloric intake and engaging in a regular exercise program does work, but
often people do not have the discipline to maintain such a regimen. People are willing to try any number of
\easy xes" for weight loss, hence the vast popularity of fen-phen. When overweight people are certain that
\nothing works" but a pharmacological intervention, they will turn to diet drugs instead of attempting to
maintain a healthy lifestyle. \Pick your poison as the cycle continues: if it's not one drug it's another. All of
them promise to make one's dream a reality, yet one must realize that the answer to trimming down is not
found in a bottle. Despite the widespread use of pharmacologic therapies, the prevalence of obesity continues
to increase, and the results of treatment remain unsatisfactory. In general, maintaining a reduced weight
requires exercise and a diet, not necessarily medical supervision or drugs."474 However, many Americans are
unable or unwilling to exercise and diet their weight away. For many people diet pills provide a psychological
474Jaime A. Wilsker, One Half-Phen In the Morning/One Fen Before Dinner: A Proposal For FDA Regulation of O-Label
Uses of Drugs, 6 J.L. & Pol'y at 843.
134benet that allows them to lose weight, with the pill serving as a crutch or impetus to a diet/exercise
program. And while Americans are willing to spend large amounts of money and risk serious side eects by
taking diet pills, that eort is \often for naught because the weight is usually gained back." immediately
after people stop taking the pills.475 In addition, one study showed the total weight lost from fen-phen use
to be only 5 and a half pounds.476
In light of the fact that Americans wish to solve their weight problems with pills instead of calorie reductions
and exercising, diet drugs will generally be \blockbuster drugs" with enormous money making potential.
Fen-phen became a national obsession, evidenced by the huge number of prescriptions written during its
heydey. The discovery of the heart problems associated with fen-phen did cause people to think twice about
diet drug use, but people are still trying to obtain fen-phen abroad and they have turned to the new \herbal
fen-phen" (no pharmacological relation to fenuramine or dexfenuramine). The fact that herbal fen-phen
is even advertised under that name belies the fact that the fen-phen asco did not scare Americans o of
diet drugs for good. Metabolife is wildly popular and is now the new quick weight loss alternative. While
Meridia has not been most doctors' drug of choice for obese patients because of its similarity to Redux and
Pondimin, Xenical has gained widespread popularity today for obesity treatment.477 Whatever happened
with fen-phen, diet drugs will be developed and will be widely used to treat obesity, which has become an
American epidemic. The issue will be how to harness the potential of those drugs for the ght against obesity
while not allowing them to be used for the non-obese. Where the benets outweigh the risks, America needs
diet drugs. But where the disease is an attempt to shed a few pounds to look better, the use of diet drugs
should be prohibited.
Cosmetic Diet Drug Use and The Resulting Recommendation that O-Label Use Should Be
Illegal For Diet Drugs
475Id at 820 { 821.
476See Jane E. Brody, Hard Evidence Building Against Fen-Phen Safety, Portland Oregonian, Sept. 3, 1997 at E12.
477See Interview with Dr. Tori Marnell (March 18, 2000).
135The fen-phen experience provided a valuable lesson about the inevitability of a diet drug being used by non-
obese people for cosmetic weight loss. Obesity is a special `disease' that warrants unique treatment by the
FDA. With other pharmaceuticals the disease that the drugs are aimed at curing or preventing is generally
more clear and easy to target than obesity. Since so many Americans are desperate to lose a few pounds
without putting forth the discipline necessary to lower their caloric intake and engage in physical activity,
diet drugs have a high propensity to be misused by those who are not clinically obese. Once word spread
about fen-phen's eectiveness in shedding pounds, the weight loss centers quickly established programs to
capitalize on the fen-phen craze and the cocktail became widely available to millions of Americans who were
not clinically obese. Our society places enormous pressure on women to maintain a slim physique, which for
many is an unattainable dream. That pressure is pervasive and overwhelming to many American women,
and it has bred a sense of desperation that led to the intense desire of these women to use fen-phen, no
matter what the risks. The PPH risk was known, and while there are debates over whether American Home
Products provided adequate warning of that risk, to many women that risk was simply disregarded in the
quest to be thin. In addition, the FDA assesses a drug's riskiness in the context of the benets it provides
against the disease it is meant to treat. The FDA acknowledged the risks presented by Redux during its
troubled approval process, and the FDA approved Redux because of the benets it was to provide in obesity
treatment. However, if o-label use is legal, the desire to be thin by taking a pill, combined with the desire
to make money, will thwart any attempt to limit diet drugs to use by the clinically obese. In the diet drug
situation, taken in the context of modern American society and looking at the fen-phen pill-mill debacle, the
FDA should make special rules for diet medications.478 The simple step of making o-label use illegal for
drugs only approved for the clinically obese would ensure that the proper risk-benet calculation is observed
478In the New Jersey Vadino trial opening statements, plaintis' lawyer Esther Berezofsy held up a barbie doll and said that
American Home Products preyed on overweight women by \promoting a distorted image of thinness and health, then selling
them drugs that were ineective in fostering long-term weight loss." She claimed, \They created a market for something that
didn't work and wasn't a cure." Bob Van Voris, A Drug Maker's Legal Migraine, Natl. L.J., Aug. 23, 1999, at B20.
136with regard to diet drugs. If doctors were liable for o-label prescribing to the non-obese, this would curb
cosmetic diet drug use. For the truly obese, even fen-phen may have been worth the risks, considering the
havoc that obesity can wreak on the human body. Yet when fen-phen was made available in today's legal
and societal context, it went to those for whom the risks far outweighed the benets. Diet drugs need to be
available to treat the clinically obese and o-label use should be legal to provide for innovative drug therapies,
especially in the oncology and AIDS contexts. The way to allow this while ending cosmetic diet drug use is
to only prevent o-label use in the diet drug context, and the way to enforce it is through physician liability.
The reality of today's world is such that this step should be taken to prevent another fen-phen situation.
In conclusion, a key fen-phen lesson learned is that in diet drug cases where cosmetic appearance is at issue,
the FDA needs to take action to ensure that drugs are safe and eective for those who use them. Namely,
the FDA needs to ensure that the proper risk-benet calculation does not break down. An admonition to
doctors that pills must only be taken by obese individuals is insucient to quell the insatiable desire of the
American population for a quick pill x to lose a few pounds. For obesity drugs where the societal context
makes it likely that the drugs will be used on a widespread basis for uses far beyond what is listed on their
labels, the FDA needs to prohibit o-label use. This will go a long way towards ensuring that the drugs
really will only go to people who suer from obesity. We can then ght obesity and also avoid another costly
and harmful fen-phen debacle.
CONCLUSION
Summary of Fen-Phen Situation and Eventual Outcome
The fen-phen situation was an overall detrimental experience for the diet drug users and for the diet drug
137makers/marketers. It has broken much legal ground in terms of medical monitoring479 for asymptomatic
plaintis and has been instrumental in detailing what characteristics are necessary for settlement class
certication after the Supreme Court's Amchem decision. The fen-phen users and their associated medical
problems have shed light on valvular heart disease and brought it to the forefront of the minds of many
American medical professionals and much of the U.S. population. Fen-phen illustrated the problem of pill-
mills for popular drugs where doctors never see patients to explain and assess the risks of medication. The
litigation also has provided a model for multi-district litigation involving injured and asymptomatic plaintis,
and Judge Bechtle set a good example with the fast-track process for the seriously ill. There are conicting
stories of who is to blame and who should pay who for what, and the eventual completion of the fen-phen
story will produce some who have lost more than others. The most likely outcome of the entire situation is
for the Settlement to be accepted, despite various threats of plaintis' lawyers for massive opt-outs. Many
plaintis will probably want the certainty of the Settlement as opposed to taking their chances in court, and
for the vast number of medical monitoring class members the Settlement provides generous benets. The
Settlement has been carefully structured in a way that is designed to secure Final Judicial Approval by Judge
Bechtle, and it would be very much in American Home Products' best interests not to walk away. Thus
forth, the Settlement will probably determine who has won and lost the most from the fen-phen experience.
Outlook for PPH Suerers
For those people with PPH, the diet drug asco is the most tragic. The PPH context is where the issue of
who is to blame becomes the most pointed. There are two sides to the story of whether American Home
Products acted responsibly with respect to Redux and Pondimin. American Home Products maintains that
479The fen-phen litigation has led to several states having to examine whether or not their law recognizes medical monitoring
claims and whether or not to certify a fen-phen medical monitoring class. See Cabraser and Vincent, Class Certication of
Medical Monitoring Claims in Mass Tort Product Liability Litigation, American Law Institute { American Bar Association
Continuing Legal Education Course of Study, July 22, 1999.
138it committed no wrongdoing with respect to warning consumers about the risks associated with Redux and
Pondimin, and that it kept the FDA informed according to the law. Plaintis' lawyers claim that American
Home Products knew of the valvular heart problems and did not inform the FDA, physicians, or consumers,
and that American Home Products failed to adequately reect the true PPH risk associated with the diet
drugs.
Based on PPH settlements so far, PPH suerers will likely receive fairly high individual settlements from
American Home Products in the neighborhood of $2 million per patient.480Some PPH suerers may not
be able to sue in court if they knew of their PPH before the opt-out date and received Fund B Settlement
benets, and those people would be the true losers in the outcome of the fen-phen litigation if the Settlement
is accepted.
Assessment of Outcome For Valvular Heart Disease Plaintis (Symptomatic and Asymp-
tomatic)
As for the valvular heart disease claims, those are encompassed in the Settlement Agreement, and in all
likelihood it will close the chapter on valvular heart disease liability for American Home Products. The
Settlement is good for the company since it eliminates the uncertainty of going jury by jury or settlement
by settlement, and it also lets American Home Products o at a fairly low price estimated at about $2.50
per share. The Settlement is also good for asymptomatic class members because they receive benets over
and above what the ACC, AHA, and DHHS recommends for Redux/Pondimin users. However, for those
who suer from serious valvular heart disease, the Settlement provides for low levels of matrix compensation
benets and makes it dicult for class members to qualify for those somewhat paltry sums. However, those
plaintis would benet from the Settlement in that they too, like American Home Products, eliminate the
480See Arian Campo-Flores, A Fen-Phen Fix { Big Suits: Top of the Docket Vadino et. al. v. AHP, The American Lawyer,
Nov. 1999.
139uncertainty of going to trial in favor of a getting a certain amount, albeit a smaller amount than they would
likely obtain if they won in court.
Overall Conclusion { Final Predictions and Hopes for the Future
The Settlement outcome, which is probably inevitable, has winners and losers, and hopefully the media
attention will have made people more cautious in the future about limiting their medications to those they
really need to combat serious health problems. The nal chapter of the fen-phen story has not been written
and will remain unknown until the fate of the Settlement is determined and all the PPH claims and claims of
opt-out plaintis have been resolved. However, it appears likely that the Settlement will be approved, that
American Home Products will have less liability than it could have had, and that the medical monitoring
plaintis will be those class members who gained the most out of the total outcome.
In sum, American Home Products can now turn to developing new drugs and perhaps nding a new merger
partner, asymptomatic diet drug users can take advantage of the medical monitoring, valvular heart disease
suerers who did not opt-out can accept their benets, those that did opt-out can sue, and PPH suerers can
also sue for damages. The FDA can consider making o-label use of diet drugs illegal and making doctors
liable for adverse eects resulting from o-label diet drug prescriptions. And hopefully the U.S. population
will have learned to exercise caution when faced with the prospect of a quick weight loss x. The best
outcome will be if a fen-phen litigation situation never again presents itself in the U.S. judicial system.
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